
<html lang="en"     class="pb-page"  data-request-id="b2cffa4c-73be-4187-b5b4-475b9bbc12b1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00821;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing" /></meta><meta name="dc.Creator" content="Li-Qiang  Sun" /></meta><meta name="dc.Creator" content="Eric  Mull" /></meta><meta name="dc.Creator" content="Barbara  Zheng" /></meta><meta name="dc.Creator" content="Stanley  D’Andrea" /></meta><meta name="dc.Creator" content="Qian  Zhao" /></meta><meta name="dc.Creator" content="Alan Xiangdong  Wang" /></meta><meta name="dc.Creator" content="Ny  Sin" /></meta><meta name="dc.Creator" content="Brian L.  Venables" /></meta><meta name="dc.Creator" content="Sing-Yuen  Sit" /></meta><meta name="dc.Creator" content="Yan  Chen" /></meta><meta name="dc.Creator" content="Jie  Chen" /></meta><meta name="dc.Creator" content="Anthony  Cocuzza" /></meta><meta name="dc.Creator" content="Donna M.  Bilder" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Bang-Chi  Chen" /></meta><meta name="dc.Creator" content="Theerthagiri  Palani" /></meta><meta name="dc.Creator" content="Sivakumar  Ganesan" /></meta><meta name="dc.Creator" content="Pirama Nayagam  Arunachalam" /></meta><meta name="dc.Creator" content="Paul  Falk" /></meta><meta name="dc.Creator" content="Steven  Levine" /></meta><meta name="dc.Creator" content="Chaoqun  Chen" /></meta><meta name="dc.Creator" content="Jacques  Friborg" /></meta><meta name="dc.Creator" content="Fei  Yu" /></meta><meta name="dc.Creator" content="Dennis  Hernandez" /></meta><meta name="dc.Creator" content="Amy K.  Sheaffer" /></meta><meta name="dc.Creator" content="Jay O.  Knipe" /></meta><meta name="dc.Creator" content="Yong-Hae  Han" /></meta><meta name="dc.Creator" content="Richard  Schartman" /></meta><meta name="dc.Creator" content="Maria  Donoso" /></meta><meta name="dc.Creator" content="Kathy  Mosure" /></meta><meta name="dc.Creator" content="Michael W.  Sinz" /></meta><meta name="dc.Creator" content="Tatyana  Zvyaga" /></meta><meta name="dc.Creator" content="Ramkumar  Rajamani" /></meta><meta name="dc.Creator" content="Kevin  Kish" /></meta><meta name="dc.Creator" content="Jeffrey  Tredup" /></meta><meta name="dc.Creator" content="Herbert E.  Klei" /></meta><meta name="dc.Creator" content="Qi  Gao" /></meta><meta name="dc.Creator" content="Alicia  Ng" /></meta><meta name="dc.Creator" content="Luciano  Mueller" /></meta><meta name="dc.Creator" content="Dennis M.  Grasela" /></meta><meta name="dc.Creator" content="Stephen  Adams" /></meta><meta name="dc.Creator" content="James  Loy" /></meta><meta name="dc.Creator" content="Paul C.  Levesque" /></meta><meta name="dc.Creator" content="Huabin  Sun" /></meta><meta name="dc.Creator" content="Hong  Shi" /></meta><meta name="dc.Creator" content="Lucy  Sun" /></meta><meta name="dc.Creator" content="William  Warner" /></meta><meta name="dc.Creator" content="Danshi  Li" /></meta><meta name="dc.Creator" content="Jialong  Zhu" /></meta><meta name="dc.Creator" content="Ying-Kai  Wang" /></meta><meta name="dc.Creator" content="Hua  Fang" /></meta><meta name="dc.Creator" content="Mark I.  Cockett" /></meta><meta name="dc.Creator" content="Nicholas A.  Meanwell" /></meta><meta name="dc.Creator" content="Fiona  McPhee" /></meta><meta name="dc.Creator" content="Paul M.  Scola" /></meta><meta name="dc.Description" content="The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (2) is described. The objective of this work was the identification of a drug with antiviral properties and to..." /></meta><meta name="Description" content="The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (2) is described. The objective of this work was the identification of a drug with antiviral properties and to..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 26, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00821" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00821" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00821" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00821" /></link>
        
    
    

<title>Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00821" /></meta><meta property="og:title" content="Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0015.jpeg" /></meta><meta property="og:description" content="The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (2) is described. The objective of this work was the identification of a drug with antiviral properties and toxicology parameters similar to 2, but with a preclinical pharmacokinetic (PK) profile that was predictive of once-daily dosing. Critical to this discovery process was the employment of an ex vivo cardiovascular (CV) model which served to identify compounds that, like 2, were free of the CV liabilities that resulted in the discontinuation of BMS-605339 (1) from clinical trials. Structure–activity relationships (SARs) at each of the structural subsites in 2 were explored with substantial improvement in PK through modifications at the P1 site, while potency gains were found with small, but rationally designed structural changes to P4. Additional modifications at P3 were required to optimize the CV profile, and these combined SARs led to the discovery of BMS-890068 (29)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00821"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00821">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00821&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00821&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00821&amp;href=/doi/10.1021/acs.jmedchem.6b00821" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 8042-8060</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00810" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00840" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Qiang++Sun">Li-Qiang Sun</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Mull">Eric Mull</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Zheng">Barbara Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stanley++D%E2%80%99Andrea">Stanley D’Andrea</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qian++Zhao">Qian Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+Xiangdong++Wang">Alan Xiangdong Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ny++Sin">Ny Sin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+L.++Venables">Brian L. Venables</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sing-Yuen++Sit">Sing-Yuen Sit</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Chen">Yan Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Chen">Jie Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Cocuzza">Anthony Cocuzza</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donna+M.++Bilder">Donna M. Bilder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⧫</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⧫</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bang-Chi++Chen">Bang-Chi Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⧫</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Theerthagiri++Palani">Theerthagiri Palani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>△</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sivakumar++Ganesan">Sivakumar Ganesan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>△</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pirama+Nayagam++Arunachalam">Pirama Nayagam Arunachalam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>△</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Falk">Paul Falk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Levine">Steven Levine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chaoqun++Chen">Chaoqun Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacques++Friborg">Jacques Friborg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Yu">Fei Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dennis++Hernandez">Dennis Hernandez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amy+K.++Sheaffer">Amy K. Sheaffer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jay+O.++Knipe">Jay O. Knipe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong-Hae++Han">Yong-Hae Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Schartman">Richard Schartman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Donoso">Maria Donoso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathy++Mosure">Kathy Mosure</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+W.++Sinz">Michael W. Sinz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tatyana++Zvyaga">Tatyana Zvyaga</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramkumar++Rajamani">Ramkumar Rajamani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Kish">Kevin Kish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Tredup">Jeffrey Tredup</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Herbert+E.++Klei">Herbert E. Klei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Gao">Qi Gao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alicia++Ng">Alicia Ng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luciano++Mueller">Luciano Mueller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+M.++Grasela">Dennis M. Grasela</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Adams">Stephen Adams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Loy">James Loy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+C.++Levesque">Paul C. Levesque</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huabin++Sun">Huabin Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shi">Hong Shi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lucy++Sun">Lucy Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William++Warner">William Warner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danshi++Li">Danshi Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jialong++Zhu">Jialong Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>▲</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying-Kai++Wang">Ying-Kai Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>◊</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Fang">Hua Fang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>◊</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+I.++Cockett">Mark I. Cockett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+A.++Meanwell">Nicholas A. Meanwell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fiona++McPhee">Fiona McPhee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+M.++Scola">Paul M. Scola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff111"><span class="aff-text"><sup>†</sup>Department of Discovery Chemistry, <sup>‡</sup>Department of Virology Discovery Biology, <sup>§</sup>Department of Computer-Assisted Drug Design, <sup>∥</sup>Department of Pharmaceutical Candidate Optimization, <sup>#</sup>Department of Lead Discovery and Optimization, and <sup>◊</sup>Department of Lead Evaluation, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div><div class="aff-info" id="aff55"><span class="aff-text"><sup>⊥</sup>Department of Clinical Development Infectious Disease, <sup>∇</sup>Department of Mechanistic Biochemistry, and <sup>●</sup>Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span></div><div class="aff-info" id="aff8"><span class="aff-symbol">○</span> <span class="aff-text">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span></div><div class="aff-info" id="aff11"><span class="aff-symbol">⧫</span> <span class="aff-text">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span></div><div class="aff-info" id="aff12"><span class="aff-symbol">△</span> <span class="aff-text">Biocon Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div><div class="aff-info" id="aff13"><span class="aff-symbol">▲</span> <span class="aff-text">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div><div class="corresp-info"><strong>*</strong>Phone, 203-677-7460; fax, 203-677-7804; e-mail, <a href="/cdn-cgi/l/email-protection#de92b78fb7bfb0b9f08dabb09ebcb3adf0bdb1b3"><span class="__cf_email__" data-cfemail="602c093109010e074e33150e20020d134e030f0d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00821&amp;href=/doi/10.1021%2Facs.jmedchem.6b00821" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 8042–8060</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 26, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 June 2016</li><li><span class="item_label"><b>Published</b> online</span>26 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00821" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00821</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8042%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLi-Qiang%2BSun%252C%2BEric%2BMull%252C%2BBarbara%2BZheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D17%26contentID%3Dacs.jmedchem.6b00821%26title%3DDiscovery%2Bof%2Ba%2BPotent%2BAcyclic%252C%2BTripeptidic%252C%2BAcyl%2BSulfonamide%2BInhibitor%2Bof%2BHepatitis%2BC%2BVirus%2BNS3%2BProtease%2Bas%2Ba%2BBack-up%2Bto%2BAsunaprevir%2Bwith%2Bthe%2BPotential%2Bfor%2BOnce-Daily%2BDosing%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8060%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00821"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1091</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">17</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00821" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Li-Qiang&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Mull&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Stanley&quot;,&quot;last_name&quot;:&quot;D’Andrea&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Xiangdong Wang&quot;},{&quot;first_name&quot;:&quot;Ny&quot;,&quot;last_name&quot;:&quot;Sin&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;L. Venables&quot;},{&quot;first_name&quot;:&quot;Sing-Yuen&quot;,&quot;last_name&quot;:&quot;Sit&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Cocuzza&quot;},{&quot;first_name&quot;:&quot;Donna&quot;,&quot;last_name&quot;:&quot;M. Bilder&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Bang-Chi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Theerthagiri&quot;,&quot;last_name&quot;:&quot;Palani&quot;},{&quot;first_name&quot;:&quot;Sivakumar&quot;,&quot;last_name&quot;:&quot;Ganesan&quot;},{&quot;first_name&quot;:&quot;Pirama&quot;,&quot;last_name&quot;:&quot;Nayagam Arunachalam&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Falk&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Levine&quot;},{&quot;first_name&quot;:&quot;Chaoqun&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jacques&quot;,&quot;last_name&quot;:&quot;Friborg&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;Hernandez&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;K. Sheaffer&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;O. Knipe&quot;},{&quot;first_name&quot;:&quot;Yong-Hae&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Schartman&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Donoso&quot;},{&quot;first_name&quot;:&quot;Kathy&quot;,&quot;last_name&quot;:&quot;Mosure&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;W. Sinz&quot;},{&quot;first_name&quot;:&quot;Tatyana&quot;,&quot;last_name&quot;:&quot;Zvyaga&quot;},{&quot;first_name&quot;:&quot;Ramkumar&quot;,&quot;last_name&quot;:&quot;Rajamani&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Kish&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Tredup&quot;},{&quot;first_name&quot;:&quot;Herbert&quot;,&quot;last_name&quot;:&quot;E. Klei&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Alicia&quot;,&quot;last_name&quot;:&quot;Ng&quot;},{&quot;first_name&quot;:&quot;Luciano&quot;,&quot;last_name&quot;:&quot;Mueller&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;M. Grasela&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Adams&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Loy&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;C. Levesque&quot;},{&quot;first_name&quot;:&quot;Huabin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Lucy&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Warner&quot;},{&quot;first_name&quot;:&quot;Danshi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jialong&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Ying-Kai&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Fang&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;I. Cockett&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;A. Meanwell&quot;},{&quot;first_name&quot;:&quot;Fiona&quot;,&quot;last_name&quot;:&quot;McPhee&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;M. Scola&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8042-8060&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00821&quot;},&quot;abstract&quot;:&quot;The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (2) is described. The objective of this work was the identification of a drug with antiviral properties and toxicology parameters similar to 2, but with a preclinical pharmacokinetic (PK) profile that was predictive of once-daily dosing. Critical to this discovery process was the employment of an ex vivo cardiovascular (CV) model which served to identify compounds that, like 2, were free of the CV liabilities that resulted in the discontinuation of BMS-605339 (1) from clinical trials. Structure–activity relationships (SARs) at each of the structural subsites in 2 were explored with substantial improvement in PK through modifications at the P1 site, while potency gains were found with small, but rationally designed structural changes to P4. Additional modifications at P3 were required to optimize the CV profile, and these combined SARs led to the discovery of BMS-890068 (29).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00821&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00821" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00821&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00821" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00821&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00821" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00821&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00821&amp;href=/doi/10.1021/acs.jmedchem.6b00821" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00821" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00821" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00821%26sid%3Dliteratum%253Aachs%26pmid%3D27564532%26genre%3Darticle%26aulast%3DSun%26date%3D2016%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2BAcyclic%252C%2BTripeptidic%252C%2BAcyl%2BSulfonamide%2BInhibitor%2Bof%2BHepatitis%2BC%2BVirus%2BNS3%2BProtease%2Bas%2Ba%2BBack-up%2Bto%2BAsunaprevir%2Bwith%2Bthe%2BPotential%2Bfor%2BOnce-Daily%2BDosing%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D17%26spage%3D8042%26epage%3D8060%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/jmcmar.2016.59.issue-17/20160908/jmcmar.2016.59.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (<b>2</b>) is described. The objective of this work was the identification of a drug with antiviral properties and toxicology parameters similar to <b>2</b>, but with a preclinical pharmacokinetic (PK) profile that was predictive of once-daily dosing. Critical to this discovery process was the employment of an ex vivo cardiovascular (CV) model which served to identify compounds that, like <b>2</b>, were free of the CV liabilities that resulted in the discontinuation of BMS-605339 (<b>1</b>) from clinical trials. Structure–activity relationships (SARs) at each of the structural subsites in <b>2</b> were explored with substantial improvement in PK through modifications at the P1 site, while potency gains were found with small, but rationally designed structural changes to P4. Additional modifications at P3 were required to optimize the CV profile, and these combined SARs led to the discovery of BMS-890068 (<b>29</b>).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis C virus (HCV) is a chronic viral infection which afflicts approximately 200 million people worldwide.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1-5)</a> In the United States (US) alone, some 4 million people are believed to be infected, with 25 000 to 40 000 new cases reported annually. HCV is one of the most common causes of liver disease and has emerged as a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplants. Moreover, the annual mortality attributed to HCV in the US has recently been shown to surpass the combined number of deaths associated with 60 notifiable infections.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> HCV has a single-stranded, positive sense RNA genome that encodes for three structural proteins (C, E1, and E2), a small viroporin designated as p7, and six nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B). The NS3 protease is comprised of the 181-residue amino terminus of the full-length protease-helicase that is optimally activated by forming a complex with its cofactor, NS4A. The NS3/4A enzyme complex processes the nonstructural elements of the HCV polyprotein to yield the mature viral replication proteins and is an essential element of the viral lifecycle. This virally encoded enzyme is an established target for drug discovery efforts, and a number of inhibitors of this protease have demonstrated clinical efficacy of which a subset have been approved by the U.S. Food and Drug Administration.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Recently we reported the discovery of BMS-605339 (<b>1</b>), a potent inhibitor of HCV NS3 protease that was advanced into early clinical development.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The antiviral activity of this compound was favorable: <b>1</b> exhibited a dose-dependent effect on viremia with a mean 1.8 log<sub>10</sub> IU/mL reduction in viral load observed in HCV genotype-1-infected subjects measured 12 h after a single 120 mg oral dose. Despite this significant antiviral response, the clinical development of <b>1</b> was halted due to a cardiac liability which manifested as mild bradycardia, PR interval prolongation, and junctional escape rhythms, all of which were asymptomatic. In response to these findings, efforts were focused on the discovery of a protease inhibitor that presented preclinical properties similar to <b>1</b> but with an optimized cardiovascular (CV) profile. This objective proved to be challenging since the profile of <b>1</b> in preclinical species did not indicate the potential for CV findings at therapeutically relevant exposures. For example, <b>1</b> induced mild bradycardia in the dog at plasma levels of 12 μM; however, in human subjects similar findings were reported at drug plasma levels as low as 150 nM. This observation suggested that humans were more sensitive to the CV effects of <b>1</b> than the preclinical toxicology species. After some experimentation, however, an <i>ex vivo</i> toxicology model, specifically the Langendorff isolated rabbit heart preparation, was employed that enabled a more detailed assessment of the CV effects of <b>1</b>.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> For example, perfusing a buffered solution of <b>1</b> directly onto an isolated rabbit heart preparation induced bradycardia in a dose-and time-dependent manner with a no-observed-effect level (NOEL) observed at concentrations of ∼100 nM of <b>1</b>. Thus, the CV effects of <b>1</b> in humans were reproduced in the isolated heart but at protein-free concentrations of >100 nM. With this finding, the Langendorff rabbit heart model was integrated into the program screening tier with the objective of identifying a compound that did not induce CV changes in this <i>ex vivo</i> model. This modification to the program screening tier was critical as it enabled the discovery of asunaprevir (<b>2</b>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Preclinically, <b>2</b> demonstrated an improved virology profile when compared to <b>1</b>, with enhanced liver exposure observed after PO dosing to rat, dog, and monkey. The higher liver-to-plasma ratios and improved potency translated to the clinic with <b>2</b> providing a similar antiviral response to <b>1</b> but at lower plasma levels. Importantly, the CV profile of <b>2</b> in humans was free of any of the findings associated with <b>1</b>, which provided confidence in the predictive value of the Langendorff isolated heart model for this chemical series. The early clinical data obtained with <b>2</b> warranted full development of this compound in combination with daclatasvir (BMS-790052, <b>3</b>), a NS5A replication complex inhibitor; this antiviral combination was approved for the treatment of individuals with chronic genotype-1b hepatitis C infection in Japan in July of 2014, becoming the first all-oral, interferon- and ribavirin-free regimen to be marketed for this indication.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> In addition, <b>2</b> is currently being evaluated clinically in combination with <b>3</b> and the non-nucleoside NS5B polymerase inhibitor beclabuvir (BMS-791325, <b>4</b>). This triple antiviral cocktail has proven effective for the treatment of individuals infected with both genotype-1a and genotype-1b infections, with the former the more challenging patient population to treat with direct-acting antiviral agents (DAAs).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0016.gif" alt="" id="GRAPHIC-d7e795-autogenerated" /></img><div class="NLM_p last">Following the discovery of <b>2</b>, a compound was sought that recapitulated the virological and CV profile of <b>2</b> but which had an improved PK profile across species that would predict for a lower efficacious dose in humans infected with HCV genotype-1. A compound with this profile was viewed as a mitigation strategy should long-term development issues emerge with <b>2</b>. Notably, a lower dose would ultimately facilitate the development of a once-daily, single tablet formulation combining a protease inhibitor with inhibitors of NS5A and NS5B for the treatment of genotype-1 infections. Herein, our efforts toward the discovery of a third protease inhibitor with the potential for a low QD dose in humans are described. In contemplating compounds that might provide an advantage over <b>2</b>, the relatively high clearance of this compound in rat provided an early point of focus. Interestingly, the high clearance observed with <b>2</b> and close analogues thereof correlated with correspondingly high liver levels of drug. Given that the primary site of replication of HCV is in hepatocytes, high liver exposure was seen as an important property to maintain in a third generation compound. However, as human dose predictions were derived from drug pharmacokinetics in plasma, a key objective in a follow-up to <b>2</b> was the identification of a compound that demonstrated high concentrations of drug in the liver after oral dosing while maintaining a PK profile in plasma that was predictive of once-daily dosing.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Initial efforts were focused on exploration of structure–activity relationships (SARs) at the P1 subsite (see <b>1</b> for the designation of subsites). In earlier studies, P1 analogues had been identified with lower clearance, although other properties had been compromised. More specifically, in the previously disclosed effort that led to the discovery of <b>2</b>, the effect of saturating the P1 vinyl moiety had been evaluated, and <b>5</b> was found to be slightly less active in the biochemical and replicon assays (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'cit9h cit9i ref16 ref17'); return false;" href="javascript:void(0);" class="ref cit9h cit9i ref16 ref17">(9h, 9i, 16, 17)</a> However, the PK profile of this compound in the rat was improved compared to <b>2</b> since the clearance of <b>5</b> was determined to be 18 mL/min/kg, 2-fold lower than that observed for <b>2</b>.<a onclick="showRef(event, 'cit9h cit9i'); return false;" href="javascript:void(0);" class="ref cit9h cit9i">(9h, 9i)</a> The improved clearance rate for <b>5</b> likely contributed to the ∼3-fold increase in half-life and ∼7-fold increase in plasma exposure observed for this compound compared to <b>2</b>. Liver levels of <b>5</b> determined 24 h after dosing were 40 μM, approximately 3-fold higher than that recorded for <b>2</b>, and the oral bioavailability was 43%, a more than 3-fold improvement when compared with <b>2</b>. The improvement in PK properties for <b>5</b> compared to <b>2</b> was compelling given the relatively small structural change that distinguishes this matched pair. As previously described,<a onclick="showRef(event, 'cit12a ref18'); return false;" href="javascript:void(0);" class="ref cit12a ref18">(12a, 18)</a><i>in vivo</i> metabolism studies had provided evidence that the dominant clearance pathway for <b>2</b> was uptake of the parent compound into the liver. Data from subsequent <i>in vitro</i> studies were suggestive that the liver uptake process was modulated by transporters, thereby providing an explanation for the relatively low plasma levels and high liver levels observed in vivo for <b>2</b>. Hence, in contemplating the differences in PK profiles between <b>2</b> and <b>5</b>, (P1 vinyl vs ethyl) the simple change in hybridization of the P1 substituent in these compounds was thought to have impacted the transport of compound from plasma into the liver.<a onclick="showRef(event, 'cit9h cit12a'); return false;" href="javascript:void(0);" class="ref cit9h cit12a">(9h, 12a)</a> The observed increase in bioavailability of <b>5</b> compared to <b>2</b> is consistent with this hypothesis. It should be noted that compound <b>5</b> had been dropped from contention as a clinical candidate based on the results from the cardiovascular screen, which implicated this compound as presenting a substantial risk for cardiac issues. Although compound <b>5</b> was limited in its progression because of the CV liability, it nonetheless served as a starting point for additional analogue synthesis.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiviral, Rat PK, and CV Profiles of Compounds <b>1</b>–<b>8</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">GT-1a = genotype-1a; HCV NS3 enzyme inhibitory activity was assessed according to the conditions described in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">GT-1b = genotype-1b; HCV replicon inhibitory activity was assessed in the presence of 10% fetal bovine serum (FBS) according to the conditions described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">IV/PO dosing levels: 5/15 mg/kg, <i>n</i> = 3. Vehicle: PEG-400/ethanol (90/10, v/v).</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Oral bioavailability.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Pharmacokinetic area under curve.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Pharmacokinetic clearance.</p></div><div class="footnote" id="t1fn7"><sup>Table g</sup><p class="last">Plasma half-life.</p></div><div class="footnote" id="t1fn8"><sup>Table h</sup><p class="last">Compounds were dosed at 10 μM for 20 min.</p></div><div class="footnote" id="t1fn9"><sup>Table i</sup><p class="last">10 μM for 60 min.</p></div><div class="footnote" id="t1fn10"><sup>Table j</sup><p class="last">HR = heart rate.</p></div><div class="footnote" id="t1fn11"><sup>Table k</sup><p class="last">SNRT = sinoatrial node recovery time. % Changes in HR and SNRT were meant to be the maximal changes over the course of the experiments. When vehicle only was dosed for 20 min, changes in HR and SNRT were −3% and 4%, <i>n</i> = 3, respectively.</p></div></div><div></div></div><div class="NLM_p">Optimizing SARs at the P1 position proved to be challenging as seemingly small modifications at this site led to a substantial erosion in potency. This was due, in part, to the relatively small invagination that structurally defines the S1 subsite. For example, replacing the P1 ethyl moiety of <b>5</b> with an isopropyl group (<b>6</b>) led to a significant reduction in biological activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In contrast, the corresponding unsaturated isomer of <b>6</b>, the isopropenyl derivative <b>7</b>, was potent in both the biochemical assay and the replicon screen. The matched pair comparison between <b>6</b> and <b>7</b> illustrates the significance of a change in the degree of saturation and therein carbon hybridization on biological activity. Unfortunately, the gain in activity observed with <b>7</b> was offset by a substantial loss in liver microsomal stability. While detailed metabolic identification studies were not conducted on <b>7</b>, we hypothesized that the methyl moiety at P1 may be subject to P450-mediated metabolism. In considering an immediate direction with respect to further analogue efforts, a model of both the active P1 isopropenyl compound <b>7</b> and the corresponding isopropyl analogue <b>6</b> was considered (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). A comparison of these analogues in the active site suggested that the loss in activity for <b>6</b> was driven by a lack of fit to the curvature of the S1 pocket as defined by residues L135, K136, S138, and F154 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). This unfavorable interaction was circumvented in the case of <b>7</b> by the presence of the olefin moiety at P1, which restricted the three carbon atoms of the vinyl methyl functionality to a single plane (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>c). On the basis of these observations, the construction of a cyclopropyl moiety as the substituent attached to the P1 cyclopropyl ring as in <b>8</b> was considered. Modeling of <b>8</b> bound to the enzyme supported this hypothesis as the cyclopropyl ring docked well in the S1 pocket (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>d). In the event, the activity of the bi-cyclopropyl analogue <b>8</b> in the biochemical and replicon assay was similar to <b>7</b>. Moreover, the <i>in vitro</i> metabolic profile of <b>8</b> in human liver microsomes (HLM) (<i>t</i><sub>1/2</sub> = 83 min) was significantly improved over <b>7</b> (<i>t</i><sub>1/2</sub> = 5 min) and approximated that of <b>6</b>. The favorable <i>in vitro</i> properties found with <b>8</b> prompted further evaluation of <i>in vivo</i> PK and in vitro CV profiling studies. The PK profile of <b>8</b> in the rat represented some improvement compared to <b>5</b>. For example, while oral bioavailability and liver levels at 24 h postdose were similar for these two analogues, the clearance of <b>8</b> was 5 mL/min/kg, ∼3-fold lower than that observed for <b>5</b>. The improved clearance rate for <b>8</b> likely contributed to the ∼2.5-fold increase in plasma exposure observed for this compound when compared to <b>5</b>. Upon perfusion in the isolated rabbit heart model, <b>8</b> had a significant effect on sinus node recovery time (SNRT) but minimal effects on heart rate (HR) over the 20 min evaluation period at a bath concentration of 10 μM. While the experimental results with <b>8</b> in this model represented an improvement over <b>5</b>, the data nonetheless suggested that this compound posed a greater risk with respect to potential CV issues compared to the clinical lead <b>2</b>, and hence further optimization would be required.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0001.jpeg" id="GRAPHIC-d7e1157-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Model of <b>2</b> bound to the active site of HCV NS3 protease. (b–d) Models of the P1 element of analogues <b>6</b>, <b>7</b>, and <b>8</b> bound to the S1 subpocket of HCV NS3 protease.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a more detailed comparison of the profiles of <b>8</b> and the <b>2</b>, the former demonstrated a 6-fold reduction in intrinsic enzyme inhibitory activity and 3-fold weaker activity in the replicon than the latter. However, <b>8</b> demonstrated a significant advantage with respect to PK in rat with clearance 8-fold less than <b>2</b>, and a plasma AUC over 24 h that was ∼20-fold greater. Moreover, the oral bioavailability of <b>8</b> was substantially improved compared to <b>2</b> (44% versus 12%), and the liver levels for <b>8</b> measured at 24 h postdose were more than twice that observed for <b>2</b>. Hence, moving forward, efforts were directed toward further optimization of the bi-cyclopropyl series with the objective of improving replicon inhibitory activity and attenuating the unfavorable aspects of the CV profile of <b>8</b>.</div><div class="NLM_p">To address these objectives, SARs at the P4 subsite of <b>8</b> were explored. Replacement of the carbamate <i>tert</i>-butyl moiety at P4 by an isopropyl group, compound <b>9</b>, resulted in a 2–3-fold loss of potency in the enzyme and replicon assays (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). However, replacement of the <i>tert</i>-butyl cap of <b>8</b> with a cyclobutyl moiety (<b>10</b>) maintained both enzyme and cellular activities. Collectively, these findings were suggestive that a threshold of lipophilic bulk was required at the P4 position for optimal activity, and, building upon this hypothesis, the P4 cyclopentyl series was explored. Interestingly, while the parent compound <b>11</b> was similar in activity to the parent P4 Boc analogue <b>8</b>, the addition of a simple methyl group to the cyclopentyl ring, as in <b>12</b>, improved activity 3–4-fold in the biochemical (IC<sub>50</sub> = 5 nM) and replicon (EC<sub>50</sub> = 3.7 nM) assays. Unfortunately, the enhanced antiviral activity observed with <b>12</b> was associated with a significant loss in liver microsomal stability, which prompted the preparation of derivatives of <b>11</b> designed to block potential metabolic soft spots on the cyclopentyl moiety. To this end, the cyclopropanated analogue <b>13</b> was prepared, which, compared to progenitor <b>8</b>, resulted in a significantly longer <i>in vitro</i> half-life in HLM, <i>t</i><sub>1/2</sub> = 118 min, while also providing a noticeable improvement in both GT-1a intrinsic activity (6-fold) and GT-1b cell-based activity (2-fold). However, additional profiling revealed that <b>13</b> was an inhibitor of cytochrome P450 3A4 (CYP 3A4) with an EC<sub>50</sub> value of 2 μM. While this level of inhibition is considered to be moderate, high and prolonged liver exposure of the compound was anticipated in HCV-infected subjects, presenting a risk for drug–drug interactions in combination therapy that precluded further evaluation of this compound. Nevertheless, the discovery of <b>13</b> was viewed as a significant advancement since it demonstrated that the targeted antiviral activity combined with enhanced microsomal stability could be achieved in the P1 bi-cyclopropyl series by optimizing the P4 functionality.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. GT-1a/1b Inhibitory Activity, <i>t</i><sub>1/2</sub> in HLM, Rat PK, and CV Profiles of P4-Modifed Analogues <b>8</b>–<b>18</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IV/PO dosing levels: 5/15 mg/kg, <i>n</i> = 3. Vehicle: PEG-400/ethanol (90/10, v/v).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Compounds were dosed at 10 μM for 20 min.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">10 μM for 60 min. % Changes in HR and SNRT were meant to be the maximal changes over the course of the experiments.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Measurement not obtainable due to inability to stimulate hearts. When vehicle only was dosed for 20 min, % change in HR and SNRT were −3 and 4, <i>n</i> = 3, respectively.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">HCV NS3 enzyme inhibition was assessed according to the conditions described in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>.</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">HCV replicon inhibition was assessed in the presence of 10% fetal bovine serum (FBS) according to the conditions described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>.</p></div></div><div></div></div><div class="NLM_p">Follow-up SAR studies continued to focus on P4 in an effort to identify a replacement group that captured the potency and stability observed with <b>13</b> but was free of the CYP 450 inhibition observed with this analogue. The observation noted above wherein lipophilicity at P4 was critical in securing optimal cell-based activity encouraged the consideration of fluorinated P4 moieties. The enhanced metabolic stability often observed with fluorination was considered as a favorable attribute.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This effort was initiated by replacing the P4 <i>tert</i>-butyl group in <b>8</b>, with a trifluoro <i>tert</i>-butyl group to afford <b>14</b>. This analogue demonstrated similar activity in the enzyme inhibitory assay as <b>8</b> but was 9-fold more potent in the replicon. Compound <b>14</b> also exhibited an increase in liver microsomal stability when compared to <b>8</b>. The <i>in vivo</i> profile of <b>14</b> in the rat was quite similar to <b>8</b>, highlighted by good oral bioavailability and low clearance. However, the CV profile of <b>14</b> in the isolated heart model was less favorable than that found for <b>8</b>, with this P4 halogenated moiety associated with a more significant change in HR and SNRT. Nonetheless, <b>14</b> was considered to be an important lead since the in vitro and in vivo (rat PK) profiles were favorable, and additional SAR studies were focused on further refining this P4 trifluoromethyl cap. For example, removal of a single fluorine atom from the P4 group of <b>14</b> provided the difluoro <i>tert</i>-butyl analogue <b>15</b> which was 30-fold less potent in the replicon. The loss in whole cell activity with <b>15</b> was attributed to the additional polarity associated with the difluoromethyl moiety compared to the symmetrically functionalized trifluoromethyl group of <b>14</b>.<a onclick="showRef(event, 'cit19e'); return false;" href="javascript:void(0);" class="ref cit19e">(19e)</a> A similar outcome resulted when the diastereotopic methyl groups in the P4 cap of <b>14</b> were removed to give <b>16</b>, with replicon potency diminished by 25-fold (EC<sub>50</sub> = 48 nM) compared to <b>14</b>. As was observed with <b>15</b>, the reduced whole cell activity associated with <b>16</b> was considered to be a consequence of an increase in polarity, realized in this case by a reduction in lipophilicity at the P4 position. Interestingly, the loss of replicon activity observed with <b>15</b> and <b>16</b> was not associated with a reduction in intrinsic activity as measured in the enzyme inhibition assay. This observation prompted further exploration of SAR around the P4 cap of <b>14</b>; specifically, the removal of a single methyl group, examined in the context of <b>17</b> and <b>18</b> which were prepared as P4 stereoisomers epimeric at the CF<sub>3</sub>-bearing carbon. These compounds proved to be significantly different from each other in their activity in both biochemical and whole cell assays. For example, <b>18</b>, which bears the (<i>R</i>)-configuration at P4, was found to be 6-fold more potent in the biochemical assay and 30-fold more potent in the cell-based assay than its isomer <b>17</b> which bears the P4 (<i>S</i>)-configuration. Molecular modeling studies of <b>17</b> and <b>18</b> suggested that the (<i>R</i>)-configured P4 cap of <b>18</b> can adopt a preferred binding mode in the S4 pocket that allows optimal van der Waals contact with the enzyme surface, while this orientation is not accessible to <b>17</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The significance of fluorination to the activity of <b>18</b> can be further appreciated by comparing the profile of this compound with that of <b>9</b>, a nonhalogenated P4 isopropyl analogue. Specifically, replacement of the P4, pro-<i>R</i> methyl of <b>9</b> with a CF<sub>3</sub>, provided <b>18</b>, and therein a 10-fold increase in activity in the biochemical assay and a corresponding 13-fold increase in the replicon assay. In contrast, replacement of the pro-<i>S</i> methyl of <b>9</b> with a CF<sub>3</sub> group provides <b>17</b> as a compound with similar activity to the progenitor. Hence, the stereoselective introduction of a CF<sub>3</sub> group to the P4 subsite resulted in the identification of a compound with potent antiviral activity and excellent microsomal activity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Model of the (<i>S</i>)-configuration CF<sub>3</sub> group of <b>17</b> bound to the S4 groove. (b) Model of the (<i>R</i>)-configuration CF<sub>3</sub> group of <b>18</b> bound to the S4 groove.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>18</b> was profiled in more detail and exhibited moderate clearance (11.5 mL/min/kg) and a long half-life of 10.3 h after IV dosing to rats at a dose of 5 mg/kg. Following oral administration at a dose of 15 mg/kg, <b>18</b> showed significantly higher liver and plasma exposure relative to <b>8</b>, with a liver concentration of 61.6 μM measured at 24 h postdose and a plasma AUC of 13.8 μM·h. Adding further to the interest in <b>18</b>, the PK profile in the dog was similarly improved over <b>2</b>, while cynomolgus monkey PK was comparable. When <b>18</b> was perfused to isolated rabbit hearts over a 20 min period at a concentration of 10 μM, only a mild decrease in HR and a mild increase in SNRT was noted. In a follow-up <i>in vivo</i> study evaluating the effect of <b>18</b> on the cardiac electrophysiology of anesthetized rabbits, no significant decrease in HR was observed. It should be noted, however, that both the QRS and HV (the interval between the His wave and the ventricular wave) intervals were prolonged in one out of three rabbits, changes that diminished slowly after completing the infusion. This finding was viewed as being consistent with the mild-to-moderate sodium channel inhibition observed with <b>18</b> in a patch-clamp assay (72% inhibition at 10 μM (1 Hz); 76% inhibition at 10 μM (4 Hz)), and progression of <b>18</b> was halted. Nonetheless, compound <b>18</b> represented a milestone compound as the targeted properties had been achieved with respect to potency, <i>in vitro</i> metabolic stability, and <i>in vivo</i> PK in both the rat and dog. Interestingly, the targeted properties in <b>18</b> had been captured by the introduction of relatively small structural changes at P1 and P4, and with these elements established, the next phase of the study focused on consideration of combining structural modifications at P2* and P3.</div><div class="NLM_p">Previous SAR studies at P2* had demonstrated that small structural changes to this element of the pharmacophore could exert a substantial impact on both the PK and CV properties.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> Consequently, the structural modifications that were considered for synthesis and evaluation at this position were limited in scope. Replacement of the C4-methoxy, C7-chloro isoquinoline of <b>18</b> with the C-3, C-6 dimethoxy analogue resulted in <b>19</b>, a compound with enhanced potency but with poor exposure after oral dosing to rats. Additionally, when <b>19</b> was evaluated in the rabbit isolated heart model, a decrease in HR was noted, to the extent that additional parameters could not be measured. Even small structural perturbations to the P2* element of <b>18</b> proved to be unfavorable. For example, moving the C-7 chloro of <b>18</b> to either the C-5 or C-6 position of the isoquinoline resulted in compounds <b>20</b> and <b>21</b>, both of which retained potent antiviral activity but demonstrated a substantial increase in clearance after IV dosing to rats. In the case of <b>20</b>, reinstalling the C-7 chloro group did not favorably modulate PK since the clearance of <b>22</b> remained high in the rat (40 mL/min/kg). These findings recapitulated the previously noted SAR trends with respect to PK and CV effects, and illustrated the importance of maintaining the P2* functionality in <b>18</b> (and <b>2</b>) in efforts to further optimize this chemical series. Hence, at this point, SAR efforts migrated to the P3 position of <b>18</b> in an effort to further optimize the CV properties of this compound while maintaining the favorable potency and PK attributes.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. GT-1a/1b Inhibitory Activity, <i>t</i><sub>1/2</sub> in HLM, Rat PK, and CV Profile of P2* Analogues <b>19</b>–<b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0012.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IV/PO dosing levels: 5/15 mg/kg, <i>n</i> = 3. Vehicle: PEG-400/ethanol (90/10, v/v).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Compounds were dosed at 10 μM for 20 min. % Changes in HR and SNRT were meant to be the maximal changes over the course of the experiments.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Measurement not obtainable due to inability to stimulate hearts. When vehicle only was dosed for 20 min, % change in HR and SNRT were −3 and 4, <i>n</i> = 3, respectively.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">HCV NS3 enzyme inhibition was assessed according to the conditions described in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">HCV replicon inhibition was assessed in the presence of 10% fetal bovine serum (FBS) according to the conditions described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>.</p></div></div><div></div></div><div class="NLM_p">The final element examined in order to improve the <i>in vivo</i> CV profile of <b>18</b> focused on modification of the P3 substituent, and the series of analogues probing alkyl substituents at this position are summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. These data demonstrate that the P3 moiety is an important modulator of potency, PK, and CV. For example, replacement of the <i>tert</i>-butyl-glycine of <b>18</b> with valine (<b>23</b>) had a negligible impact on inhibitory activity; however, the PK profile of <b>23</b> was significantly compromised when compared to <b>18</b>. Moreover, similarly close analogues such as the cyclopropyl derivative <b>24</b>, the isoleucine-based <b>25</b>, the cyclobutyl analogue <b>26</b>, and the 3-pentyl homologue <b>27</b> each resulted in a reduction of antiviral potency. However, the cyclopentyl and cyclohexyl derivatives <b>28</b> and <b>29</b> proved to be potent antiviral agents and demonstrated PK properties in the rat that were similar to <b>18</b>. Compounds <b>28</b> and <b>29</b> were investigated in the rabbit isolated heart model, and both analogues exerted a minimal effect on HR and SNRT during the 20 min perfusion period at a bath concentration of 10 μM (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). When the perfusion time was extended to 60 min in a follow-up study, again only mild effects on HR and SNRT were observed. These findings were similar to those observed with both vehicle and <b>2</b>, while the concentration of <b>28</b> and <b>29</b> in atrial tissues, measured at the end of the experiment, was significantly higher (<b>28</b> = 225 μM, <b>29</b> = 204 μM) relative to <b>2</b> (61 μM). The CV findings described herein, in conjunction with those described as part of the identification of <b>2</b>, add further to the suggestion that no single structural feature is responsible for the CV signal but is rather an effect based on the overall composition of the molecule.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. GT-1a/1b Inhibitory Activity, <i>t</i><sub>1/2</sub> in HLM, and CV Profile of P3-Modified Derivatives <b>23</b>–<b>29</b><a class="ref internalNav" href="#t4fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0013.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0014.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup>Table a</sup><p class="last">10 μM for 60 min. % Changes in HR and SNRT were meant to be the maximal changes over the course of the experiments. When vehicle only was dosed for 20 min, the % change in HR and SNRT was −3 and 4, <i>n</i> = 3, respectively.</p></div><div class="footnote" id="t4fn3"><sup>Table b</sup><p class="last">HCV NS3 enzyme inhibition was assessed according to the conditions described in ref <a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">16</a>.</p></div><div class="footnote" id="t4fn4"><sup>Table c</sup><p class="last">HCV replicon inhibition was assessed in the presence of 10% fetal bovine serum (FBS) according to the conditions described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>.</p></div><div class="footnote" id="t4fn1"><sup>Table d</sup><p class="last">Astertisk (*): Compounds were dosed at 10 μM for 20 min.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>28</b> and <b>29</b> were subsequently evaluated in the dog and cynomolgus monkey where both compounds demonstrated good PK profiles, with lower clearance, enhanced bioavailability, significantly improved plasma exposure, and longer half-lives relative to <b>2</b> and <b>18</b>. As a point of differentiation, after PO dosing to the cynomolgus monkey at 10 mg/kg, <b>28</b> showed signs of gastrointestinal (GI) irritation (mild vomiting and diarrhea), while no signs of GI tract irritation were noted for <b>29</b>. While this observation was anecdotal in nature since it was not part of a formal toxicology study, it nonetheless shifted the focus toward <b>29</b>, and this compound was further profiled, including a more extensive <i>in vitro</i> assessment of properties and potential liabilities as well as toxicology studies in both the rat and dog.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Properties of Compounds <b>2</b>, <b>8</b>, <b>18</b>, <b>19</b>, <b>20</b>, <b>28</b>, and <b>29</b> in the Rat, Dog, and Cynomolgus Monkey<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center" char="."><b>2</b></th><th class="colsep0 rowsep0" align="center" char="."><b>8</b></th><th class="colsep0 rowsep0" align="center" char="."><b>18</b></th><th class="colsep0 rowsep0" align="center" char="."><b>19</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20</b></th><th class="colsep0 rowsep0" align="center" char="."><b>28</b></th><th class="colsep0 rowsep0" align="center" char="."><b>29</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rat</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">38.4</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">14.0</td><td class="colsep0 rowsep0" align="char" char=".">40.7</td><td class="colsep0 rowsep0" align="char" char=".">12.4</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">44.2</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">121.8</td><td class="colsep0 rowsep0" align="char" char=".">66.0</td><td class="colsep0 rowsep0" align="char" char=".">86.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">1.26</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td><td class="colsep0 rowsep0" align="char" char=".">13.8</td><td class="colsep0 rowsep0" align="char" char=".">0.794</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">15.0</td><td class="colsep0 rowsep0" align="char" char=".">21.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO liver @ 24 h (μM)</td><td class="colsep0 rowsep0" align="char" char=".">15.2</td><td class="colsep0 rowsep0" align="char" char=".">35.7</td><td class="colsep0 rowsep0" align="char" char=".">61.6</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char=".">49.3</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">51.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dog</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">18.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">157</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">57.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)</td><td class="colsep0 rowsep0" align="char" char=".">2.20</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">12.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">9.5</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">19.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">15.8</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">12.9</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">21.9</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.772</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Respective IV/PO dosing levels: rat (5/15 mg/kg, <i>n</i> = 3), dog (1/3 mg/kg, <i>n</i> = 3), monkey (1/3 mg/kg for <b>1</b> and <b>17</b>; 3/10 mg/kg for <b>31</b> and <b>32</b>, <i>n</i> = 3). Vehicle: PEG-400/ethanol (90/10, v/v) for rat-IV/PO and PEG-400/water (85:15, v/v) for dog-IV/PO and monkey IV/PO.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Plasma half-life.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Pharmacokinetic clearance.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Oral bioavailability.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Pharmacokinetic area under curve.</p></div></div></div><div class="NLM_p">The spectrum of genotype inhibition associated with <b>29</b> was assessed by determining IC<sub>50</sub> values toward HCV NS3 protease complexes representative of six of the major genotypes of HCV, and these data are summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>.<a onclick="showRef(event, 'cit12b'); return false;" href="javascript:void(0);" class="ref cit12b">(12b)</a> In these assays, the profile of <b>29</b> was comparable to <b>2</b>, as both compounds demonstrated single digit nanomolar activity against genotypes 1, 4, 5, and 6 with a loss in potency observed against genotypes 2 and 3. The activity of <b>29</b> and <b>2</b> as inhibitors of HCV RNA replication was measured using replicons representing genotypes 1a and 1b, as well as the 2a JFH-1 strain. In addition, the effects of <b>29</b> toward hybrid replicons encoding the NS3 protease domain representing genotypes 2b, 3a, and 4a were also determined.<a onclick="showRef(event, 'cit12b'); return false;" href="javascript:void(0);" class="ref cit12b">(12b)</a> As shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, the replicon profile of compound <b>29</b> across genotypes was similar to that for <b>2</b> and a recapitulation of the enzymatic activity of these compounds. The activity of analogues <b>2</b> and <b>29</b> against resistant mutants were similar in nature, with a significant loss in activity observed toward specific viruses, data summarized in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The similar virology profile of compounds <b>2</b> and <b>29</b> was not surprising since these analogues share a common silhouette when bound to the enzyme. More specifically, <b>29</b> is 106-fold less potent toward GT-1b NS3 incorporating an A156V change, 32-fold less active toward D168E GT-1b NS3 protease, 1900-fold less potent toward GT-1b NS3 with a D168V mutation and 65-fold less active toward a GT-1a NS3 enzyme incorporating R155K. It should be noted that activity against GT 2b and 3a, as well as the resistant variants noted, was ultimately addressed by employing a macrocyclization strategy, and these findings will be communicated in due course.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Compound <b>29</b> was shown to be specific for the HCV NS3 serine protease, with no significant inhibitory activity measured against the closely related GBV-B NS3 protease (IC<sub>50</sub> > 25 μM) and human leukocyte elastase (IC<sub>50</sub> = 21 μM) enzymes or bovine viral diarrhea virus (BVDV) and HIV-1 in cell culture. Further <i>in vitro</i> profiling included evaluation of <b>29</b> in a hERG patch-clamp assay which revealed an IC<sub>50</sub> of 12.5 μM, while in a sodium channel patch-clamp assay 46.4% inhibition was observed at a concentration of 10 μM (4 Hz). The result for <b>29</b> in the sodium channel assay represented an improvement over that for <b>18</b>, a more favorable outcome that was recapitulated <i>in vivo</i>. Specifically, evaluation of <b>29</b> in anesthetized rabbits given as a 30 mg/kg IV infusion revealed benign effects similar to those measured with <b>2</b>: no effect on either HR, SNRT, QRS, or PR interval was noted, while mild prolongation of QTcf, but not QTcv, was observed at the end of the dosing period. The plasma concentration of <b>29</b> in this experiment (253 μM) matched that found with <b>2</b> (240 μM) at the same dose and was 10-fold higher than the concentration at which <b>1</b> induced bradycardia in this model. Compound <b>29</b> was also evaluated in a single-dose, cardiovascular telemetry study in dogs at 30 and 100 mg/kg, which resulted in no significant findings with respect to HR or related CV parameters. Collectively these results classified <b>29</b> as a compound with minimal CV risk.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibitory Activities of Compounds <b>2</b> and <b>29</b> against Recombinant Full-Length HCV NS3/4A Protease Complexes Representing Different HCV Genotypes<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">genotype (strain)</th><th class="colsep0 rowsep0" align="center" char="."><b>2</b></th><th class="colsep0 rowsep0" align="center" char="."><b>29</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1a (H77)</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1b (J4L6S)</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2a (HC-J6)</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2b (HC-J8)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3a (S52)</td><td class="colsep0 rowsep0" align="char" char=".">488</td><td class="colsep0 rowsep0" align="char" char=".">1402</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4a (ED43)</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5a (SA13)</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6a (HK-6A)</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Data are the mean values from at least three independent experiments.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Cell Culture Potency of Compounds <b>2</b> and <b>29</b> in HCV Replicons<a class="ref internalNav" href="#t7fn2" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">genotype (strain)</th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1a (H77)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1b (Con1)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2a (JFH1)</td><td class="colsep0 rowsep0" align="left">217</td><td class="colsep0 rowsep0" align="left">136</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2b (HC-J8)<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">621</td><td class="colsep0 rowsep0" align="left">562</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3a (S52)<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">1650</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4a (ED43)<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">2.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn2"><div class="footnote" id="t7fn2"><sup>a</sup><p class="last">Data are the mean values from at least three independent experiments.</p></div><div class="footnote" id="t7fn1"><sup>b</sup><p class="last">Hybrid replicons were used to assess the NS3 protease activity representing specified genotypes. For the genotype 4a NS3 construct, the replicon backbone was genotype 1b while for the genotype 2b and 3a NS3 constructs, the replicon backbone was genotype 2a.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Fold Loss in Potency of Compounds <b>2</b> and <b>29</b> against Known Resistance Substitutions</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">fold resistance<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">replicon</th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a NS3-R155K</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b NS3-A156V</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b NS3-D168E</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b NS3-D168V</td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="left">1900</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Fold resistance represents the compound EC50 value against a replicon harboring an NS3 substitution divided by the compound EC50 value against wild-type replicon (GT-1a for GT-1a NS3 substitutions and GT-1b for GT-1b NS3 substitutions.</p></div></div></div><div class="NLM_p">Compound <b>29</b> was advanced through human CYP 450 inhibition assessment with no significant liability identified. In addition, the cytotoxic effects of <b>29</b> toward HepG2, HuH-7, HEK 293T, HeLa, and MRC5 cell lines was found to be low, with CC<sub>50</sub> values ranging from 8 to 14 μM. Compound <b>29</b> was negative in an AMES assay with and without S9 activation. This favorable profile for <b>29</b> led to the initiation of toxicology studies in the rat and the dog. A single dose exploratory toxicokinetic study conducted with <b>29</b> in rats at doses of 30, 100, and 300 mg/kg surfaced no significant issues. Similarly, a single dose toxicokinetic and tolerability study in dogs that evaluated <b>29</b> at doses of 20, 60, and 200 mg/kg provided a similarly favorable outcome, with no significant issues identified.</div><div class="NLM_p last">Compound <b>29</b> emerged from this preclinical assessment as a compound that met the criteria that had been set for a NS3 protease inhibitor clinical candidate. While both the potency of <b>29</b> and the CV profile were similar to that observed with <b>2</b>, the PK properties were significantly improved across species, with lower clearance and higher oral bioavailability. The improved pharmacokinetic parameters coupled with low nanomolar whole cell antiviral activity associated with <b>29</b> resulted in a human dose prediction of 6 mg once daily to cover GT-1a and GT-1b viruses, which met our primary objective and triggered the onset of early development activities with this compound.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The subtle structural changes that distinguish <b>29</b> (BMS-890068) from <b>2</b>, that is, modifications to P1, P4 and ultimately P3, underscore the significance of relatively small structural changes on the key properties of potency, PK, and CV profiles of analogues in this chemical series.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of the P1 bi-cyclopropane acylsulfonamide tripeptide <b>29</b> as a representative example is outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, and this route was used to provide general access to all of the analogues described herein. In the case of <b>29</b>, the synthesis started from <b>30</b>, as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, to which the introduction of the cyclopropane motif was achieved via a directed cyclopropanation using Pd(OAc)<sub>2</sub> as the catalyst in the presence of an excess of diazomethane, a protocol that has been shown to efficiently cyclopropanate a wide variety of olefins.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, the reaction failed to proceed to completion (∼50% conversion based on liquid chromatography/mass spectrometry (LC/MS)), and the product <b>31</b> was inseparable from the starting material <b>30</b> by silica gel chromatography. While the screening of modified reaction conditions did not improve the conversion of <b>30</b> to <b>31</b>, we were pleased to find that full conversion was achieved in 78% yield after the product mixture was resubjected to the reaction conditions for 2–3 cycles. The next series of reactions involved converting the ester functionality of <b>31</b> to the corresponding P1–P1′ acylsulfonamide <b>33</b>. In the event, ester <b>31</b> was hydrolyzed with aqueous NaOH to afford the corresponding carboxylic acid <b>32</b>, which, in turn, was converted into acylsulfonamide <b>33</b> using HATU and cyclopropanesulfonamide<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> in the presence of DBU as the base. Removal of the Boc protecting group from <b>33</b> followed by HATU-mediated coupling with the previously described proline derivative <b>35</b><a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> afforded the dipeptide acylsulfonamide <b>36</b> in 93% yield over the two steps.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of P1 Bi-cyclopropane-Based Dipeptide <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>2</sub>N<sub>2</sub>, Pd(OAc)<sub>2</sub>, ether, 0 °C to RT, 78%; (b) NaOH, MeOH, H<sub>2</sub>O, reflux, 98%; (c) CDI, cyclopropanesulfonamide, DBU, THF, reflux to RT, 88%; (d) 4 M HCl, dioxane, RT, quantitative yield; (e) HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 93%.</p></p></figure><div class="NLM_p">In view of the difficulty of completing the cyclopropanation reaction and the challenging purification of <b>31</b> from <b>30</b>, an alternative approach to <b>36</b> was developed in which the cyclopropane moiety was installed after the introduction of the functionalized proline derivative <b>35</b>, as summarized in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. HATU-mediated coupling of <b>35</b> with amine salt <b>37</b>, prepared from <b>30</b> by deprotection of the Boc group, provided vinyl ester <b>38</b>. In this example, the Pd-catalyzed cyclopropanation of <b>38</b> with diazomethane generated <i>in situ</i> from <i>N</i>-methyl-<i>N</i>-nitrosourea–NaOH in Et<sub>2</sub>O proceeded almost to completion in good yield (88%), and <b>39</b> was easily purified by column chromatography. Ester <b>39</b> was hydrolyzed with aqueous NaOH to yield the corresponding carboxylic acid <b>40</b>, which, in turn, was transformed into acylsulfonamide <b>36</b> using HATU and cyclopropanesulfonamide in the presence of DBU. This alternative approach offered a more convenient procedure to synthesize <b>36</b> and proceeded in a higher overall yield.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. An Alternative Route for Synthesis of P1 Bi-cyclopropanedipeptide <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1<i>R</i>,2<i>S</i>)-ethyl 1-amino-2-vinylcyclopropanecarboxylate (HCl salt, <b>37</b>), HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 88%; (b) CH<sub>2</sub>N<sub>2</sub>, Pd(OAc)<sub>2</sub>, ether, 0 °C to RT, 88%; (c) NaOH, MeOH, H<sub>2</sub>O, reflux, quantitative yield; (d) CDI, cyclopropanesulfonamide, DBU, THF, reflux to RT, 94%.</p></p></figure><div class="NLM_p">Conversion of <b>36</b> to the final compound <b>29</b> was then accomplished as outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Removal of the Boc protecting group from <b>36</b> using HCl in dioxane was followed by HATU-mediated coupling with the commercially available (<i>S</i>)-2-(<i>tert</i>-butoxycarbonylamino)-2-cyclohexylacetic acid to produce the tripeptide <b>42</b>. Compound <b>42</b> was deprotected to provide the amine salt <b>43</b>, which was then coupled with (<i>R</i>)-pyridin-2-yl 1,1,1-trifluoropropan-2-yl carbonate <b>44</b>, prepared from commercially available (<i>R</i>)-1,1,1-trifluoropropan-2-ol,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> to provide the final compound <b>29</b> in 98% yield over the two steps. The absolute stereochemistry of <b>29</b> was determined by single crystal X-ray diffraction analysis, and the structure is presented in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of P1 Bi-cyclopropane-Based Tripeptide <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4 M HCl, dioxane, RT, quantitative yield; (b) HATU, <i>i</i>-Pr<sub>2</sub>NEt, (<i>S</i>)-2-(<i>tert</i>-butoxycarbonylamino)-2-cyclohexylacetic acid, DCM, RT, 92%; (c) 4 M HCl, dioxane, RT, quantitative yield; (d) <b>44</b>, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 98%.</p></p></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single crystal X-ray structure of <b>29</b>. The molecular structure of <b>29</b> free acid determined by X-ray crystallography from a monohydrate crystal. Water molecules are excluded for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described efforts to optimize a series of HCV NS3 protease inhibitors which culminated in the discovery of <b>29</b>, a compound which preserves the favorable properties of clinical compound <b>2</b> while demonstrating improved PK parameters predictive of once daily oral dosing in humans. The optimization campaign began first with replacement of the P1 terminal alkene with a cyclopropane moiety, represented by <b>8</b>. This change significantly improved the PK profile in rat and likewise improved the metabolic stability in HLM but was accompanied by a loss in potency. Optimization of the P4 substituent restored potency in both the isolated enzyme and replicon assays while maintaining all an optimal PK and microsomal stability profile, represented by compound <b>18</b>. In an attempt to mitigate an unfavorable CV signal observed with this molecule, replacements for P2* were surveyed. While analogues with enhanced potency were identified, such tuning of the P2* region failed to fully resolve the CV liability. Finally, structural modifications to the P3 region afforded <b>29</b>, a compound that demonstrated a favorable balance of potency, metabolic stability, PK parameters, and CV safety. This compound was moved to the development stage and was positioned as a backup clinical candidate to <b>2</b> as it offered a projected benefit of once daily dosing based on preclinical PK parameters.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52213" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52213" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reagents were purchased from commercial suppliers and used without purification unless otherwise noted. All anhydrous reactions were performed under a N<sub>2</sub> atmosphere using SureSeal solvents from Aldrich. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker AM FT 300 MHz spectrometer, a Bruker Avance-III 500 MHz spectrometer, or a Bruker Ultrashield 400 MHz spectrometer, each equipped with a 5 mm TXI cryoprobe. All spectra were determined in the solvents indicated, and residual protio-solvent was used as internal standard for chemical shift assignments. Interproton coupling constants are reported in Hertz (Hz). Multiplicity patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets; dt, doublet of triplets; dq, doublet of quartets. Most spectra were analyzed using the ACDLABS SpecManager 12.0 program software. Liquid chromatography/mass spectra (LC/MS) were performed on a Shimadzu LC instrument coupled to a Water Micromass ZQ instrument, and the LC/MS conditions are compiled in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>. Purities of the final compounds were determined by HPLC and were greater than 95%. HPLC conditions to assess purity are compiled in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. LC/MS Conditions Used in the Characterization of All Compounds Found in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">LC/MS condition<a class="ref internalNav" href="#t8Afn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Col<a class="ref internalNav" href="#t8Afn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">GT<a class="ref internalNav" href="#t8Afn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">FR<a class="ref internalNav" href="#t8Afn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">Sol A<a class="ref internalNav" href="#t8Afn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">Sol B<a class="ref internalNav" href="#t8Afn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method A<a class="ref internalNav" href="#t8Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method B</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method C<a class="ref internalNav" href="#t8Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method D</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method E</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method F</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method G</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method H</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method I</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method J</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method K<a class="ref internalNav" href="#t8Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method L</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method M</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method N<a class="ref internalNav" href="#t8Afn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method O</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method P</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8Afn1"><div class="footnote" id="t8Afn1"><sup>a</sup><p class="last">Gradient = 0%B to 100%B.</p></div><div class="footnote" id="t8Afn2"><sup>b</sup><p class="last">Gradient = 30%B to 100%B; wavelength (λ) = 220 nm; injection volume = 5 μL unless otherwise stated.</p></div><div class="footnote" id="t8Afn3"><sup>c</sup><p class="last">Col = Column where column 1 = Phenomenex-Luna C18 (4.6 × 30 mm, S10); column 2 = Phenomenex-Luna C18 (2.0 × 30 mm, 3 μm); column 3 = Phenomenex-Luna C18 (3.0 × 50 mm, S10); Column 4 = Phenomenex-Luna (4.6 × 50 mm, S10).</p></div><div class="footnote" id="t8Afn4"><sup>d</sup><p class="last">GT = gradient time (min).</p></div><div class="footnote" id="t8Afn5"><sup>e</sup><p class="last">FR = flow rate (mL/min).</p></div><div class="footnote" id="t8Afn6"><sup>f</sup><p class="last">Sol A = Solvent A where solvent A1 = 0.1% TFA/10% MeOH/90% H<sub>2</sub>O; A2 = 0.1% TFA/10% MeCN/90% H<sub>2</sub>O.</p></div><div class="footnote" id="t8Afn7"><sup>g</sup><p class="last">Sol B = Solvent B where solvent B1 = 0.1% TFA/90% MeOH/10% H<sub>2</sub>O; B2 = 0.1% TFA/90% MeCN/10% H<sub>2</sub>O.</p></div></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. HPLC Purity Conditions Used in the Characterization of All Compounds Found in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">HPLC condition<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Col<a class="ref internalNav" href="#t9fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center" char=".">GT<a class="ref internalNav" href="#t9fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center" char=".">FR<a class="ref internalNav" href="#t9fn9" aria-label="i">i</a></th><th class="colsep0 rowsep0" align="center">Sol A<a class="ref internalNav" href="#t9fn10" aria-label="j">j</a></th><th class="colsep0 rowsep0" align="center">Sol B<a class="ref internalNav" href="#t9fn11" aria-label="k">k</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method A</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method B</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method C</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method D</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method E</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method F</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method G<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method H<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method I<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method J<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method K<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method L<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method M<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method N<a class="ref internalNav" href="#t9fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method O<a class="ref internalNav" href="#t9fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method P<a class="ref internalNav" href="#t9fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method Q</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A3</td><td class="colsep0 rowsep0" align="left">B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method R</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A3</td><td class="colsep0 rowsep0" align="left">B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method S<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method T<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method U<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method V<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A1</td><td class="colsep0 rowsep0" align="left">B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Method W<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">A2</td><td class="colsep0 rowsep0" align="left">B2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Gradient = 10%B to 100%B.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Gradient = 40%B to 100%B.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">Gradient = 60%B to 100%B.</p></div><div class="footnote" id="t9fn4"><sup>d</sup><p class="last">Gradient = 70%B to 100%B.</p></div><div class="footnote" id="t9fn5"><sup>e</sup><p class="last">Gradient = 80%B to 100%B.</p></div><div class="footnote" id="t9fn6"><sup>f</sup><p class="last">Gradient = 30%B to 100%B; wavelength (λ) = 220 nm; injection volume = 5 μL unless otherwise stated.</p></div><div class="footnote" id="t9fn7"><sup>g</sup><p class="last">Col = Column where column 1 = Waters Sunfire C18 (4.6 × 150 mm, 3.5 μm); column 2 = Xbridge Phenyl (4.6 × 150 mm, 3.5 μm); column 3 = XSELECT SCH C18 (3.0 × 150 mm, 3.5 μm); column 4 = Zorbax Bonus-RP (3.0 × 150 mm, 3.5 μm); Column 5 = Sunfire C18 (3.0 × 150 mm, 3.5 μm); Column 6 = Xbridge Phenyl (3.0 × 150 mm, 3.5 μm); Column 7 = Phenomenex (4.6 × 150 mm, 5 μm C-18); Column 8 = Xbridge C18 (3.0 × 150 mm, 3.5 μm).</p></div><div class="footnote" id="t9fn8"><sup>h</sup><p class="last">GT = gradient time (min).</p></div><div class="footnote" id="t9fn9"><sup>i</sup><p class="last">FR = flow rate (mL/min).</p></div><div class="footnote" id="t9fn10"><sup>j</sup><p class="last">Sol A = Solvent A where solvent A1 = 0.1% TFA/5% ACN/95% H<sub>2</sub>O; solvent A2 = 10% MeOH/90% H<sub>2</sub>O/0.2% H<sub>3</sub>PO<sub>4</sub>; solvent A3 = 10 mM NH<sub>4</sub>HCO<sub>3</sub>/5% MeOH/95% H<sub>2</sub>0.</p></div><div class="footnote" id="t9fn11"><sup>k</sup><p class="last">Solvent B = Solvent B where solvent B1 = 0.1% TFA/95% ACN/5% H<sub>2</sub>O; solvent B2 = 90% MeOH/10% H<sub>2</sub>O/0.2% H<sub>3</sub>PO<sub>4</sub>; solvent B3 = 10 mM NH<sub>4</sub>HCO<sub>3</sub>/95% MeOH/5% H<sub>2</sub>0.</p></div></div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (1<i>S</i>,2<i>R</i>)-Ethyl 2-((<i>tert</i>-butoxycarbonyl)amino)-[1,1′-bi(cyclopropane)]-2-carboxylate (<b>31</b>)</h3><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>S</i>)-ethyl 1-(<i>tert</i>-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate (<b>30</b>, 2.4 g, 9.40 mmol) and diacetoxypalladium (120 mg, 0.535 mmol) was added 0.8 M diazomethane in ether (40 mL, 32.0 mmol) dropwise at 0 °C. The formed black suspension was stirred at 0 °C for 2 h, warmed to RT, and stirred for 2 h. The reaction was incomplete as indicated by LC/MS, and the mixture contained 50% starting material. After filtration through a Celite plug and washing with 50% ether in THF, the filtrate was concentrated to give 2.45 g of a residue that was resubjected to the cyclopropanation reaction conditions described above until no starting material was detected by LC/MS (the reaction was typically repeated 2–3 times). The resulting residue was purified by silica gel chromatography (20% EtOAc in hexanes) to provide <b>31</b> (2.08 g, 78%) as a solid that was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 4.29–4.06 (m, 2H), 1.59 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 1.44 (s, 9H), 1.30–1.23 (m, 3H), 1.20–1.13 (m, 1H), 1.11–1.01 (m, 1H), 0.81 (qt, <i>J</i> = 7.9, 4.9 Hz, 1H), 0.60–0.52 (m, 1H), 0.48–0.41 (m, 1H), 0.37–0.26 (m, 2H); LC/MS (Method A): <i>t</i><sub>R</sub> = 2.67 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>23</sub>NO<sub>4</sub>: 269.16; found: 292.26 (M + Na)<sup>+</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (1<i>S</i>,2<i>R</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-[1,1′-bi(cyclopropane)]-2-carboxylic acid (<b>32</b>)</h3><div class="NLM_p last">To a solution of <b>31</b> (36 g, 149 mmol) in MeOH (400 mL) and H<sub>2</sub>O (200 mL) was added NaOH (12.18 g, 304 mmol). After heating at reflux for 1 h, the mixture was concentrated, neutralized with 1 N HCl, and extracted with EtOAc. The combined extracts were washed with brine, dried over MgSO<sub>4</sub>, and concentrated to give crude <b>32</b> (36 g, 98%), which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 1.60–1.47 (m, 1H), 1.41 (s, 9H), 1.18–1.10 (m, 1H), 1.00 (q, <i>J</i> = 8.4 Hz, 1H), 0.85 (qt, <i>J</i> = 8.1, 4.8 Hz, 1H), 0.56–0.41 (m, 2H), 0.36–0.23 (m, 2H); LC/MS (Method P): <i>t</i><sub>R</sub> = 1.95 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>19</sub>NO<sub>4</sub>: 241.13; found: 264.27 (M + Na)<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>tert</i>-Butyl ((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamate (<b>33</b>)</h3><div class="NLM_p last">A solution of <b>32</b> (40 g, 166 mmol) and CDI (40.3 g, 249 mmol) in THF (414 mL) was heated at reflux for 2 h. After cooling to RT, cyclopropanesulfonamide (32.1 g, 265 mmol) and DBU (40.0 mL, 265 mmol) were added to the solution which was stirred overnight. After concentration, the residue was extracted with EtOAc, the extracts were washed with 1 N HCl and brine, and dried over MgSO<sub>4</sub>. The solution was filtered and concentrated, and the residual solid crystallized from EtOAc (300 mL) to yield <b>33</b> (48 g) as a white solid. The mother liquor was concentrated, and the residue was crystallized from ethyl acetate (20 mL) to yield an additional 2 g of <b>33</b>, amounting to a combined yield of 88%. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 2.96 (br. s., 1H), 1.68 (dd, <i>J</i> = 6.4, 4.4 Hz, 1H), 1.43 (s, 9H), 1.32–0.97 (m, 6H), 0.72–0.59 (m, 1H), 0.56–0.42 (m, 2H), 0.33–0.19 (m, 2H); LCMS (Method P): <i>t</i><sub>R</sub> = 1.95 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S: 344.14; found: 367.30 (M + Na)<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (1<i>S</i>,2<i>R</i>)-2-Amino-<i>N</i>-(cyclopropylsulfonyl)-[1,1′-bi(cyclopropane)]-2-carboxamide, HCl salt (<b>34</b>)</h3><div class="NLM_p last">A solution of <b>33</b> (48 g, 139 mmol) and 4 M HCl in dioxane (139 mL, 557 mmol) was stirred for 4 h. Concentration gave <b>34</b> (39.1 g, quantitative yield) as a slightly hygroscopic white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 3.06 (tt, <i>J</i> = 8.0, 4.8 Hz, 1H), 2.04–1.89 (m, 1H), 1.57–1.41 (m, 2H), 1.34–1.06 (m, 4H), 0.88–0.75 (m, 1H), 0.71–0.56 (m, 2H), 0.49–0.27 (m, 2H); LCMS (Method A): <i>t</i><sub>R</sub> = 0.18 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S: 244.08; found: 267.10 (M + Na)<sup>+</sup></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (2<i>S</i>,4<i>R</i>)-<i>tert</i>-Butyl 4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidine-1-carboxylate (<b>36</b>)</h3><div class="NLM_p last">HATU (21.58 g, 56.8 mmol) was added to a solution of <b>35</b> (20 g, 47.3 mmol), <b>34</b> (14.61 g, 52.0 mmol), and <i>i</i>-Pr<sub>2</sub>NEt (41.3 mL, 236 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and the mixture was stirred for 4 h. After concentration, the residue was purified by silica gel chromatography eluting with 20% acetone in hexanes to afford <b>36</b> (33 g, 93%) as a solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.15–8.05 (m, 2H), 7.72 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.58 (s, 1H), 5.73 (br. s., 1H), 4.40 (dd, <i>J</i> = 9.5, 7.0 Hz, 1H), 4.02 (s, 3H), 3.92–3.77 (m, 2H), 3.06–2.95 (m, 1H), 2.61–2.48 (m, 1H), 2.35–2.22 (m, 1H), 1.80 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H), 1.48 (s, 9H), 1.35–0.97 (m, 6H), 0.94–0.84 (m, 1H), 0.66–0.49 (m, 2H), 0.36 (d, <i>J</i> = 4.0 Hz, 2H); LC/MS (Method A): <i>t</i><sub>R</sub> = 2.75 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>ClN<sub>4</sub>O<sub>8</sub>S: 648.20; found: 649.25 (M + H)<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (2<i>S</i>,4<i>R</i>)-<i>tert</i>-Butyl 4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>R</i>,2<i>S</i>)-1-(ethoxycarbonyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidine-1-carboxylate (<b>38</b>)</h3><div class="NLM_p last">HATU (11.87 g, 31.2 mmol) was added to a solution of <b>35</b> (11 g, 26.0 mmol), (1<i>R</i>,2<i>S</i>)-ethyl 1-amino-2-vinylcyclopropanecarboxylate, HCl salt (<b>37</b>) (4.99 g, 26.0 mmol) and <i>i</i>-Pr<sub>2</sub>NEt (22.72 mL, 130 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and the mixture was stirred for 4 h. After concentration, the residue was purified by silica gel chromatography eluting with 20% acetone in hexanes to give <b>38</b> (13 g, 88%) as a solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.05 (d, <i>J</i> = 9.1 Hz, 1H), 8.01 (d, <i>J</i> = 2.0 Hz, 1H), 7.66 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.52 (s, 1H), 5.83–5.70 (m, 1H), 5.69–5.63 (m, 1H), 5.36–5.24 (m, 1H), 5.14–5.05 (m, 1H), 4.46–4.36 (m, 1H), 4.19–4.06 (m, 2H), 3.98 (s, 3H), 3.86 (d, <i>J</i> = 2.5 Hz, 2H), 2.70–2.56 (m, 1H), 2.39 (ddd, <i>J</i> = 13.6, 8.4, 4.9 Hz, 1H), 2.20 (q, <i>J</i> = 8.7 Hz, 1H), 1.83–1.66 (m, 1H), 1.46–1.38 (m, 10H), 1.23 (t, <i>J</i> = 7.2 Hz, 3H); LCMS (Method A): t<sub>R</sub> = 2.79 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>34</sub>ClN<sub>3</sub>O<sub>7</sub>: 559.20; found: 560.24 (M + H)<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (2<i>S</i>,4<i>R</i>)-<i>tert</i>-Butyl 4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-(ethoxycarbonyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidine-1-carboxylate (<b>39</b>)</h3><div class="NLM_p last">A solution of diazomethane in Et<sub>2</sub>O (49.1 mL, 0.8 M, 39.3 mmol) was added dropwise to a solution of <b>38</b> (2.2 g, 3.93 mmol) and diacetoxypalladium (0.220 g, 0.982 mmol) in THF (19.64 mL) maintained at 0 °C. The formed black suspension was stirred at 0 °C for 2 h, warmed to RT, and stirred overnight. After filtration through a Celite plug washed with 50% ether in THF, the filtrate was concentrated to give 2.5 g of a residue that was purified by silica gel chromatography eluting with 10–20% hexanes in acetone to provide <b>39</b> (2.0 g, 88%) as a solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.05 (d, <i>J</i> = 8.8 Hz, 1H), 8.00 (d, <i>J</i> = 1.8 Hz, 1H), 7.66 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.52 (s, 1H), 5.71–5.60 (m, 1H), 4.43–4.33 (m, 1H), 4.16 (q, <i>J</i> = 7.1 Hz, 2H), 3.98 (s, 3H), 3.88–3.80 (m, 2H), 2.68–2.54 (m, 1H), 2.37 (ddd, <i>J</i> = 13.4, 8.5, 4.8 Hz, 1H), 1.70–1.53 (m, 1H), 1.40 (s, 9H), 1.30–1.06 (m, 5H), 0.92–0.80 (m, 1H), 0.64–0.51 (m, 1H), 0.51–0.36 (m, 2H), 0.35–0.26 (m, 1H); LCMS (Method A): <i>t</i><sub>R</sub> = 2.79 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>36</sub>ClN<sub>3</sub>O<sub>7</sub>: 574.06; found: 574.27 (M + H)<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (1<i>S</i>,2<i>R</i>)-2-((2<i>S</i>,4<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)pyrrolidine-2-carboxamido)-[1,1′-bi(cyclopropane)]-2-carboxylic acid (<b>40</b>)</h3><div class="NLM_p last">A mixture of <b>39</b> (2.4 g, 4.18 mmol), NaOH (0.669 g, 16.72 mmol), MeOH (10 mL), and H<sub>2</sub>O (5 mL) was heated at reflux for 1 h. After concentration, the residue was neutralized with 1 N HCl, extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated to give crude <b>40</b> (2.283 g, quantitative yield), which was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.15–8.00 (m, 1H), 7.70 (br. s., 1H), 7.57 (br. s., 1H), 5.68 (br. s., 1H), 4.42 (br. s., 1H), 4.17–4.08 (m, 1H), 4.02 (br. s., 3H), 3.88 (br. s., 2H), 2.65 (br. s., 1H), 2.40 (br. s., 1H), 1.70–1.56 (m, 1H), 1.45 (br. s., 9H), 1.33–1.17 (m, 2H), 1.08 (d, <i>J</i> = 7.9 Hz, 1H), 0.96 (br. s., 1H), 0.67–0.42 (m, 3H), 0.38–0.26 (m, 1H); LCMS (Method A): <i>t</i><sub>R</sub> = 2.64 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>7</sub>: 545.13; found: 546.15 (M + H)<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (2<i>S</i>,4<i>R</i>)-<i>tert</i>-Butyl 4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidine-1-carboxylate (<b>36</b>)</h3><div class="NLM_p last">A solution of <b>40</b> (16.5 g, 30.2 mmol) and CDI (7.35 g, 45.3 mmol) in THF (100 mL) was heated at reflux for 2 h. After cooling to RT, cyclopropanesulfonamide (5.86 g, 48.4 mmol) and DBU (7.29 mL, 48.4 mmol) were added to the mixture. The resulting solution was stirred overnight and concentrated, and the residue was acidified with 1 N HCl. The mixture was extracted with EtOAc, and the combined extracts were dried over MgSO<sub>4</sub>, concentrated, and purified by silica gel chromatography eluting with 20% acetone in hexanes to yield <b>36</b> (18.6 g, 94%) as a solid.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (2<i>S</i>,4<i>R</i>)-4-((7-Chloro-4-methoxyisoquinolin-1-yl)oxy)-<i>N</i>-((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)pyrrolidine-2-carboxamide HCl salt (<b>41</b>)</h3><div class="NLM_p last">A solution of <b>36</b> (2.6 g, 4.01 mmol) and 4 M HCl in dioxane (8 mL, 32.0 mmol) was stirred for 4 h. Concentration in vacuo gave <b>41</b> (2.348 g, quantitative yield) as the HCl salt which was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.29 (s, 1H), 8.15 (d, <i>J</i> = 8.9 Hz, 1H), 7.79–7.72 (m, 1H), 7.59 (s, 1H), 5.90 (br. s., 1H), 4.73–4.65 (m, 1H), 4.03 (s, 3H), 3.90–3.74 (m, 2H), 3.09–2.98 (m, 1H), 2.90 (dd, <i>J</i> = 14.2, 7.5 Hz, 1H), 2.43–2.32 (m, 1H), 1.88–1.79 (m, 1H), 1.37–1.03 (m, 6H), 0.84–0.73 (m, 1H), 0.64–0.49 (m, 2H), 0.41–0.29 (m, 2H); LCMS (Method A): <i>t</i><sub>R</sub> = 1.70 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>ClN<sub>4</sub>O<sub>6</sub>S: 548.15; found: 549.04 (M + H)<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>tert</i>-Butyl ((<i>S</i>)-2-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)carbamate (<b>42</b>)</h3><div class="NLM_p last">HATU (2.84 g, 7.48 mmol) was added to a solution of <b>41</b> (3.1 g, 4.98 mmol), (<i>S</i>)-2-(<i>tert</i>-butoxycarbonylamino)-2-cyclohexylacetic acid (1.411 g, 5.48 mmol) and <i>i</i>-Pr<sub>2</sub>NEt (4.35 mL, 24.92 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the mixture was stirred for 4 h. After concentration, the residue was purified by silica gel chromatography eluting with 30% acetone in hexanes to afford <b>42</b> (3.6 g, 92%) as a solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.16–8.04 (m, 2H), 7.69 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.58 (s, 1H), 5.81 (br. s., 1H), 4.63–4.47 (m, 2H), 4.09–3.96 (m, 5H), 3.05–2.94 (m, 1H), 2.56 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.37–2.25 (m, 1H), 1.87–1.62 (m, 7H), 1.37–0.82 (m, 22H), 0.65–0.46 (m, 2H), 0.40–0.25 (m, 2H); LCMS (Method A): <i>t</i><sub>R</sub> = 2.97 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>38</sub>H<sub>50</sub>ClN<sub>5</sub>O<sub>9</sub>S: 787.30; found: 788.30 (M + H)<sup>+</sup>.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (2<i>S</i>,4<i>R</i>)-1-((<i>S</i>)-2-Amino-2-cyclohexylacetyl)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-<i>N</i>-((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)pyrrolidine-2-carboxamide HCl salt (<b>43</b>)</h3><div class="NLM_p last">A solution of <b>42</b> (24 g, 30.4 mmol) and 4 M HCl in dioxane (122 mL) was stirred for 4 h. Concentration provided <b>43</b> (22.03 g, quantitative yield) as the HCl salt that was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.14–8.05 (m, 2H), 7.72 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.56 (s, 1H), 5.86 (br. s., 1H), 4.64 (dd, <i>J</i> = 10.4, 6.9 Hz, 1H), 4.23–4.15 (m, 1H), 4.14–4.05 (m, 2H), 3.99 (s, 3H), 3.05–2.93 (m, 1H), 2.69–2.54 (m, 1H), 2.33 (ddd, <i>J</i> = 14.1, 10.2, 4.4 Hz, 1H), 2.01–1.65 (m, 7H), 1.40–1.04 (m, 11H), 0.89–0.77 (m, 1H), 0.64–0.45 (m, 2H), 0.38–0.24 (m, 2H); LCMS (Method A): <i>t</i><sub>R</sub> = 1.89 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>42</sub>ClN<sub>5</sub>O<sub>7</sub>S: 687.24; found: 688.25 (M + H)<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl ((<i>S</i>)-2-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)carbamate (<b>29</b>)</h3><div class="NLM_p last">A solution of <b>43</b> (3.476 g, 4.33 mmol), <i>i</i>-Pr<sub>2</sub>NEt, (3.78 mL, 21.66 mmol), and (<i>R</i>)-pyridin-2-yl 1,1,1-trifluoropropan-2-yl carbonate (1.223 g, 5.20 mmol) (<b>44</b>) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was stirred overnight. After concentration, the residue was purified by silica gel chromatography eluting with 25–33% acetone in hexanes to give <b>29</b> (3.50 g, 98%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.37 (s, 1 H), 8.89 (br. s., 1H), 8.09 (d, <i>J</i> = 1.94 Hz, 1H), 8.07 (d, <i>J</i> = 9.16 Hz, 1H)), 7.95 (d, <i>J</i> = 5.55 Hz, 1H), 7.79 (dd, <i>J</i> = 9.02, 2.08 Hz, 1H), 7.66 (s, 1H), 5.72 (br. s., 1H), 4.78 (ddd, <i>J</i> = 13.46, 6.66, 6.52 Hz, 1H), 4.36–4.47 (m, 2H), 3.97 (s, 3H), 3.82–3.93 (m, 2H), 2.90–3.00 (m, 1H), 2.45 (dd, <i>J</i> = 13.59, 6.66 Hz, 1H), 2.15–2.26 (m, 1H), 1.82 (d, <i>J</i> = 11.65 Hz, 1 H), 1.73 (t, <i>J</i> = 12.21 Hz, 2H), 1.50–1.68 (m, 4H), 1.17 (d, <i>J</i> = 6.38 Hz, 3H), 1.07–1.15 (m, 5H), 0.82–1.03 (m, 6H), 0.64–0.78 (m, 1H), 0.38–0.57 (m, 2H), 0.16–0.29 (m, 2H); HPLC purity (retention time): 100% (13.90 min, method U); 100% (11.30 min, method V); LCMS (Method A): <i>t</i><sub>R</sub> = 3.06 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>45</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 828.29; found: 850.46 (M + Na)<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>tert</i>-Butyl (<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>8</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.13–8.02 (m, 2H), 7.69 (d, <i>J</i> = 8.3 Hz, 1H), 7.58 (s, 1H), 5.81 (br. s., 1H), 4.62–4.50 (m, 1H), 4.44 (d, <i>J</i> = 11.5 Hz, 1H), 4.20 (d, <i>J</i> = 9.5 Hz, 1H), 4.09–3.95 (m, 4H), 3.04–2.94 (m, 1H), 2.58 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.35–2.21 (m, 1H), 1.78 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.34–0.97 (m, 24H), 0.91–0.80 (m, 1H), 0.64–0.47 (m, 2H), 0.38–0.26 (m, 2H); HPLC purity (retention time): 96.7% (16.3 min, method P); 96.3% (17.7 min, method J); LCMS (Method J): <i>t</i><sub>R</sub> = 3.39 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>48</sub>ClN<sub>5</sub>O<sub>9</sub>S: 761.29; found: 762.65 (M + H)<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Isopropyl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((7-Chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>9</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.15–8.06 (m, 2H), 7.70 (dd, <i>J</i> = 8.9, 1.9 Hz, 1H), 7.58 (s, 1H), 5.81 (br. s., 1H), 4.59–4.42 (m, 2H), 4.29–4.22 (m, 1H), 4.09–3.99 (m, 4H), 3.04–2.95 (m, 1H), 2.59 (dd, <i>J</i> = 13.8, 7.0 Hz, 1H), 2.34–2.22 (m, 1H), 1.78 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.38–0.81 (m, 23H), 0.64–0.48 (m, 2H), 0.33 (d, J = 4.5 Hz, 2H); HPLC purity (retention time): 99.4% (13.67 min, method R); 100% (13.01 min, method Q); LCMS (Method L): <i>t</i><sub>R</sub> = 2.43 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>46</sub>ClN<sub>5</sub>O<sub>9</sub>S: 747.27; found: 748.34 (M + H)<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Cyclobutyl (<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)-bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>10</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 9.01 (s, 1H), 8.16–8.07 (m, 2H), 7.72 (dd, <i>J</i> = 8.9, 1.9 Hz, 1H), 7.59 (s, 1H), 5.82 (br. s., 1H), 4.61–4.50 (m, 2H), 4.43 (d, <i>J</i> = 11.5 Hz, 1H), 4.24 (s, 1H), 4.10–4.01 (m, 4H), 3.06–2.95 (m, 1H), 2.60 (dd, <i>J</i> = 13.8, 6.8 Hz, 1H), 2.35–2.23 (m, 1H), 2.14 (br. s., 1H), 2.09–1.98 (m, 1H), 1.98–1.90 (m, 1H), 1.90–1.82 (m, 1H), 1.79 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.74–1.63 (m, 1H), 1.55–1.43 (m, 1H), 1.32–1.22 (m, 3H), 1.18–1.09 (m, 3H), 1.06 (s, 9H), 0.92–0.79 (m, 1H), 0.65–0.49 (m, 2H), 0.34 (d, <i>J</i> = 3.8 Hz, 2H); HPLC purity (retention time): 97.9% (14.3 min, method K); 97.4% (14.3 min, method L); LCMS (Method J): <i>t</i><sub>R</sub> = 2.86 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>46</sub>ClN<sub>5</sub>O<sub>9</sub>S: 759.27; found: 760.41 (M + H)<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Cyclopentyl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((7-Chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>11</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.15–8.05 (m, 2H), 7.70 (d, <i>J</i> = 8.8 Hz, 1H), 7.58 (s, 1H), 5.81 (br. s., 1H), 4.67 (br. s., 1H), 4.61–4.51 (m, 1H), 4.43 (d, <i>J</i> = 12.0 Hz, 1H), 4.25 (s, 1H), 4.09–3.99 (m, 4H), 3.05–2.92 (m, 1H), 2.59 (dd, <i>J</i> = 13.4, 6.9 Hz, 1H), 2.35–2.20 (m, 1H), 1.82–0.78 (m, 25H), 0.65–0.48 (m, 2H), 0.33 (d, <i>J</i> = 4.5 Hz, 2H); HPLC purity (retention time): 98.9% (10.5 min, method O); 98.8% (13.4 min, method F); LCMS (Method H): <i>t</i><sub>R</sub> = 3.28 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>48</sub>ClN<sub>5</sub>O<sub>9</sub>S: 773.29; found: 774.03 (M + H)<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-Methylcyclopentyl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>12</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.12 (d, <i>J</i> = 8.8 Hz, 1H), 8.07 (d, <i>J</i> = 1.8 Hz, 1H), 7.71 (d, <i>J</i> = 8.8 Hz, 1H), 7.60 (s, 1H), 5.81 (br. s., 1H), 4.63–4.42 (m, 2H), 4.25–4.19 (m, 1H), 4.11–3.99 (m, 4H), 3.02–2.96 (m, 1 H); 2.59 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.39–2.23 (m, 1H), 1.89 (d, <i>J</i> = 9.0 Hz, 1H), 1.83–0.98 (m, 25H), 0.94–0.83 (m, 2H), 0.65–0.50 (m, 2H), 0.34 (d, J = 2.5 Hz, 2H); HPLC purity (retention time): 99.2% (11.8 min, method O); 100% (13.8 min, method F); LC/MS (Method H): <i>t</i><sub>R</sub> = 3.40 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>38</sub>H<sub>50</sub>ClN<sub>5</sub>O<sub>9</sub>S: 787.30; found: 809.90 (M + Na)<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (1<i>R</i>,3<i>r</i>,5<i>S</i>)-Bicyclo[3.1.0]hexan-3-yl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>13</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.02–8.14 (m, 2H), 7.67 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.54 (s, 1H), 6.87 (d, <i>J</i> = 9.3 Hz, 1H), 5.76 (br. s., 1H), 4.68 (t, <i>J</i> = 6.9 Hz, 1H), 4.52 (dd, <i>J</i> = 10.4, 6.9 Hz, 1H), 4.37 (d, <i>J</i> = 11.8 Hz, 1H), 4.21 (d, <i>J</i> = 9.6 Hz, 1H), 3.93–4.11 (m, 5H), 2.93–3.01 (m, 1H), 2.56 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.19–2.31 (m, 1H), 1.92–2.04 (m, 1H), 1.71–1.88 (m, 2H), 1.66 (d, <i>J</i> = 14.6 Hz, 1H), 1.40 (d, J = 14.6 Hz, 1H), 1.03–1.33 (m, 10H), 0.91–1.03 (m, 10H), 0.83 (ddt, <i>J</i> = 12.7, 8.2, 4.0 Hz, 2H); HPLC purity (retention time): 99% (13.89 min, method S); 97% (10.34 min, method T); LC/MS (Method J): <i>t</i><sub>R</sub> = 3.01 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>38</sub>H<sub>48</sub>ClN<sub>5</sub>O<sub>9</sub>S: 786.33; found: 786.16 (M + H)<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1,1,1-Trifluoro-2-methylpropan-2-yl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)-bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>14</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.14–8.03 (m, 2H), 7.70 (dd, <i>J</i> = 9.0, 2.0 Hz, 1H), 7.59 (s, 1H), 5.80 (br. s., 1H), 4.58 (dd, <i>J</i> = 10.5, 6.8 Hz, 1H), 4.44 (d, <i>J</i> = 11.8 Hz, 1H), 4.17 (s, 1H), 4.09–3.96 (m, 4H), 3.04–2.94 (m, 1H), 2.59 (dd, <i>J</i> = 13.8, 6.8 Hz, 1H), 2.34–2.21 (m, 1H), 1.78 (dd, <i>J</i> = 8.2, 5.4 Hz, 1H), 1.43–0.99 (m, 21H), 0.92–0.79 (m, 1H), 0.57 (dd, <i>J</i> = 18.4, 8.2 Hz, 2H), 0.33 (d, J = 4.5 Hz, 2H); HPLC purity (retention time): 95% (15.6 min, method E); 97.1% (13.6 min, method F); LC/MS (Method O): <i>t</i><sub>R</sub> = 4.23 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>45</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 815.25; found: 816.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1,1-Difluoro-2-methylpropan-2-yl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)-bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>15</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.12–8.03 (m, 2H), 7.69 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.58 (s, 1H), 5.77 (br. s., 1H), 4.58 (dd, <i>J</i> = 10.5, 6.8 Hz, 1H), 4.47 (d, <i>J</i> = 11.5 Hz, 1H), 4.15 (d, <i>J</i> = 8.8 Hz, 1H), 4.06–3.98 (m, 4H), 3.04–2.94 (m, 1H), 2.64–2.55 (m, 1H), 2.33–2.22 (m, 1H), 1.78 (dd, <i>J</i> = 8.3, 5.3 Hz, 1H), 1.33–1.22 (m, 3H), 1.20–0.99 (m, 19H), 0.90–0.80 (m, 1H), 0.64–0.48 (m, 2H), 0.35–0.30 (m, 2H); HPLC purity (retention time): 96.3% (14.9 min, method N); 98.4% (13.2 min, method F); LCMS (Method J): <i>t</i><sub>R</sub> = 2.90 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>46</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>9</sub>S: 797.26; found: 798.37 (M + H)<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2,2,2-Trifluoroethyl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)-bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>16</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.16–8.02 (m, 2H), 7.68 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.55 (s, 1H), 5.79–5.74 (m, 1H), 5.47 (s, 1H), 4.51 (dd, <i>J</i> = 10.6, 7.1 Hz, 1H), 4.44–4.30 (m, 2H), 4.24 (s, 1H), 4.23–4.13 (m, 1H), 4.05–3.97 (m, 4H), 3.01–2.90 (m, 1H), 2.58 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.23 (ddd, <i>J</i> = 13.9, 10.3, 4.3 Hz, 1H), 1.75 (dd, <i>J</i> = 8.2, 5.4 Hz, 1H), 1.31–1.18 (m, 3H), 1.14–1.01 (m, 11H), 0.86–0.75 (m, 1H), 0.61–0.46 (m, 2H), 0.29 (q, <i>J</i> = 4.6 Hz, 2H); HPLC purity (retention time): 98.7% (14.57 min, method E); 100% (12.83 min, method F); LCMS (Method E): <i>t</i><sub>R</sub> = 3.04 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>41</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 787.23; found: 788.30 (M + H)<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-1,1,1-Trifluoropropan-2-yl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)-bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>17</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.13–8.08 (m, 2H), 7.70 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.58 (s, 1H), 5.79 (br. s., 1H), 4.99–4.90 (m, 1H), 4.55 (dd, <i>J</i> = 10.3, 7.0 Hz, 1H), 4.44 (d, J = 11.8 Hz, 1H), 4.29–4.23 (m, 1H), 4.07–4.00 (m, 4H), 2.99 (tt, <i>J</i> = 8.0, 4.8 Hz, 1H), 2.61 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.27 (ddd, <i>J</i> = 14.0, 10.4, 4.3 Hz, 1H), 1.78 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.33–1.22 (m, 4H), 1.18–1.03 (m, 14H), 0.87–0.79 (m, 1H), 0.63–0.50 (m, 2H), 0.35–0.28 (m, 2H); HPLC purity (retention time): 95.7% (14.1 min, method R); 95.5% (13.5 min, method Q); LCMS (Method E): <i>t</i><sub>R</sub> = 3.05 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd C<sub>35</sub>H<sub>43</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 801.24; found: 802.14 (M + H)<sup>+</sup>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>18</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.17–8.06 (m, 2H), 7.70 (dd, <i>J</i> = 9.0, 2.0 Hz, 1H), 7.58 (s, 1H), 5.81 (br. s., 1H), 4.56 (dd, <i>J</i> = 10.4, 6.9 Hz, 1H), 4.46 (d, <i>J</i> = 11.8 Hz, 1H), 4.27 (s, 1H), 4.09–3.98 (m, 4H), 3.06–2.94 (m, 1H), 2.61 (dd, <i>J</i> = 13.8, 7.0 Hz, 1H), 2.35–2.22 (m, 1H), 1.79 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.35–1.21 (m, 7H), 1.18–1.04 (m, 11H), 0.90–0.73 (m, 1H), 0.65–0.48 (m, 2H), 0.33 (d, J = 4.5 Hz, 2H); HPLC purity (retention time): 97.9% (9.6 min, method O); 96.9% (12.4 min, method N); LC/MS (Method J): <i>t</i><sub>R</sub> = 2.92 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 801.24; found: 802.19 (M + H)<sup>+</sup>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-(<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)bi(cyclopropan)-2-ylcarbamoyl)-4-(3,6-dimethoxyisoquinolin-1-yloxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (<b>19</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.88 (d, <i>J</i> = 9.1 Hz, 1H), 7.00 (d, <i>J</i> = 2.3 Hz, 1H), 6.81 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 6.53 (s, 1H), 5.83–5.78 (m, 1H), 4.93–4.87 (m, 1H), 4.48 (dd, <i>J</i> = 10.3, 7.1 Hz, 1H), 4.41 (d, <i>J</i> = 11.3 Hz, 1H), 4.30 (s, 1H), 4.04 (dd, <i>J</i> = 11.7, 3.7 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.01–2.92 (m, 1H), 2.57 (dd, <i>J</i> = 13.8, 7.1 Hz, 1H), 2.24 (ddd, <i>J</i> = 13.8, 10.1, 4.3 Hz, 1H), 1.75 (dd, <i>J</i> = 8.1, 5.3 Hz, 1H), 1.30–1.18 (m, 6H), 1.14–0.99 (m, 12H), 0.88–0.75 (m, 1H), 0.62–0.45 (m, 2H), 0.35–0.22 (m, 2H); HPLC purity (retention time): 100% (13.89 min, method A); 100% (12.72 min, method B); LCMS (Method F): <i>t</i><sub>R</sub> = 3.11 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>46</sub>F<sub>3</sub>N<sub>5</sub>O<sub>10</sub>S: 797.29; found: 798.46 (M + H)<sup>+</sup>.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (R)-1,1,1-Trifluoropropan-2-yl ((S)-1-((2<i>S</i>,4<i>R</i>)-4-((5-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>20</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.10 (dd, <i>J</i> = 8.3, 1.3 Hz, 1H), 7.73 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.64 (s, 1H), 7.41 (t, <i>J</i> = 7.9 Hz, 1H), 5.79–5.75 (m, 1H), 4.73 (quin, <i>J</i> = 6.7 Hz, 1H), 4.50 (dd, <i>J</i> = 10.4, 7.2 Hz, 1H), 4.41 (d, <i>J</i> = 11.3 Hz, 1H), 4.24 (s, 1H), 4.01 (dd, <i>J</i> = 11.7, 3.7 Hz, 1H), 3.93 (s, 3H), 3.02–2.92 (m, 1H), 2.56 (dd, <i>J</i> = 13.7, 7.2 Hz, 1H), 2.24 (ddd, <i>J</i> = 13.9, 10.3, 4.3 Hz, 1H), 1.75 (dd, <i>J</i> = 8.1, 5.3 Hz, 1H), 1.30–1.19 (m, 6H), 1.14–1.05 (m, 3H), 1.02 (s, 9H), 0.88–0.75 (m, 1H), 0.62–0.45 (m, 2H), 0.29 (q, <i>J</i> = 4.8 Hz, 2H); HPLC purity (retention time): 100% (14.76 min, method E); 100% (12.99 min, method F); LCMS (Method D): <i>t</i><sub>R</sub> = 2.28 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 801.24; found: 802.22 (M + H)<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (R)-1,1,1-Trifluoropropan-2-yl ((S)-1-((2<i>S</i>,4<i>R</i>)-4-((6-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>21</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.19–7.97 (m, 2H), 7.57 (s, 1H), 7.47 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 5.77 (br. s., 1H), 4.82–4.72 (m, 1H), 4.50 (dd, <i>J</i> = 10.2, 6.9 Hz, 1H), 4.39 (d, <i>J</i> = 12.1 Hz, 1H), 4.24 (s, 1H), 4.08–3.96 (m, 4H), 3.02–2.90 (m, 1H), 2.56 (dd, <i>J</i> = 13.5, 7.2 Hz, 1H), 2.23 (ddd, <i>J</i> = 14.0, 10.2, 4.3 Hz, 1H), 1.75 (dd, <i>J</i> = 8.1, 5.3 Hz, 1H), 1.34–1.18 (m, 6H), 1.15–0.97 (m, 12H), 0.88–0.75 (m, 1H), 0.53 (dd, <i>J</i> = 18.5, 8.4 Hz, 2H), 0.29 (d, <i>J</i> = 4.8 Hz, 2H); HPLC purity (retention time): 100% (14.04 min, method S); 100% (10.32 min, method T); LC/MS (Method A): tR = 2.97 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>ClF<sub>3</sub>N5O<sub>9</sub>S: 801.24; found: 802.38 (M + H)<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl ((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)-4-((5,7-dichloro-4-methoxyisoquinolin-1-yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (<b>22</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 9.01 (b, 1H), 8.12 (d, <i>J</i> = 2.0 Hz, 1H), 7.78 (d, <i>J</i> = 2.3 Hz, 1H), 7.71 (s, 1H), 5.80 (br. s., 1H), 4.56 (dd, <i>J</i> = 10.3, 7.0 Hz, 1H), 4.48 (d, <i>J</i> = 11.8 Hz, 1H), 4.22 (s, 1H), 4.03 (dd, <i>J</i> = 11.8, 3.5 Hz, 1H), 3.97 (s, 3H), 3.04–2.96 (m, 1H), 2.61 (dd, <i>J</i> = 13.4, 6.9 Hz, 1H), 2.29 (ddd, <i>J</i> = 13.9, 10.3, 4.1 Hz, 1H), 1.79 (dd, <i>J</i> = 7.9, 5.4 Hz, 1H), 1.38–1.22 (m, 5H), 1.18–1.00 (m, 11H), 0.93–0.77 (m, 1H), 0.66–0.49 (m, 2H), 0.38–0.27 (m, 2H); HPLC purity (retention time): 97.2% (17.8 min, method I); 97.5% (27.4 min, method W); LC/MS (Method C): <i>t</i><sub>R</sub> = 2.93 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>42</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 835.20; found: 836.10 (M + H)<sup>+</sup>.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-((<i>S</i>)-2-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclopropyl-2-oxoethyl)carbamate (<b>23</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.14 (d, <i>J</i> = 1.8 Hz, 1H), 8.04–8.11 (m, 1H), 7.67 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.53 (s, 1H), 5.77 (br. s., 1H), 4.78–4.83 (m, 1H), 4.53 (dd, <i>J</i> = 10.3, 7.1 Hz, 1H), 4.40 (d, <i>J</i> = 11.3 Hz, 1H), 3.93–4.04 (m, 4H), 3.73 (d, <i>J</i> = 9.1 Hz, 1H), 3.31–3.35 (m, 4H), 3.18–3.27 (m, 2H), 3.11 (dt, <i>J</i> = 3.3, 1.6 Hz, 1H), 2.94–3.03 (m, 1H), 2.55 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.29 (ddd, <i>J</i> = 14.0, 10.2, 4.3 Hz, 1H), 1.78 (dd, <i>J</i> = 7.7, 4.9 Hz, 1H), 1.02–1.32 (m, 12H); HPLC purity (retention time): 100% (12.07 min, method U); 100% (10.10 min, method V); LCMS (Method N): <i>t</i><sub>R</sub> = 2.79 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>39</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 786.21; found: 786.20 (M + H)<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (2<i>R</i>)-1,1,1-Trifluoropropan-2-yl-<i>N-</i>[(2<i>S</i>)-1-[(2<i>S</i>,4<i>R</i>)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-2-{[(1<i>R</i>,2<i>S</i>)-1-[(cyclopropanesulfonyl)carbamoyl]-2-cyclopropylcyclopropyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (<b>24</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-d4) δ 8.15–8.04 (m, 2H), 7.68 (d, <i>J</i> = 8.5 Hz, 1H), 7.56 (s, 1H), 5.80 (br. s., 1H), 4.78–4.71 (m, 1H), 4.60–4.51 (m, 2H), 4.05–3.97 (m, 5H), 3.04–2.94 (m, 1H), 2.58 (dd, <i>J</i> = 13.9, 6.9 Hz, 1H), 2.31 (ddd, <i>J</i> = 14.0, 10.4, 4.3 Hz, 1H), 2.16–2.05 (m, 1H), 1.80 (dd, <i>J</i> = 8.0, 5.0 Hz, 1H), 1.33–1.27 (m, 2H), 1.26–1.20 (m, 4H), 1.16–1.08 (m, 3H), 0.99 (t, <i>J</i> = 6.7 Hz, 6H), 0.92–0.82 (m, 1H), 0.64–0.56 (m, 1H), 0.56–0.48 (m, 1H), 0.39–0.28 (m, 2H); HPLC purity (retention time): 98.4% (14.2 min, method K); 98.2% (14.2 min, method L); LC/MS (Method J): <i>t</i><sub>R</sub> = 2.84 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>41</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 787.23; found: 788.15 (M + H)<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-(2<i>S</i>,3<i>R</i>)-1-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxopentan-2-ylcarbamate (<b>25</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.13–8.07 (m, 2H), 7.68 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.57 (s, 1H), 5.80 (t, <i>J</i> = 3.1 Hz, 1H), 4.76–4.67 (m, 1H), 4.60–4.52 (m, 2H), 4.10–4.04 (m, 1H), 4.04–3.97 (m, 4H), 3.04–2.96 (m, 1H), 2.59 (dd, <i>J</i> = 13.6, 6.8 Hz, 1H), 2.31 (ddd, <i>J</i> = 13.9, 10.3, 4.1 Hz, 1H), 1.91 (dt, <i>J</i> = 9.3, 6.6 Hz, 1H), 1.80 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.68–1.54 (m, 1H), 1.36–1.06 (m, 10H), 0.99–0.80 (m, 7H), 0.64–0.48 (m, 2H), 0.38–0.27 (m, 2H); HPLC purity (retention time): 95.0% (15.2 min, method L); 97.4% (13.5 min, method Q); LCMS (Method J): <i>t</i><sub>R</sub> = 2.96 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 801.24; found: 802.30 (M + H)<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-(<i>S</i>)-2-((2<i>S</i>,4<i>R</i>)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-((1<i>S</i>,2<i>R</i>)-2-(cyclopropylsulfonylcarbamoyl)bi(cyclopropan)-2-ylcarbamoyl)pyrrolidin-1-yl)-1-cyclobutyl-2-oxoethylcarbamate (<b>26</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.18–7.94 (m, 2H), 7.68 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.57 (s, 1H), 5.86–5.75 (m, 1H), 4.60–4.47 (m, 2H), 4.32 (d, <i>J</i> = 9.3 Hz, 1H), 4.11–3.96 (m, 4H), 2.84–2.72 (m, 1H), 2.58 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.30 (ddd, <i>J</i> = 13.9, 10.2, 4.3 Hz, 1H), 2.13–1.99 (m, 2H), 1.94–1.75 (m, 5H), 1.45–1.06 (m, 11H), 0.93–0.79 (m, 1H), 0.65–0.48 (m, 2H), 0.39–0.26 (m, 2H); HPLC purity (retention time): 95.5% (14.7 min, method N); 95.2% (15.8 min, method E); LCMS (Method J): <i>t</i><sub>R</sub> = 2.93 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>41</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 799.22; found: 800.38 (M + H)<sup>+</sup>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-((<i>S</i>)-1-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-3-ethyl-1-oxopentan-2-yl)carbamate (<b>27</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (MeOH-<i>d</i><sub>4</sub>) δ 8.03–8.11 (m, 2H), 7.66 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.53–7.57 (m, 1H), 5.77 (br. s., 1H), 4.63–4.71 (m, 1H), 4.49–4.58 (m, 2H), 4.25 (d, <i>J</i> = 9.3 Hz, 1H), 3.96–4.02 (m, 4H), 2.93–3.00 (m, 1H), 2.56 (dd, <i>J</i> = 13.8, 6.8 Hz, 1H), 2.24–2.33 (m, 1H), 1.74–1.86 (m, 2H), 1.54–1.02 (m, 16H), 1.00–1.15 (m, 8H); HPLC purity (retention time): 99% (14.30 min, method S); 99% (10.53 min, method T); LC/MS (Method A): <i>t</i><sub>R</sub> = 2.93 min; LC/MS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>45</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 816.28; found: 838.31 (M + Na)<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>R</i>)-1,1,1-Trifluoropropan-2-yl-((<i>S</i>)-2-((2<i>S</i>,4<i>R</i>)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1<i>S</i>,2<i>R</i>)-2-((cyclopropylsulfonyl)carbamoyl)-[1,1′-bi(cyclopropan)]-2-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclopentyl-2-oxoethyl)carbamate (<b>28</b>)</h3><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.02–8.17 (m, 2H), 7.66 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 7.54 (s, 1H), 5.73–5.80 (m, 1H), 4.47–4.73 (m, 3H), 3.90–4.17 (m, 5H), 2.93–3.02 (m, 1H), 2.56 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.21–2.37 (m, 2H), 1.69–1.87 (m, 3H), 1.45–1.69 (m, 5H), 1.35 (br. s., 1H), 1.02–1.31 (m, 14H); HPLC purity (retention time): 98% (13.39 min, method U); 98% (11.02 min, method V); LC/MS (Method A): <i>t</i><sub>R</sub> = 2.95 min; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>43</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>9</sub>S: 814.27; found: 814.53 (M + H)<sup>+</sup>.</div><div id="sec5_34_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Isolated Perfused Rabbit Heart</h4><div class="NLM_p">Hearts were excised from anesthetized rabbits and perfused in a retrograde manner through the aorta at a constant pressure and temperature (37 ± 0.2 °C) with oxygenated Krebs-Henseleit bicarbonate buffer. A bipolar ECG was recorded via electrodes connected to an ECG amplifier, and a pair of recording electrodes were placed on the epicardium of the left atrium and pair of stimulating electrodes was placed on the epicardium of the right atrium for atrial stimulation. Flow of the perfusate through the coronary arteries was monitored and recorded via an extracorporeal flow probe. The atrial electrogram, ECG and coronary flow were continuously monitored and recorded via a Po-Neh-Mah physiology platform. Data were expressed as mean ± SD and were compared using student <i>t</i> test.</div><div class="NLM_p last">The primary end point of the studies was SA node function; the secondary end points were cardiac conduction (A-V conduction, QRS duration), QT interval, and coronary flow. SA node function was evaluated by measuring SA node recovery time (SNRT) and sinus rate (HR). SNRT was defined as the longest A<sub>1</sub>–A<sub>2</sub> cycle length after atrial pacing. In some experiments, test agents were perfused at different concentrations in ascending order in each heart. Each concentration was perfused for 10 min without washout between concentrations. All parameters were measured at baseline and after 10 min perfusion at each concentration. Data were averaged from 1 min recording at baseline and after 10 min perfusion at each dose. To study the effects of a single concentration of test agent over a longer time period, rabbit hearts were perfused for 1 h with test agent and data were analyzed every 10 min throughout the perfusion period.</div></div><div id="sec5_34_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Anesthetized Rabbit Electrophysiology</h4><div class="NLM_p last">Rabbits were anesthetized with propofol-fentanyl and a decapolar electrode catheter was inserted into the heart with the distal electrode placed in the right ventricle (RV) and the proximal electrode located in the right atrium (RA). The femoral artery was cannulated for measuring blood pressure and to take blood samples. The primary end point was SA node function reflected by SA node recovery time (SNRT) and sinus rate (HR). SNRT is defined as the longest A<sub>1</sub>-A<sub>2</sub> cycle length after atrial pacing. A<sub>1</sub> represents the last beat of an atrial pacing train, and A<sub>2</sub> the first spontaneous sinus beat after pacing. The secondary end points were cardiac conduction (A-V conduction, QRS duration) and QT interval. The atrial and His-bundle electrograms were continuously monitored and recorded via intracardiac leads that were connected to Prucka CardioLab 7000. Body surface ECG (lead II and III) and arterial blood pressure (BP) were continuously monitored and recorded at 500 Hz via Po-Neh-Mah at a logging rate of 10 s. Compound <b>29</b> was intravenously infused at 30 mg/kg, via an infusion pump over 10 min. Blood samples were taken at 5 min during the infusion and immediately at the end of the infusion; and then at 10, 20, 40, and 60 min after the end of the infusion. PEG400: ethanol (9:1) was used as the vehicle. Data were averaged from a 1 min recording interval immediately before blood sampling and are expressed as the mean ± SEM. Data were compared with vehicle control using student <i>t</i> test. In addition to blood samples, liver and heart (atrium and ventricle) samples were collected at the end of the observations for <b>29</b> concentration analyses.</div></div><div id="sec5_34_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> In Vivo Pharmacokinetic Studies</h4><div class="NLM_p last">All animal studies were performed under the approval of the Bristol-Myers Squibb Animal Care and Use Committee and in accordance with the American Association for Accreditation of Laboratory Animal Care (AAALAC).</div></div><div id="sec5_34_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Mouse PK Studies</h4><div class="NLM_p last">The pharmacokinetic parameters of compound <b>29</b> were characterized in male FVB mice (Harlan Breeding Laboratories, Indianapolis, IN). Mice dosed orally were fasted overnight, while those intravenously dosed were not fasted. Two groups of mice (<i>N</i> = 9 per group, 20–25 g) received drug either as an intravenous (IV) bolus dose (2 mg/kg; vehicle of PEG-400/ethanol, 9:1) via the tail vein or by oral gavage (5 mg/kg; vehicle of PEG 400/ethanol, 9:1). Serum concentrations were measured at 0.05 (IV only), 0.25 (PO only), 0.5, 1, 3, 6, 8, and 24 h following dosing. Serum samples were stored at −20 °C until analysis by LC/MS/MS for <b>29</b>. To evaluate tissue exposure, livers and brains were removed from the FVB mice at the terminal sampling points for each group (6, 8, and 24 h). The excised tissues were rinsed, blotted dry, weighed and stored at −20 °C until processed for analysis by LC/MS/MS for <b>29</b>.</div></div><div id="sec5_34_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Rat PK Studies</h4><div class="NLM_p last">Male Sprague–Dawley rats (300–350 g, Hilltop Lab Animals, Inc., Scottsdale, PA) with single or dual indwelling cannulae implanted in the jugular vein were used in the pharmacokinetic studies of compounds <b>18</b>, <b>28</b> and <b>29</b>. Rats dosed orally were fasted overnight, while those intravenously dosed were not fasted. Drugs were administered to rats (N = 3 per group) as a 10 min infusion (5 mg/kg) via jugular vein cannula or orally by gavage (15 mg/kg). The vehicle used for dosing both IV and PO was PEG-400/ethanol (9:1). Serial blood samples were obtained from the jugular vein cannulae of all animals at 0 (predose) and at 0.17 (or 0.25 for oral), 0.5, 0.75, 1, 2, 4, 6, 8, 24 h postdose. These samples (∼0.3 mL) were collected into K<sub>3</sub>EDTA-containing tubes and then centrifuged at 4 °C (1500–2000<i>g</i>) to obtain plasma, which was stored at −20 °C until analysis by LC/MS/MS for each analyte. To evaluate liver exposure, livers were removed at the terminal sampling time point for each dosing route. Sample preparation was the same as described below.</div></div><div id="sec5_34_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Dog PK studies</h4><div class="NLM_p last">The pharmacokinetics of compounds <b>18</b>, <b>28</b>, and <b>29</b> were evaluated in male beagle dogs (<i>∼</i>9–12 kg, Marshall Farms USA Inc., North Rose, NY) bearing vascular access ports. The studies were conducted in a crossover design (N = 2), with a two week washout period between the IV and PO doses. Dogs were fasted overnight prior to oral dosing, but not fasted prior to IV dosing and all dogs were fed 4 h after dosing. In the IV study, each compound was infused at 1 mg/kg over 5 min (solution in 85%PEG-400/15% water) into the cephalic vein. Serial blood samples were collected from a venous vascular access port at 0.08, 0.167, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 h postdose. In the PO study, compounds were administered by oral gavage at 3 mg/kg (solution in 85% PEG-400/15% water). Serial blood samples were collected from the venous vascular access port at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 h postdose. Plasma was prepared from the blood samples and the concentrations of each compound in plasma samples were determined by LC/MS/MS.</div></div><div id="sec5_34_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Cynomolgus Monkey PK Studies</h4><div class="NLM_p last">The pharmacokinetics of compounds <b>18</b>, <b>28</b>, and <b>29</b> were conducted in three male cynomolgus monkeys bearing vascular access ports (3.1–5.7 kg, Charles River Biomedical Research Foundation, Houston, TX), with a two week washout period between doses. Monkeys were fasted overnight prior to oral dosing, but not prior to IV dosing and all animals were fed 4 h after dosing. For IV dosing, each compound was infused at 3 mg/kg over 5 min into the venous vascular port. Serial blood samples were collected via an arterial vascular access port at 0.08, 0.167, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 h postdose. In the PO study, each compound was administered by oral gavage at 10 mg/kg. Both IV and PO dose solutions were prepared in 85 %PEG-400/15% water. Serial blood samples were collected via arterial vascular access port at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 24 h postdose. Plasma was prepared from the blood samples and the concentrations of each analyte were determined by LC/MS/MS.</div></div><div id="sec5_34_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Data Analysis</h4><div class="NLM_p last">The pharmacokinetic parameters of compounds <b>18</b>, <b>28</b>, and <b>29</b> were obtained by noncompartmental analysis of plasma concentration versus time data (KINETICA software, Version 2.4, InnaPhase Corporation, Philadelphia, PA). The peak concentration (<i>C</i><sub>max</sub>) and time for <i>C</i><sub>max</sub> (<i>T</i><sub>max</sub>) were recorded directly from experimental observations. The area under the curve from time zero to the last sampling time (AUC<sub>(0–T)</sub>) and the area under the curve from time zero to infinity (AUC<sub>(INF)</sub>) were calculated using a combination of linear and log trapezoidal summations. The whole body plasma clearance (Cl), steady-state volume of distribution (<i>V</i><sub>ss</sub>), apparent terminal <i>t</i><sub>1/2</sub>, and mean residence time (MRT) were estimated following intravenous administration. The absolute oral bioavailability (<i>F</i>) was estimated as the ratio of dose-normalized AUC values following PO and IV doses.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d7e6693-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00821">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00821" class="ext-link">10.1021/acs.jmedchem.6b00821</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES codes and GT-1a/1b inhibitory activity for compounds <b>6</b>–<b>29</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00821/suppl_file/jm6b00821_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00821/suppl_file/jm6b00821_si_001.csv">jm6b00821_si_001.csv (3.59 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00821" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Qiang Sun</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f0bc99a199919e97dea3859eb0929d83de939f9d"><span class="__cf_email__" data-cfemail="377b5e665e5659501964425977555a441954585a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Mull</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Zheng</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanley D’Andrea</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian Zhao</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Xiangdong Wang</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ny Sin</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian L. Venables</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sing-Yuen Sit</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Chen</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Chen</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Cocuzza</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donna M. Bilder</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bang-Chi Chen</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theerthagiri Palani</span> - <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sivakumar Ganesan</span> - <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pirama Nayagam Arunachalam</span> - <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Falk</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Levine</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chaoqun Chen</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacques Friborg</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Yu</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis Hernandez</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy K. Sheaffer</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay O. Knipe</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong-Hae Han</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Schartman</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Donoso</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathy Mosure</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael W. Sinz</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatyana Zvyaga</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramkumar Rajamani</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Kish</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Tredup</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Herbert E. Klei</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Gao</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alicia Ng</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luciano Mueller</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis M. Grasela</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Adams</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Loy</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul C. Levesque</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huabin Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shi</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucy Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Warner</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danshi Li</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jialong Zhu</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying-Kai Wang</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Fang</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark I. Cockett</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas A. Meanwell</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fiona McPhee</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul M. Scola</span> - <span class="hlFld-Affiliation affiliation">†Department of Discovery
Chemistry, ‡Department of Virology Discovery Biology, §Department of Computer-Assisted Drug
Design, ∥Department of Pharmaceutical Candidate Optimization, #Department of Lead Discovery and Optimization, and ◊Department of
Lead Evaluation, Bristol-Myers Squibb Research
and Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span class="hlFld-Affiliation affiliation">⊥Department of Clinical Development Infectious Disease, ∇Department of Mechanistic
Biochemistry, and ●Department of Protein Science and Structure, Bristol-Myers Squibb Research and Development, P.O. Box 5400 Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Development, Bristol-Myers Squibb Research and Development, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, Bristol-Myers Squibb Research and Development, Route 206 and Provinceline Road, Princeton, New Jersey 08543, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Biocon
Bristol-Myers Squibb R&D Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6687-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the following members of our analytical group for the roles that they played in enabling the work described in this paper: Xiaohu Huang, Jingfang Cutrone, Dieter Drexler, Edward S. Kozlowski, Christopher J. Poronsky, and Julia M. Nielson.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i64" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i64"> Abbreviations Used</h2><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cardiovascular</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]-pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">US</td><td class="NLM_def"><p class="first last">United States</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">apparent volume of distribution at steady state</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kim, W. R.</span><span> </span><span class="NLM_article-title">Global epidemiology and burden of hepatitis C</span> <span class="citation_source-journal">Microbes Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span><span class="refDoi"> DOI: 10.1016/S1286-4579(02)01649-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2FS1286-4579%2802%2901649-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=12467763" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=1219-1225&author=W.+R.+Kim&title=Global+epidemiology+and+burden+of+hepatitis+C&doi=10.1016%2FS1286-4579%2802%2901649-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1286-4579%2802%2901649-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1286-4579%252802%252901649-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BR.%26atitle%3DGlobal%2520epidemiology%2520and%2520burden%2520of%2520hepatitis%2520C%26jtitle%3DMicrobes%2520Infect.%26date%3D2002%26volume%3D4%26spage%3D1219%26epage%3D1225%26doi%3D10.1016%2FS1286-4579%2802%2901649-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">WHO</span><span> </span><span class="NLM_article-title">Hepatitis C global prevalence (update)</span> <span class="citation_source-journal">Weekly Epidemiol. Rec.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10645164" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1999&pages=425-427&author=WHO&title=Hepatitis+C+global+prevalence+%28update%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DHepatitis%2520C%2520global%2520prevalence%2520%2528update%2529%26jtitle%3DWeekly%2520Epidemiol.%2520Rec.%26date%3D1999%26volume%3D74%26spage%3D425%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hanafiah, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groeger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiersma, S. T.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span><span class="refDoi"> DOI: 10.1002/hep.26141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.26141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23172780" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1333-1342&author=K.+M.+Hanafiahauthor=J.+Groegerauthor=A.+D.+Flaxmanauthor=S.+T.+Wiersma&title=Global+epidemiology+of+hepatitis+C+virus+infection%3A+new+estimates+of+age-specific+antibody+to+HCV+seroprevalence&doi=10.1002%2Fhep.26141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhep.26141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26141%26sid%3Dliteratum%253Aachs%26aulast%3DHanafiah%26aufirst%3DK.%2BM.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520new%2520estimates%2520of%2520age-specific%2520antibody%2520to%2520HCV%2520seroprevalence%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D1333%26epage%3D1342%26doi%3D10.1002%2Fhep.26141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hajarazadeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grebely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23817321" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553-562&author=B.+Hajarazadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarazadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26epage%3D562%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Gravitz, L.</span><span> </span><span class="NLM_article-title">Introduction: a smouldering public-health crisis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">S2</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1038/474S2a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2F474S2a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=S2-4&author=L.+Gravitz&title=Introduction%3A+a+smouldering+public-health+crisis&doi=10.1038%2F474S2a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F474S2a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F474S2a%26sid%3Dliteratum%253Aachs%26aulast%3DGravitz%26aufirst%3DL.%26atitle%3DIntroduction%253A%2520a%2520smouldering%2520public-health%2520crisis%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3DS2%26epage%3D4%26doi%3D10.1038%2F474S2a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Pathophysiology of hepatitis C virus infection and related liver disease</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.tim.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.tim.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=96-102&author=J.-M.+Pawlotsky&title=Pathophysiology+of+hepatitis+C+virus+infection+and+related+liver+disease&doi=10.1016%2Fj.tim.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DPathophysiology%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520related%2520liver%2520disease%26jtitle%3DTrends%2520Microbiol.%26date%3D2004%26volume%3D12%26spage%3D96%26epage%3D102%26doi%3D10.1016%2Fj.tim.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, T.</span><span> </span><span class="NLM_article-title">Pathogenesis of hepatitis C-associated hepatocellular carcinoma</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">S62</span><span class="NLM_x">–</span> <span class="NLM_lpage">S71</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1053%2Fj.gastro.2004.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=15508105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGmtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2004&pages=S62-S71&author=T.+J.+Liangauthor=T.+Heller&title=Pathogenesis+of+hepatitis+C-associated+hepatocellular+carcinoma&doi=10.1053%2Fj.gastro.2004.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of hepatitis C-associated hepatocellular carcinoma</span></div><div class="casAuthors">Liang, T. Jake; Heller, Theo</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5, Suppl. 1</span>),
    <span class="NLM_cas:pages">S62-S71</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Epidemiol., clin., and virol. data have shown a close assocn. between chronic infection with hepatitis C virus (HCV) and the development of hepatocellular carcinoma (HCC).  In many countries of the developed world, HCV infection accounts for more than half of the cases of HCC.  HCC usually arises after 2-4 decades of infection, typically in the context of an underlying cirrhosis.  Treatment of hepatitis C with interferon-alpha can lead to sustained clearance of HCV, and small prospective studies as well as larger retrospective analyses suggest that interferon therapy leads to a decrease in the incidence of HCC.  Without a reliable tissue culture system or a small animal model of HCV infection, anal. of the mechanisms by which HCV leads to cancer has been difficult.  Nevertheless, both in vitro expression systems and in vivo transgenic mice studies suggest that HCV has an inherent carcinogenic potential.  Understanding the pathogenesis of HCV-assocd. HCC is important in developing effective means of prevention and treatment of this highly malignant form of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3d-IaWg73rVg90H21EOLACvtfcHk0lihZoDYMxvRag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGmtb7F&md5=57f58df6ef197dcf191bfb8d5e53301f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DHeller%26aufirst%3DT.%26atitle%3DPathogenesis%2520of%2520hepatitis%2520C-associated%2520hepatocellular%2520carcinoma%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D127%26spage%3DS62%26epage%3DS71%26doi%3D10.1053%2Fj.gastro.2004.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Brown, R. S.</span><span> </span><span class="NLM_article-title">Hepatitis C and liver transplantation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature04083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnature04083" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=973-978&author=R.+S.+Brown&title=Hepatitis+C+and+liver+transplantation&doi=10.1038%2Fnature04083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature04083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04083%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DR.%2BS.%26atitle%3DHepatitis%2520C%2520and%2520liver%2520transplantation%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D973%26epage%3D978%26doi%3D10.1038%2Fnature04083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Rising mortality associated with hepatitis C virus in the United States, 2003–2013</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1093/cid/ciw111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1093%2Fcid%2Fciw111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=26936668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A280%3ADC%252BC28jms1GmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=1287-1288&author=K.+N.+Lyauthor=E.+M.+Hughesauthor=R.+B.+Jilesauthor=S.+D.+Holmberg&title=Rising+mortality+associated+with+hepatitis+C+virus+in+the+United+States%2C+2003%E2%80%932013&doi=10.1093%2Fcid%2Fciw111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013</span></div><div class="casAuthors">Ly Kathleen N; Hughes Elizabeth M; Jiles Ruth B; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1287-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the United States, hepatitis C virus (HCV)-associated mortality is increasing.  From 2003-2013, the number of deaths associated with HCV has now surpassed 60 other nationally notifiable infectious conditions combined.  The increasing HCV-associated mortality trend underscores the urgency in finding, evaluating, and treating HCV-infected persons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoe_9g9I16MQwxfk_AGB-EfW6udTcc2eaAT8wdLxmkv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jms1GmsA%253D%253D&md5=46b872aaba7df1c731a1a068f2f5da54</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciw111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciw111%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DHughes%26aufirst%3DE.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DRising%2520mortality%2520associated%2520with%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%252C%25202003%25E2%2580%25932013%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D62%26spage%3D1287%26epage%3D1288%26doi%3D10.1093%2Fcid%2Fciw111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sr George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+Sr+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0lg0n1URJdj4DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSr%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grand-Maître, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre-Paquette, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.-M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-activity+study+on+a+novel+series+of+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0lg0n1URJdj4DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-activity%2520study%2520on%2520a%2520novel%2520series%2520of%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6466</span><span class="NLM_x">–</span> <span class="NLM_lpage">6476</span><span class="refDoi"> DOI: 10.1021/jm100690x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100690x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6466-6476&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=D.+N.+Goudreauauthor=P.+K.+Bhardwajauthor=J.+Bordeleauauthor=M.+B%C3%B6sauthor=Y.+Bousquetauthor=M.+G.+Cordingleyauthor=J.+Duanauthor=P.+Forgioneauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=S.+H.+Kawaiauthor=J.+Naudauthor=M.+A.+Poupartauthor=P.+W.+White&title=Discovery+of+a+potent+and+selective+noncovalent+linear+inhibitor+of+the+hepatitis+C+virus+NS3+protease+%28BI+201335%29&doi=10.1021%2Fjm100690x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Goudreau, Nathalie; Bhardwaj, Punit K.; Bordeleau, Josee; Bos, Michael; Bousquet, Yves; Cordingley, Michael G.; Duan, Jiamin; Forgione, Pat; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Goulet, Sylvie; Halmos, Ted; Kawai, Stephen H.; Naud, Julie; Poupart, Marc-Andre; White, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6466-6476</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Terminal carboxylic acid contg. inhibitors of the NS3 protease are reported.  A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described.  A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors.  The introduction of a C8 Me group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well.  Exploration of C8-substitutions led to the identification of the bromo deriv. as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors.  Structure-activity studies on the C8-bromo derivs. ultimately led to the discovery of clin. candidate 29 (BI 201335), a very potent and selective inhibitor of genotype1 NS3 protease with a promising PK profile in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxIrNdDYPMvbVg90H21EOLACvtfcHk0lj-GqHSzRcIuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLvI&md5=cec8d519d94e2946dd2700d4e0d4476e</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1021%2Fjm100690x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100690x%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DGoudreau%26aufirst%3DD.%2BN.%26aulast%3DBhardwaj%26aufirst%3DP.%2BK.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBousquet%26aufirst%3DY.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DForgione%26aufirst%3DP.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DNaud%26aufirst%3DJ.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520noncovalent%2520linear%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520%2528BI%2520201335%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6466%26epage%3D6476%26doi%3D10.1021%2Fjm100690x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.bmcl.2008.07.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=18678486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=%C3%85.+Rosenquistauthor=M.+Nilssonauthor=L.+Salvador-Odenauthor=T.+I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+Wahlingauthor=K.+Wickstromauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure-activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3%2F4A+protease+leading+to+the+discovery+of+TMC435350&doi=10.1016%2Fj.bmcl.2008.07.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span></div><div class="casAuthors">Raboisson, Pierre; de Kock, Herman; Rosenquist, Asa; Nilsson, Magnus; Salvador-Oden, Lourdes; Lin, Tse-I.; Roue, Natalie; Ivanov, Vladimir; Wahling, Horst; Wickstrom, Kristina; Hamelink, Elizabeth; Edlund, Michael; Vrang, Lotta; Vendeville, Sandrine; Van de Vreken, Wim; McGowan, David; Tahri, Abdellah; Hu, Lili; Boutton, Carlo; Lenz, Oliver; Delouvroy, Frederic; Pille, Geert; Surleraux, Dominique; Wigerinck, Piet; Samuelsson, Bertil; Simmen, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4853-4858</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">SAR anal. performed with a limited set of cyclopentane-contg. macrocycles led to the identification of TMC435350 (I) as a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).  TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies.  TMC435350 is currently being evaluated in the clinics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbRb8GhLBkJ7Vg90H21EOLACvtfcHk0lj-GqHSzRcIuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbvE&md5=001abd8307658a926479ff77496b6ff9</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.088%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DWahling%26aufirst%3DH.%26aulast%3DWickstrom%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure-activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858%26doi%3D10.1016%2Fj.bmcl.2008.07.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraznenok, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nystrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span><span class="refDoi"> DOI: 10.1002/anie.200906696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fanie.200906696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1652-1655&author=M.+D.+Cummingsauthor=J.+Lindbergauthor=T.-I.+Linauthor=H.+de+Kockauthor=O.+Lenzauthor=E.+Liljaauthor=S.+Fellanderauthor=V.+Baraznenokauthor=S.+Nystromauthor=M.+Nilssonauthor=L.+Vrangauthor=M.+Edlundauthor=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.+Raboissonauthor=K.+Simmen&title=Induced-fit+binding+of+the+macrocyclic+noncovalent+inhibitor+TMC435+to+its+HCV+NS3%2FNS4A+protease+target&doi=10.1002%2Fanie.200906696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9eR"><div class="casContent"><span class="casTitleNuber">9e</span><div class="casTitle"><span class="NLM_cas:atitle">Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target</span></div><div class="casAuthors">Cummings, Maxwell D.; Lindberg, Jimmy; Lin, Tse-I.; de Kock, Herman; Lenz, Oliver; Lilja, Elisabet; Fellander, Sara; Baraznenok, Vera; Nystrom, Susanne; Nilsson, Magnus; Vrang, Lotta; Edlund, Michael; Rosenquist, Asa; Samuelsson, Bertil; Raboisson, Pierre; Simmen, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1652-1655, S1652/1-S1652/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We have detd. the crystal structure of the macrocyclic inhibitor TMC435 bound to its HCV NS3/4A protease target at a resoln. of 2.4 Å, providing at. detail of induced fit to an extended S2 subsite.  The complex structure helps to rationalize the impact of key modifications in the optimization path that led to 1, and is guiding our understanding of resistance patterns.  Future modeling and structure-based design efforts aimed at NS3/NS4A protease should benefit from the new structure, which represents the first example of a noncovalent NS3/NS4A protease-inhibitor complex deposited in the PDB and details the induced fit involved in accommodating a large P2 substituent.  Inhibitors with large P2 groups that occupy the extended S2 subsite probe the crystallog. obsd. helicase-protease interface, and it is hoped that future studies will clarify the relevance of interfacial contacts to protease activity and protease inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEYqCPA57hLVg90H21EOLACvtfcHk0lgART2GNpNoAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVaktbs%253D&md5=535b340784d1af62df32e8cf3bd3fe87</span></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1002%2Fanie.200906696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200906696%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DLilja%26aufirst%3DE.%26aulast%3DFellander%26aufirst%3DS.%26aulast%3DBaraznenok%26aufirst%3DV.%26aulast%3DNystrom%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DInduced-fit%2520binding%2520of%2520the%2520macrocyclic%2520noncovalent%2520inhibitor%2520TMC435%2520to%2520its%2520HCV%2520NS3%252FNS4A%2520protease%2520target%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1652%26epage%3D1655%26doi%3D10.1002%2Fanie.200906696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BeumontMauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.+O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+BeumontMauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9fR"><div class="casContent"><span class="casTitleNuber">9f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0lgART2GNpNoAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumontMauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1021/ja711120r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2-P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fja711120r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9gR"><div class="casContent"><span class="casTitleNuber">9g</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Based Approach to Potent P2-P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Liverton, Nigel J.; Holloway, M. Katharine; McCauley, John A.; Rudd, Michael T.; Butcher, John W.; Carroll, Steven S.; DiMuzio, Jillian; Fandozzi, Christine; Gilbert, Kevin F.; Mao, Shi-Shan; McIntyre, Charles J.; Nguyen, Kevin T.; Romano, Joseph J.; Stahlhut, Mark; Wan, Bang-Lin; Olsen, David B.; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4607-4609</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors.  Optimization of initial compds. provided 25a.  The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYenMBNqdeLVg90H21EOLACvtfcHk0liB0UkxF5IHGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D&md5=5e7bb98bdb19c30bebb30f03a702838d</span></div><a href="/servlet/linkout?suffix=cit9g&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2-P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609%26doi%3D10.1021%2Fja711120r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.-L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.-S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9hR"><div class="casContent"><span class="casTitleNuber">9h</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0liB0UkxF5IHGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit9h&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9iR"><div class="casContent"><span class="casTitleNuber">9i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lhAAbBypm8xdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit9i&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">P2-Quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-Quinazolinones+and+bis-macrocycles+as+new+templates+for+next-generation+hepatitis+C+virus+NS3%2F4a+protease+inhibitors%3A+discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9jR"><div class="casContent"><span class="casTitleNuber">9j</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lhAAbBypm8xdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit9j&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-Quinazolinones%2520and%2520bis-macrocycles%2520as%2520new%2520templates%2520for%2520next-generation%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%253A%2520discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Neelamkavil, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockunier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chackalamannil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chelliah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clasby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colandrea, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eagen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcantonio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruck, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperbeck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velazquez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of MK-8831, A novel spiro-proline macrocycle as a pan-genotypic HCV- NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=111-116&author=S.+F.+Neelamkavilauthor=S.+Agrawalauthor=T.+Baraauthor=C.+Bennettauthor=S.+Bhatauthor=D.+Biswasauthor=L.+Brockunierauthor=N.+Buistauthor=D.+Burnetteauthor=M.+Cartwrightauthor=S.+Chackalamannilauthor=R.+Chaseauthor=M.+Chelliahauthor=A.+Chenauthor=M.+Clasbyauthor=V.+J.+Colandreaauthor=I.+W.+Daviesauthor=K.+Eagenauthor=Z.+Guoauthor=Y.+Hanauthor=J.+Howeauthor=C.+Jayneauthor=H.+Josienauthor=S.+Kargmanauthor=K.+Marcantonioauthor=S.+Miaoauthor=R.+Millerauthor=A.+Noltingauthor=P.+Pintoauthor=M.+Rajagopalanauthor=R.+T.+Ruckauthor=U.+Shahauthor=A.+Sorianoauthor=D.+Sperbeckauthor=F.+Velazquezauthor=J.+Wuauthor=Y.+Xiaauthor=S.+Venkatraman&title=Discovery+of+MK-8831%2C+A+novel+spiro-proline+macrocycle+as+a+pan-genotypic+HCV-+NS3%2F4a+protease+inhibitor&doi=10.1021%2Facsmedchemlett.5b00425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9k&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00425%26sid%3Dliteratum%253Aachs%26aulast%3DNeelamkavil%26aufirst%3DS.%2BF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DBara%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DC.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DBiswas%26aufirst%3DD.%26aulast%3DBrockunier%26aufirst%3DL.%26aulast%3DBuist%26aufirst%3DN.%26aulast%3DBurnette%26aufirst%3DD.%26aulast%3DCartwright%26aufirst%3DM.%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DChelliah%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DClasby%26aufirst%3DM.%26aulast%3DColandrea%26aufirst%3DV.%2BJ.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26aulast%3DEagen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJayne%26aufirst%3DC.%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DMarcantonio%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DNolting%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DRajagopalan%26aufirst%3DM.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DShah%26aufirst%3DU.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DSperbeck%26aufirst%3DD.%26aulast%3DVelazquez%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520MK-8831%252C%2520A%2520novel%2520spiro-proline%2520macrocycle%2520as%2520a%2520pan-genotypic%2520HCV-%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D111%26epage%3D116%26doi%3D10.1021%2Facsmedchemlett.5b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condroski, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serebryany, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madduru, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geck Do, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stengel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigelman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, S. D.</span><span> </span><span class="NLM_article-title">Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1021/jm400164c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400164c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1753-1769&author=Y.+Jiangauthor=S.+W.+Andrewsauthor=K.+R.+Condroskiauthor=B.+Buckmanauthor=V.+Serebryanyauthor=S.+Wenglowskyauthor=A.+L.+Kennedyauthor=M.+R.+Madduruauthor=B.+Wangauthor=M.+Lyonauthor=G.+A.+Dohertyauthor=B.+T.+Woodardauthor=C.+Lemieuxauthor=M.+Geck+Doauthor=H.+Zhangauthor=J.+Ballardauthor=G.+Vigersauthor=B.+J.+Brandhuberauthor=P.+Stengelauthor=J.+A.+Joseyauthor=L.+Beigelmanauthor=L.+Blattauthor=S.+D.+Seiwert&title=Discovery+of+danoprevir+%28ITMN-191%2FR7227%29%2C+a+highly+selective+and+potent+inhibitor+of+hepatitis+C+virus+%28HCV%29+NS3%2F4A+protease&doi=10.1021%2Fjm400164c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9lR"><div class="casContent"><span class="casTitleNuber">9l</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease</span></div><div class="casAuthors">Jiang, Yutong; Andrews, Steven W.; Condroski, Kevin R.; Buckman, Brad; Serebryany, Vlad; Wenglowsky, Steve; Kennedy, April L.; Madduru, Machender R.; Wang, Bin; Lyon, Michael; Doherty, George A.; Woodard, Benjamin T.; Lemieux, Christine; Do, Mary Geck; Zhang, Hailong; Ballard, Joshua; Vigers, Guy; Brandhuber, Barbra J.; Stengel, Peter; Josey, John A.; Beigelman, Leonid; Blatt, Lawrence; Seiwert, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1753-1769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system.  Through structure-based drug design and optimization, macrocyclic peptidomimetic mols. bearing both a lipophilic P2 isoindoline carbamate and a P1/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepd. that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7).  Danoprevir (compd. 49) was selected as the clin. development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species.  X-ray crystallog. studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to the iterative structure-based design strategy of the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplS3sgoIBu_7Vg90H21EOLACvtfcHk0lh-cVaJRZ7e0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D&md5=2a979cd1202b9360bcef316dddd8382f</span></div><a href="/servlet/linkout?suffix=cit9l&amp;dbid=16384&amp;doi=10.1021%2Fjm400164c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400164c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DCondroski%26aufirst%3DK.%2BR.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DA.%2BL.%26aulast%3DMadduru%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DWoodard%26aufirst%3DB.%2BT.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DGeck%2BDo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DStengel%26aufirst%3DP.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520danoprevir%2520%2528ITMN-191%252FR7227%2529%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1753%26epage%3D1769%26doi%3D10.1021%2Fjm400164c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Sheng, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, W. E.,  IV</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerffler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pakdaman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyun, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. U.</span><span> </span><span class="NLM_article-title">Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1396</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.bmcl.2011.12.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1394-1396&author=X.+C.+Shengauthor=A.+Casarezauthor=R.+Caiauthor=M.+O.+Clarkeauthor=X.+Chenauthor=A.+Choauthor=W.+E.+Delaneyauthor=E.+Doerfflerauthor=M.+Jiauthor=M.+Mertzmanauthor=R.+Pakdamanauthor=H.-J.+Pyunauthor=T.+Roweauthor=Q.+Wuauthor=J.+Xuauthor=C.+U.+Kim&title=Discovery+of+GS-9256%3A+a+novel+phosphinic+acid+derived+inhibitor+of+the+hepatitis+C+virus+NS3%2F4A+protease+with+potent+clinical+activity&doi=10.1016%2Fj.bmcl.2011.12.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DX.%2BC.%26aulast%3DCasarez%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DR.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DPakdaman%26aufirst%3DR.%26aulast%3DPyun%26aufirst%3DH.-J.%26aulast%3DRowe%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DC.%2BU.%26atitle%3DDiscovery%2520of%2520GS-9256%253A%2520a%2520novel%2520phosphinic%2520acid%2520derived%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520with%2520potent%2520clinical%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1394%26epage%3D1396%26doi%3D10.1016%2Fj.bmcl.2011.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1755&author=P.+M.+Scolaauthor=A.+Wangauthor=A.+C.+Goodauthor=L.-Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.+Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.+H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1755%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Langendorff, O.</span><span> </span><span class="NLM_article-title">Untersuchungen am uberleberden saugerleizen</span> <span class="citation_source-journal">Pfluegers Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1895</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span><span class="refDoi"> DOI: 10.1007/BF01812150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2FBF01812150" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1895&pages=291-332&author=O.+Langendorff&title=Untersuchungen+am+uberleberden+saugerleizen&doi=10.1007%2FBF01812150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2FBF01812150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01812150%26sid%3Dliteratum%253Aachs%26aulast%3DLangendorff%26aufirst%3DO.%26atitle%3DUntersuchungen%2520am%2520uberleberden%2520saugerleizen%26jtitle%3DPfluegers%2520Arch.%26date%3D1895%26volume%3D61%26spage%3D291%26epage%3D332%26doi%3D10.1007%2FBF01812150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lgGRXSM3beq1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span> </span><span class="NLM_article-title">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5387</span><span class="NLM_x">–</span> <span class="NLM_lpage">5396</span><span class="refDoi"> DOI: 10.1128/AAC.01186-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.01186-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=22869577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5387-5396&author=F.+McPheeauthor=A.+K.+Sheafferauthor=J.+Friborgauthor=D.+Hernandezauthor=P.+Falkauthor=G.+Zhaiauthor=S.+Levineauthor=S.+Chaniewskiauthor=F.+Yuauthor=D.+Barryauthor=C.+Chenauthor=M.+S.+Leeauthor=K.+Mosureauthor=L.-Q.+Sunauthor=M.+Sinzauthor=N.+A.+Meanwellauthor=R.+J.+Colonnoauthor=J.+Knipeauthor=P.+Scola&title=Preclinical+profile+and+characterization+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir+%28BMS-650032%29&doi=10.1128%2FAAC.01186-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span></div><div class="casAuthors">McPhee, Fiona; Sheaffer, Amy K.; Friborg, Jacques; Hernandez, Dennis; Falk, Paul; Zhai, Guangzhi; Levine, Steven; Chaniewski, Susan; Yu, Fei; Barry, Diana; Chen, Chaoqun; Lee, Min S.; Mosure, Kathy; Sun, Li-Qiang; Sinz, Michael; Meanwell, Nicholas A.; Colonno, Richard J.; Knipe, Jay; Scola, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5387-5396</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients chronically infected with HCV genotype 1 when combined with alfa interferon and/or the NS5A replication complex inhibitor daclatasvir.  ASV competitively binds to the NS3/4A protease complex, with Ki values of 0.4 and 0.24 nM against recombinant enzymes representing genotypes 1a (H77) and 1b (J4L6S), resp.  Selectivity was demonstrated by the absence of any significant activity against the closely related GB virus-B NS3 protease and a panel of human serine or cysteine proteases.  In cell culture, ASV inhibited replication of HCV replicons representing genotypes 1 and 4, with 50% effective concns. (EC50s) ranging from 1 to 4 nM, and had weaker activity against genotypes 2 and 3 (EC50, 67 to 1,162 nM).  Selectivity was again demonstrated by the absence of activity (EC50, >12 μM) against a panel of other RNA viruses.  ASV exhibited additive or synergistic activity in combination studies with alfa interferon, ribavirin, and/or inhibitors specifically targeting NS5A or NS5B.  Plasma and tissue exposures in vivo in several animal species indicated that ASV displayed a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥110-fold above the inhibitor EC50s obsd. with HCV genotype-1 replicons.  Based on these virol. and exposure properties, ASV holds promise for future utility in a combination with other anti-HCV agents in the treatment of HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvSH5FRWqFbVg90H21EOLACvtfcHk0ljv1pV9A7Pz9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL&md5=9bbf4ea33b5c4ef48850ade4af9cfd1d</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01186-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01186-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DScola%26aufirst%3DP.%26atitle%3DPreclinical%2520profile%2520and%2520characterization%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520%2528BMS-650032%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5387%26epage%3D5396%26doi%3D10.1128%2FAAC.01186-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/hep.24724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders&doi=10.1002%2Fhep.24724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fhep.24724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villegas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1128/AAC.05854-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.05854-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1838-1844&author=C.+Pasquinelliauthor=F.+McPheeauthor=T.+Eleyauthor=C.+Villegasauthor=K.+Sandyauthor=P.+Sheridanauthor=A.+Perssonauthor=S.-P.+Huangauthor=D.+Hernandezauthor=A.+K.+Sheafferauthor=P.+Scolaauthor=T.+Marburyauthor=E.+Lawitzauthor=R.+Goldwaterauthor=M.+Rodriguez-Torresauthor=M.+DeMiccoauthor=D.+Wrightauthor=M.+Charltonauthor=W.+K.+Kraftauthor=J.-C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Single-+and+multiple-ascending-dose+studies+of+the+NS3+protease+inhibitor+asunaprevir+in+subjects+with+or+without+chronic+hepatitis+C&doi=10.1128%2FAAC.05854-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1128%2FAAC.05854-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05854-11%26sid%3Dliteratum%253Aachs%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DVillegas%26aufirst%3DC.%26aulast%3DSandy%26aufirst%3DK.%26aulast%3DSheridan%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DDeMicco%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DD.%26aulast%3DCharlton%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DW.%2BK.%26aulast%3DLopez-Talavera%26aufirst%3DJ.-C.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DSingle-%2520and%2520multiple-ascending-dose%2520studies%2520of%2520the%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520in%2520subjects%2520with%2520or%2520without%2520chronic%2520hepatitis%2520C%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1838%26epage%3D1844%26doi%3D10.1128%2FAAC.05854-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options&doi=10.1016%2Fj.jhep.2012.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lhOmbE5bRxfbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.jhep.2012.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+pegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders&doi=10.1016%2Fj.jhep.2013.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0lhOmbE5bRxfbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520pegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499%26doi%3D10.1016%2Fj.jhep.2013.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2091</span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=2083-2091&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D2083%26epage%3D2091%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Poole, R.</span><span> </span><span class="NLM_article-title">Daclatasvir + asunaprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1007/s40265-014-0279-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2Fs40265-014-0279-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25117197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1559-1571&author=R.+Poole&title=Daclatasvir+%2B+asunaprevir%3A+first+global+approval&doi=10.1007%2Fs40265-014-0279-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir + Asunaprevir: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1559-1571</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.  Daclatasvir + asunaprevir has received its first global approval in this indication in Japan.  Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication.  This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF9-lXzdKBdbVg90H21EOLACvtfcHk0lizftGXspv1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M&md5=efde97ee214598388e1db80bb303d1c6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0279-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0279-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%26atitle%3DDaclatasvir%2520%252B%2520asunaprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1559%26epage%3D1571%26doi%3D10.1007%2Fs40265-014-0279-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.10.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-naive+patients+with+HCV+genotype+1+infection&doi=10.1053%2Fj.gastro.2013.10.057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-naive%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429%26doi%3D10.1053%2Fj.gastro.2013.10.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rege, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1204</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2014.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25559328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1204-1206&author=T.+Hassaneinauthor=K.+D.+Simsauthor=M.+Bennettauthor=N.+Gitlinauthor=R.+Lawitzauthor=T.+Nguyenauthor=L.+Websterauthor=Z.+Younossiauthor=H.+Schwartzauthor=P.+J.+Thuluvathauthor=H.+Zhouauthor=B.+Regeauthor=F.+McPheeauthor=N.+Zhouauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=A.+Griffiesauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=A+randomized+trial+of+daclatasvir+in+combination+with+asunaprevir+and+beclabuvir+in+patients+with+chronic+hepatitis+C+virus+genotype+4+infection&doi=10.1016%2Fj.jhep.2014.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection</span></div><div class="casAuthors">Hassanein, Tarek; Sims, Karen D.; Bennett, Michael; Gitlin, Norman; Lawitz, Eric; Nguyen, Tuan; Webster, Lynn; Younossi, Zobair; Schwartz, Howard; Thuluvath, Paul J.; Zhou, Helen; Rege, Bhaskar; McPhee, Fiona; Zhou, Nannan; Wind-Rotolo, Megan; Chung, Ellen; Griffies, Amber; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1204-1206</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This article study on randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.  This exploratory evaluation, 12 wk of treatment with the IFN- and ribavirin-free combination of daclatasvir, asunaprevir and beclabuvir was well tolerated and resulted in a high rate of SVR in previously untreated patients with chronic HCV genotype 4 infection, consistent with previous results in genotype 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcm7Cxr3vteLVg90H21EOLACvtfcHk0ljBj9ZvzCwEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWksrs%253D&md5=32599c24e540bf543d1e471ab5e12b0f</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DLawitz%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DRege%26aufirst%3DB.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DA%2520randomized%2520trial%2520of%2520daclatasvir%2520in%2520combination%2520with%2520asunaprevir%2520and%2520beclabuvir%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25204%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D1204%26epage%3D1206%26doi%3D10.1016%2Fj.jhep.2014.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Toyota, J; Karino, Y.; Suzuki, F.; Ikeda, F.; Ido, A.; Tanaka, K.; Takaguchi, K.; Naganuma, A.; Tomita, E.; Chayama, K.; Fujiyama, S.; Inada, Y.; Yoshiji, H.; Watanabe, H.; Ishikawa, H.; Hu, W.; McPhee, F.; Linaberry, M.; Yin, P. D.; Swenson, E. S.; Kumada, H.</span><span> </span><span class="NLM_article-title">Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection</span>.  <span class="citation_source-journal">J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span>ASAP, DOI <span class="refDoi"> DOI: 10.1007/s00535-016-1245-6</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2Fs00535-016-1245-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=26456168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J+Toyota&author=Y.+Karino&author=F.+Suzuki&author=F.+Ikeda&author=A.+Ido&author=K.+Tanaka&author=K.+Takaguchi&author=A.+Naganuma&author=E.+Tomita&author=K.+Chayama&author=S.+Fujiyama&author=Y.+Inada&author=H.+Yoshiji&author=H.+Watanabe&author=H.+Ishikawa&author=W.+Hu&author=F.+McPhee&author=M.+Linaberry&author=P.+D.+Yin&author=E.+S.+Swenson&author=H.+Kumada&title=Daclatasvir%2Fasunaprevir%2Fbeclabuvir+fixed-dose+combination+in+Japanese+patients+with+HCV+genotype+1+infection&doi=10.1007%2Fs00535-016-1245-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1007%2Fs00535-016-1245-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00535-016-1245-6%26sid%3Dliteratum%253Aachs%26aulast%3DToyota%26aufirst%3DJ%26atitle%3DDaclatasvir%252Fasunaprevir%252Fbeclabuvir%2520fixed-dose%2520combination%2520in%2520Japanese%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Gastroenterol.%26date%3D2015%26doi%3D10.1007%2Fs00535-016-1245-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wang, X. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A.</span><span> </span><span class="NLM_article-title">Hepatitis C virus inhibitors</span>. U.S. Patent 6,995,174,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=X.+A.+Wang&author=L.-Q.+Sun&author=S.-Y.+Sit&author=N.+Sin&author=P.+M.+Scola&author=P.+Hewawasam&author=A.+C.+Good&author=Y.+Chen&author=J.+A.+Campbell&title=Hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26atitle%3DHepatitis%2520C%2520virus%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system and its application to molecular studies</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=657-664&author=T.+Pietschmannauthor=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system+and+its+application+to+molecular+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%2520and%2520its%2520application%2520to%2520molecular%2520studies%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2001%26volume%3D4%26spage%3D657%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span><span class="refDoi"> DOI: 10.3851/IMP1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.3851%2FIMP1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=21817192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ejtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=705-718&author=A.+K.+Sheafferauthor=M.+S.+Leeauthor=D.+Hernandezauthor=S.+Chaniewskiauthor=F.+Yuauthor=P.+Falkauthor=J.+Friborgauthor=G.+Zhaiauthor=F.+McPhee&title=Development+of+a+chimeric+replicon+system+for+phenotypic+analysis+of+NS3+protease+sequences+from+HCV+clinical+isolates&doi=10.3851%2FIMP1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates</span></div><div class="casAuthors">Sheaffer, Amy K.; Lee, Min S.; Hernandez, Dennis; Chaniewski, Susan; Yu, Fei; Falk, Paul; Friborg, Jacques; Zhai, Guangzhi; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-718</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Background: To support clin. development of HCV non-structural protein (NS) 3 protease inhibitors (PIs), phenotypic monitoring of patient isolates is a prerequisite for understanding the emergence of resistance.  HCV isolates typically fail to replicate in cell culture, necessitating the use of alternative phenotyping methods.  Methods: An NS3 protease chimeric replicon system was developed to monitor the phenotype of clin. isolates.  The transfer of NS3 protease domain sequences from HCV-infected patients to the background of genotype (Gt) 1a-H77c, 1b-Con1 and 2a-JFH-1 lab strain replicons adapted to high-level cell culture replication was investigated.  Results: NS3 protease sequences derived from HCVGt 1a or Gt 1b infected patients were transferred into Gt 1a and 1b replicons, resp.  Replication was detected for 20% of Gt 1a and 75% of Gt 1b sequences.  Incorporation of known cell culture adaptive change NS3-E17GG improved replication of Gt 1b but not of Gt 1a sequences.  Transfer of Gt 1a clin. sequences into the Gt 1b background enhanced replication and allowed phenotypic anal. of all sequences.  A correlation was obsd. between clin. isolate sequence polymorphisms and reduced susceptibility to NS3 PI.  In mixed populations contg. known NS3 PI resistance changes NS3-R155K or D168E/V, sensitivity of resistance detection was ≥10%.  Conclusions: An HCV replicon capable of supporting phenotypic characterization of patient-derived HCV NS3 protease sequences was developed.  Pre-existence of amino acid changes assocd. with NS3 PI resistance highlights the need for combination therapies in the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJOI_kZXu-LVg90H21EOLACvtfcHk0ljBj9ZvzCwEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ejtb%252FN&md5=bfc492cd71ce4dbbbc9ce17e2b8f83c5</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.3851%2FIMP1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP1825%26sid%3Dliteratum%253Aachs%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520replicon%2520system%2520for%2520phenotypic%2520analysis%2520of%2520NS3%2520protease%2520sequences%2520from%2520HCV%2520clinical%2520isolates%26jtitle%3DAntiviral%2520Ther.%26date%3D2011%26volume%3D16%26spage%3D705%26epage%3D718%26doi%3D10.3851%2FIMP1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1002/jps.24356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fjps.24356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=2813-2823&author=K.+W.+Mosureauthor=J.+O.+Knipeauthor=M.+Browningauthor=V.+Aroraauthor=Y.+Z.+Shuauthor=T.+Phillipauthor=F.+Mcpheeauthor=P.+Scolaauthor=A.+Balakrishnanauthor=M.+G.+Soarsauthor=K.+Santoneauthor=M.+Sinz&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+asunaprevir+%28BMS-650032%29%2C+a+potent+hepatitis+C+virus+NS3+protease+inhibitor&doi=10.1002%2Fjps.24356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fjps.24356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24356%26sid%3Dliteratum%253Aachs%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBrowning%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DPhillip%26aufirst%3DT.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DSantone%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D2813%26epage%3D2823%26doi%3D10.1002%2Fjps.24356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gillis, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8315</span><span class="NLM_x">–</span> <span class="NLM_lpage">8359</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lhDO3FrGZeJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Diana, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevear, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldous, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutko, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oglesby, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkots, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reurnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerniak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppermand, J.</span><span> </span><span class="NLM_article-title">Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1021/jm00008a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADyaK2MXkvVWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1355-1371&author=G.+D.+Dianaauthor=P.+Rudewiczauthor=D.+C.+Pevearauthor=T.+J.+Nitzauthor=S.+C.+Aldousauthor=D.+J.+Aldousauthor=D.+T.+Robinsonauthor=T.+Draperauthor=F.+J.+Dutkoauthor=C.+Aldiauthor=G.+Gendronauthor=R.+C.+Oglesbyauthor=D.+L.+Volkotsauthor=M.+Reurnanauthor=T.+R.+Baileyauthor=R.+Czerniakauthor=T.+Blockauthor=R.+Rolandauthor=J.+Oppermand&title=Picornavirus+inhibitors%3A+trifluoromethyl+substitution+provides+a+global+protective+effect+against+hepatic+metabolism&doi=10.1021%2Fjm00008a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism</span></div><div class="casAuthors">Diana, Guy D.; Rudewicz, Patrick; Pevear, Daniel C.; Nitz, Theodore J.; Aldous, Suzanne C.; Aldous, David J.; Robinson, David T.; Draper, Tandy; Dutko, Frank J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several modifications of the oxazoline ring of WIN 54954, a broad spectrum antipicornavirus compd., have been prepd. to address the acid lability and metabolic instability of this compd.  The authors have previously shown that the oxadiazole analog (I) displayed comparable activity against a variety of rhinoviruses and appeared to be stable to acid.  A monkey liver microsomal assay was developed to examine the metabolic stability in vitro of both compds., and it was detd. that WIN 54954 displayed 18 metabolic products while I was converted to 8 products.  Two major products of I were detd. by LC-MS/MS to be monohydroxylated at each of the terminal Me groups.  Replacement of the Me on the isoxazole ring with a trifluoromethyl group, while preventing hydroxylation at this position, did not reduce the sensitivity of the mol. to microsomal metab. at other sites.  However, the (trifluoromethyl)oxadiazole not only prevented hydroxylation at this position but also provided protection at the isoxazole end of the mol., resulting in only two minor products to the extent of 4%.  The major product was identified as the monohydroxylated compd.  The global metabolic protective effect of trifluoromethyl group on the oxadiazole ring was further demonstrated by examg. a variety of analogous including heterocyclic replacements of the isoxazole ring.  In each case, the trifluoromethyl analog displayed a protective effect when compared to the corresponding Me analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMwEotZAx-bVg90H21EOLACvtfcHk0lhDO3FrGZeJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvVWqtLs%253D&md5=36a8ac2604f10f57d2aad9b131d84734</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a014%26sid%3Dliteratum%253Aachs%26aulast%3DDiana%26aufirst%3DG.%2BD.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DPevear%26aufirst%3DD.%2BC.%26aulast%3DNitz%26aufirst%3DT.%2BJ.%26aulast%3DAldous%26aufirst%3DS.%2BC.%26aulast%3DAldous%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DD.%2BT.%26aulast%3DDraper%26aufirst%3DT.%26aulast%3DDutko%26aufirst%3DF.%2BJ.%26aulast%3DAldi%26aufirst%3DC.%26aulast%3DGendron%26aufirst%3DG.%26aulast%3DOglesby%26aufirst%3DR.%2BC.%26aulast%3DVolkots%26aufirst%3DD.%2BL.%26aulast%3DReurnan%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DT.%2BR.%26aulast%3DCzerniak%26aufirst%3DR.%26aulast%3DBlock%26aufirst%3DT.%26aulast%3DRoland%26aufirst%3DR.%26aulast%3DOppermand%26aufirst%3DJ.%26atitle%3DPicornavirus%2520inhibitors%253A%2520trifluoromethyl%2520substitution%2520provides%2520a%2520global%2520protective%2520effect%2520against%2520hepatic%2520metabolism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1355%26epage%3D1371%26doi%3D10.1021%2Fjm00008a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalchick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">(2<i>R</i>)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-<i>a</i>]pyrazin-7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5D-triazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+a+potent%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255D-triazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520a%2520potent%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Barnes-Seeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatsis, P.</span><span> </span><span class="NLM_article-title">Metabolically stable tertbutyl replacement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/ml400045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=514-516&author=D.+Barnes-Seemanauthor=M.+Jainauthor=L.+Bellauthor=S.+Ferreiraauthor=S.+Cohenauthor=X.+H.+Chenauthor=J.+Aminauthor=B.+Snodgrassauthor=P.+Hatsis&title=Metabolically+stable+tertbutyl+replacement&doi=10.1021%2Fml400045j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1021%2Fml400045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400045j%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DAmin%26aufirst%3DJ.%26aulast%3DSnodgrass%26aufirst%3DB.%26aulast%3DHatsis%26aufirst%3DP.%26atitle%3DMetabolically%2520stable%2520tertbutyl%2520replacement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D514%26epage%3D516%26doi%3D10.1021%2Fml400045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Huchet, Q. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratochwil, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span> </span><span class="NLM_article-title">Fluorination patterning: a study of structural motifs that impact physicochemical properties of relevance to drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9041</span><span class="NLM_x">–</span> <span class="NLM_lpage">9060</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9041-9060&author=Q.+A.+Huchetauthor=B.+Kuhnauthor=B.+Wagnerauthor=N.+A.+Kratochwilauthor=H.+Fischerauthor=M.+Kansyauthor=D.+Zimmerliauthor=E.+M.+Carreiraauthor=K.+Muller&title=Fluorination+patterning%3A+a+study+of+structural+motifs+that+impact+physicochemical+properties+of+relevance+to+drug+discovery&doi=10.1021%2Facs.jmedchem.5b01455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19eR"><div class="casContent"><span class="casTitleNuber">19e</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorination Patterning: A Study of Structural Motifs That Impact Physicochemical Properties of Relevance to Drug Discovery</span></div><div class="casAuthors">Huchet, Quentin A.; Kuhn, Bernd; Wagner, Bjorn; Kratochwil, Nicole A.; Fischer, Holger; Kansy, Manfred; Zimmerli, Daniel; Carreira, Erick M.; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9041-9060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a collection of 3-substituted indole derivs. incorporating partially fluorinated Pr and Bu groups is described along with an in-depth study of the effects of various fluorination patterns on their properties, such as lipophilicity, aq. soly., and metabolic stability.  The exptl. observations confirm predictions of a marked lipophilicity decrease imparted by a vic-difluoro unit when compared to the gem-difluoro counterparts.  The data involving the comparison of the two substitution patterns is expected to benefit mol. design in medicinal chem. and, more broadly, in life as well as materials sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp49KCeC1WDm7Vg90H21EOLACvtfcHk0livua5S8DBDeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsrzM&md5=20d7a36b75501c02570744857c82f325</span></div><a href="/servlet/linkout?suffix=cit19e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01455%26sid%3Dliteratum%253Aachs%26aulast%3DHuchet%26aufirst%3DQ.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKratochwil%26aufirst%3DN.%2BA.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DFluorination%2520patterning%253A%2520a%2520study%2520of%2520structural%2520motifs%2520that%2520impact%2520physicochemical%2520properties%2520of%2520relevance%2520to%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9041%26epage%3D9060%26doi%3D10.1021%2Facs.jmedchem.5b01455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3670</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1128/AAC.00308-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.00308-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=22508297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2is7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3670-3681&author=F.+McPheeauthor=J.+Friborgauthor=S.+Levineauthor=C.+Chenauthor=P.+Falkauthor=F.+Yuauthor=D.+Hernandezauthor=M.+S.+Leeauthor=S.+Chaniewskiauthor=A.+K.+Sheafferauthor=C.+Pasquinelli&title=Resistance+analysis+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir&doi=10.1128%2FAAC.00308-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir</span></div><div class="casAuthors">McPhee, Fiona; Friborg, Jacques; Levine, Steven; Chen, Chaoqun; Falk, Paul; Yu, Fei; Hernandez, Dennis; Lee, Min S.; Chaniewski, Susan; Sheaffer, Amy K.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3670-3681</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor demonstrating efficacy in alfa interferon-sparing, direct-acting antiviral dual-combination regimens (together with the NS5A replication complex inhibitor daclatasvir) in patients chronically infected with HCV genotype 1b.  Here, we describe a comprehensive in vitro genotypic and phenotypic anal. of asunaprevir-assocd. resistance against genotypes 1a and 1b using HCV replicons and patient samples obtained from clin. studies of short-term asunaprevir monotherapy.  During genotype 1a resistance selection using HCV replicons, the primary NS3 protease substitutions identified were R155K, D168G, and I170T, which conferred low- to moderate-level asunaprevir resistance (5- to 21-fold) in transient-transfection susceptibility assays.  For genotype 1b, a higher level of asunaprevir-assocd. resistance was obsd. at the same selection pressures, ranging from 170- to 400-fold relative to the wild-type control.  The primary NS3 protease substitutions identified occurred predominantly at amino acid residue D168 (D168A/G/H/V/Y) and were assocd. with high-level asunaprevir resistance (16- to 280-fold) and impaired replication capacity.  In asunaprevir single-ascending-dose and 3-day multiple-ascending-dose studies in HCV genotype 1a- or 1b-infected patients, the predominant pre-existing NS3 baseline polymorphism was NS3-Q80K.  This substitution impacted initial virol. response rates in a single-ascending-dose study, but its effects after multiple doses were more ambiguous.  Interestingly, for patient NS3 protease sequences contg. Q80 and those contg. K80, susceptibilities to asunaprevir were comparable when tested in an enzyme assay.  No resistance-assocd. variants emerged in these clin. studies that significantly impacted susceptibility to asunaprevir.  Importantly, asunaprevir-resistant replicons remained susceptible to an NS5A replication complex inhibitor, consistent with a role for asunaprevir in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNf2shzFcn47Vg90H21EOLACvtfcHk0livua5S8DBDeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2is7s%253D&md5=713c87d4123a5769f47eb51d52ebd044</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.00308-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00308-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DResistance%2520analysis%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3670%26epage%3D3681%26doi%3D10.1128%2FAAC.00308-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Scola, P. M.; Sun, L.-Q.; Gillis, E. P.; Bowsher, M. S.; Chen, J.; Wang, X. A.; Sit, S.-Y.; Chen, Y.; Zheng, Z.; D’Andrea, S.; Sin, N.; Venables, B.; Mull, E.; Chen, Q.; Kandhasamy, S.; Pulicharla, N.; Vishwakrishnan, S.; Reddy, S.; Trivedi, R.; Sinha, S.; Sivaprasad, S.; Rao, A.; Desai, S.; Ghosh, K.; Rajamani, R.; Friborg, J.; Levine, S.; Chen, C.; Falk, P.; Jenkins, S.; Kramer, M.; Haskel, R.; Johnson, K.; Loy, J.; Levesque, P.; Zhu, J.; Cockett, M.; Meanwell, N. A.; McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery of a second generation, pan genotype NS3/4A protease inhibitor (BMS-986144) for the treatment of hepatitis C</span>. 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16–20,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-309.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+M.+Scola&author=L.-Q.+Sun&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=J.+Chen&author=X.+A.+Wang&author=S.-Y.+Sit&author=Y.+Chen&author=Z.+Zheng&author=S.+D%E2%80%99Andrea&author=N.+Sin&author=B.+Venables&author=E.+Mull&author=Q.+Chen&author=S.+Kandhasamy&author=N.+Pulicharla&author=S.+Vishwakrishnan&author=S.+Reddy&author=R.+Trivedi&author=S.+Sinha&author=S.+Sivaprasad&author=A.+Rao&author=S.+Desai&author=K.+Ghosh&author=R.+Rajamani&author=J.+Friborg&author=S.+Levine&author=C.+Chen&author=P.+Falk&author=S.+Jenkins&author=M.+Kramer&author=R.+Haskel&author=K.+Johnson&author=J.+Loy&author=P.+Levesque&author=J.+Zhu&author=M.+Cockett&author=N.+A.+Meanwell&author=F.+McPhee&title=Discovery+of+a+second+generation%2C+pan+genotype+NS3%2F4A+protease+inhibitor+%28BMS-986144%29+for+the+treatment+of+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520second%2520generation%252C%2520pan%2520genotype%2520NS3%252F4A%2520protease%2520inhibitor%2520%2528BMS-986144%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">The human <i>V</i>ss and clearance values for compound <b>29</b> were determined via allometric scaling using species-invariant modeling of preclinical species. Absorption kinetics in humans were assumed to be the average determined from rat, dog and monkey following solution dosing. The efficacious dose was projected by translating the in vitro replicon potency to clinical viral load decline as stated in ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a>, and this resulted in a once daily dose projection of 6 mg for <b>29</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Paulissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teyssie, Ph.</span><span> </span><span class="NLM_article-title">Transition metal catalysed cyclopropanation of olefin</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1466</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)84656-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2FS0040-4039%2801%2984656-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1972&pages=1465-1466&author=R.+Paulissenauthor=R.+J.+Hubertauthor=Ph.+Teyssie&title=Transition+metal+catalysed+cyclopropanation+of+olefin&doi=10.1016%2FS0040-4039%2801%2984656-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2984656-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252984656-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaulissen%26aufirst%3DR.%26aulast%3DHubert%26aufirst%3DR.%2BJ.%26aulast%3DTeyssie%26aufirst%3DPh.%26atitle%3DTransition%2520metal%2520catalysed%2520cyclopropanation%2520of%2520olefin%26jtitle%3DTetrahedron%2520Lett.%26date%3D1972%26volume%3D13%26spage%3D1465%26epage%3D1466%26doi%3D10.1016%2FS0040-4039%2801%2984656-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P. M.</span><span> </span><span class="NLM_article-title">A facile synthesis of 1-substituted cyclopropylsulfonamides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span><span class="refDoi"> DOI: 10.1055/s-2006-933130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1055%2Fs-2006-933130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=725-728&author=J.+Liauthor=D.+Smithauthor=H.+S.+Wongauthor=J.+A.+Campbellauthor=N.+A.+Meanwellauthor=P.+M.+Scola&title=A+facile+synthesis+of+1-substituted+cyclopropylsulfonamides&doi=10.1055%2Fs-2006-933130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933130%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DA%2520facile%2520synthesis%2520of%25201-substituted%2520cyclopropylsulfonamides%26jtitle%3DSynlett%26date%3D2006%26spage%3D725%26epage%3D728%26doi%3D10.1055%2Fs-2006-933130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hiebert, S.; Rajamani, R.; Sun, L.-Q.; Mull, Eric; Gillis, E. P.; Bowsher, M. S.; Zhao, Q.; Meanwell, N. A.; Renduchintala, K. V.; Sarkunam, K.; Nagalakshmi, P.; Babu, P. V. K. S.; Scola, P. M.</span><span> </span><span class="NLM_article-title">Preparation of macrocyclic peptides, especially proline-containing peptides, as inhibitors of hepatitis C virus replication</span>. World Patent Application, WO 2012151195.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hiebert%2C+S.%3B+Rajamani%2C+R.%3B+Sun%2C+L.-Q.%3B+Mull%2C+Eric%3B+Gillis%2C+E.+P.%3B+Bowsher%2C+M.+S.%3B+Zhao%2C+Q.%3B+Meanwell%2C+N.+A.%3B+Renduchintala%2C+K.+V.%3B+Sarkunam%2C+K.%3B+Nagalakshmi%2C+P.%3B+Babu%2C+P.+V.+K.+S.%3B+Scola%2C+P.+M.+Preparation+of+macrocyclic+peptides%2C+especially+proline-containing+peptides%2C+as+inhibitors+of+hepatitis+C+virus+replication.+World+Patent+Application%2C+WO+2012151195."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHiebert%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520macrocyclic%2520peptides%252C%2520especially%2520proline-containing%2520peptides%252C%2520as%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span>Full X-ray crystallographic data have been deposited with the Cambridge Crystallographic Data Center (CCDC reference number 1491198). Copies of the data can be obtained free of charge via the internet at <a href="http://www.ccdc.cam.ac.uk" class="extLink">http://www.ccdc.cam.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Full+X-ray+crystallographic+data+have+been+deposited+with+the+Cambridge+Crystallographic+Data+Center+%28CCDC+reference+number+1491198%29.+Copies+of+the+data+can+be+obtained+free+of+charge+via+the+internet+at+http%3A%2F%2Fwww.ccdc.cam.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e','cit9f','cit9g','cit9h','cit9i','cit9j','cit9k','cit9l','cit9m'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c','cit19d','cit19e'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 17 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Li-Qiang Sun, Eric Mull, Stanley D’Andrea, Barbara Zheng, Sheldon Hiebert, Eric Gillis, Michael Bowsher, Sarkunam Kandhasamy, Venkata Rao Baratam, Sunitha Puttaswamy, Nagalakshmi Pulicharla, Sureshbabu Vishwakrishnan, Subba Reddy, Ravi Trivedi, Sarmistha Sinha, Sankar Sivaprasad, Abhijith Rao, Salil Desai, Kaushik Ghosh, Rushith Anumula, Amit Kumar, Ramkumar Rajamani, Ying-Kai Wang, Hua Fang, Arvind Mathur, Richard Rampulla, Tatyana A. Zvyaga, Kathy Mosure, Susan Jenkins, Paul Falk, Debarati M. Tagore, Chaoqun Chen, Kishore Rendunchintala, James Loy, Nicholas A. Meanwell, Fiona McPhee, <span class="NLM_string-name hlFld-ContribAuthor">Paul M. Scola</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14740-14760. <a href="https://doi.org/10.1021/acs.jmedchem.0c01296" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01296%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986144%25252C%252Ba%252BThird-Generation%25252C%252BPan-Genotype%252BNS3%25252F4A%252BProtease%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DSun%26aufirst%3DLi-Qiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24072020%26date%3D23112020%26volume%3D63%26issue%3D23%26spage%3D14740%26epage%3D14760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5822-5880. <a href="https://doi.org/10.1021/acs.jmedchem.7b01788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFluorine%252Band%252BFluorinated%252BMotifs%252Bin%252Bthe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bfor%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05122017%26date%3D05022018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Zheng</span>, <span class="hlFld-ContribAuthor ">Stanley V.  D’Andrea</span>, <span class="hlFld-ContribAuthor ">Li-Qiang  Sun</span>, <span class="hlFld-ContribAuthor ">Alan Xiangdong  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Peter  Hrnciar</span>, <span class="hlFld-ContribAuthor ">Jacques  Friborg</span>, <span class="hlFld-ContribAuthor ">Paul  Falk</span>, <span class="hlFld-ContribAuthor ">Dennis  Hernandez</span>, <span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Amy K.  Sheaffer</span>, <span class="hlFld-ContribAuthor ">Jay O.  Knipe</span>, <span class="hlFld-ContribAuthor ">Kathy  Mosure</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Andrew C.  Good</span>, <span class="hlFld-ContribAuthor ">Kevin  Kish</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Tredup</span>, <span class="hlFld-ContribAuthor ">Herbert E.  Klei</span>, <span class="hlFld-ContribAuthor ">Manjula  Paruchuri</span>, <span class="hlFld-ContribAuthor ">Alicia  Ng</span>, <span class="hlFld-ContribAuthor ">Qi  Gao</span>, <span class="hlFld-ContribAuthor ">Richard A.  Rampulla</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Fiona  McPhee</span>, and <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 143-148. <a href="https://doi.org/10.1021/acsmedchemlett.7b00503" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00503</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00503%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%252BInhibitors%252Bof%252BHepatitis%252BC%252BVirus%252BNS3%252BProtease%25253A%252BEmployment%252Bof%252Ba%252BDifluoromethyl%252BGroup%252Bas%252Ba%252BHydrogen-Bond%252BDonor%26aulast%3DZheng%26aufirst%3DBarbara%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D04122017%26date%3D19012018%26date%3D24012018%26date%3D08022018%26date%3D19012018%26volume%3D9%26issue%3D2%26spage%3D143%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian S.  Young</span>, <span class="hlFld-ContribAuthor ">Yuping  Qiu</span>, <span class="hlFld-ContribAuthor ">Michael J.  Smith</span>, <span class="hlFld-ContribAuthor ">Michael B.  Hay</span>, and <span class="hlFld-ContribAuthor ">Wendel W.  Doubleday</span>  . </span><span class="cited-content_cbyCitation_article-title">Preparation of a Tricyclopropylamino Acid Derivative via Simmons–Smith Cyclopropanation with Downstream Intramolecular Aminoacetoxylation for Impurity Control. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (12)
                                     , 2108-2115. <a href="https://doi.org/10.1021/acs.oprd.6b00334" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00334</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00334%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DPreparation%252Bof%252Ba%252BTricyclopropylamino%252BAcid%252BDerivative%252Bvia%252BSimmons%2525E2%252580%252593Smith%252BCyclopropanation%252Bwith%252BDownstream%252BIntramolecular%252BAminoacetoxylation%252Bfor%252BImpurity%252BControl%26aulast%3DYoung%26aufirst%3DIan%2BS.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D08102016%26date%3D22112016%26date%3D16122016%26volume%3D20%26issue%3D12%26spage%3D2108%26epage%3D2115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gullapalli  Kumaraswamy</span>, <span class="hlFld-ContribAuthor ">Vankudoth  Ramesh</span>, <span class="hlFld-ContribAuthor ">Swargam  Vijaykumar</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective total synthesis of sesquiterpenoid phellilane L and its diastereomer. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>87 </em>, 132110. <a href="https://doi.org/10.1016/j.tet.2021.132110" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132110%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DEnantioselective%252Btotal%252Bsynthesis%252Bof%252Bsesquiterpenoid%252Bphellilane%252BL%252Band%252Bits%252Bdiastereomer%26aulast%3DKumaraswamy%26aufirst%3DGullapalli%26date%3D2021%26volume%3D87%26spage%3D132110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid G.  Menchikov</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shulishov</span>, <span class="hlFld-ContribAuthor ">Yury V.  Tomilov</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the catalytic cyclopropanation of unsaturated compounds with diazomethane. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2021,</strong> <em>90 </em>
                                    (2)
                                     , 199-230. <a href="https://doi.org/10.1070/RCR4982" title="DOI URL">https://doi.org/10.1070/RCR4982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4982%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bcatalytic%252Bcyclopropanation%252Bof%252Bunsaturated%252Bcompounds%252Bwith%252Bdiazomethane%26aulast%3DMenchikov%26aufirst%3DLeonid%2BG.%26date%3D2021%26volume%3D90%26issue%3D2%26spage%3D199%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yichao  Wan</span>, <span class="hlFld-ContribAuthor ">Yuanhua  Li</span>, <span class="hlFld-ContribAuthor ">Chunxing  Yan</span>, <span class="hlFld-ContribAuthor ">Jiajun  Wen</span>, <span class="hlFld-ContribAuthor ">Zilong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104217. <a href="https://doi.org/10.1016/j.bioorg.2020.104217" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104217%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bindazole-acylsulfonamide%252Bhybrids%252Bas%252Bselective%252BMcl-1%252Binhibitors%26aulast%3DWan%26aufirst%3DYichao%26date%3D2020%26volume%3D104%26spage%3D104217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley N.  Matthew</span>, <span class="hlFld-ContribAuthor ">Jacqueto  Zephyr</span>, <span class="hlFld-ContribAuthor ">Desaboini  Nageswara Rao</span>, <span class="hlFld-ContribAuthor ">Mina  Henes</span>, <span class="hlFld-ContribAuthor ">Wasih  Kamran</span>, <span class="hlFld-ContribAuthor ">Klajdi  Kosovrasti</span>, <span class="hlFld-ContribAuthor ">Adam K.  Hedger</span>, <span class="hlFld-ContribAuthor ">Gordon J.  Lockbaum</span>, <span class="hlFld-ContribAuthor ">Jennifer  Timm</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, <span class="hlFld-ContribAuthor ">Nese  Kurt Yilmaz</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>, . </span><span class="cited-content_cbyCitation_article-title">Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">mBio</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     <a href="https://doi.org/10.1128/mBio.00172-20" title="DOI URL">https://doi.org/10.1128/mBio.00172-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/mBio.00172-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FmBio.00172-20%26sid%3Dliteratum%253Aachs%26jtitle%3DmBio%26atitle%3DAvoiding%252BDrug%252BResistance%252Bby%252BSubstrate%252BEnvelope-Guided%252BDesign%25253A%252BToward%252BPotent%252Band%252BRobust%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitors%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2020%26volume%3D11%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nigel J.  Liverton</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of HCV NS3/4a Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 231-259. <a href="https://doi.org/10.1007/7355_2018_39" title="DOI URL">https://doi.org/10.1007/7355_2018_39</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_39%26sid%3Dliteratum%253Aachs%26atitle%3DEvolution%252Bof%252BHCV%252BNS3%25252F4a%252BProtease%252BInhibitors%26aulast%3DLiverton%26aufirst%3DNigel%2BJ.%26date%3D2019%26date%3D2019%26spage%3D231%26epage%3D259%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Chen</span>, <span class="hlFld-ContribAuthor ">Guanglin  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of acyl sulfonamides from carboxyic acids using the Mukaiyama reagent. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (3)
                                     , 268-271. <a href="https://doi.org/10.1016/j.tetlet.2018.12.030" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.12.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.12.030%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DFacile%252Bsynthesis%252Bof%252Bacyl%252Bsulfonamides%252Bfrom%252Bcarboxyic%252Bacids%252Busing%252Bthe%252BMukaiyama%252Breagent%26aulast%3DChen%26aufirst%3DLing%26date%3D2019%26volume%3D60%26issue%3D3%26spage%3D268%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N. V.  Yashin</span>. </span><span class="cited-content_cbyCitation_article-title">Methods for the preparation of 1-Aminocyclopropanecarboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">Review Journal of Chemistry</span><span> <strong>2018,</strong> <em>8 </em>
                                    (4)
                                     , 373-401. <a href="https://doi.org/10.1134/S2079978018040040" title="DOI URL">https://doi.org/10.1134/S2079978018040040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S2079978018040040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS2079978018040040%26sid%3Dliteratum%253Aachs%26jtitle%3DReview%2520Journal%2520of%2520Chemistry%26atitle%3DMethods%252Bfor%252Bthe%252Bpreparation%252Bof%252B1-Aminocyclopropanecarboxylic%252BAcids%26aulast%3DYashin%26aufirst%3DN.%2BV.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D4%26spage%3D373%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Bowsher</span>, <span class="hlFld-ContribAuthor ">Sheldon  Hiebert</span>, <span class="hlFld-ContribAuthor ">Rongti  Li</span>, <span class="hlFld-ContribAuthor ">Alan X.  Wang</span>, <span class="hlFld-ContribAuthor ">Jacques  Friborg</span>, <span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Dennis  Hernandez</span>, <span class="hlFld-ContribAuthor ">Ying-Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Herbert  Klei</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Kathy  Mosure</span>, <span class="hlFld-ContribAuthor ">Jay O.  Knipe</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Fiona  McPhee</span>, <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (1)
                                     , 43-48. <a href="https://doi.org/10.1016/j.bmcl.2017.11.005" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bdiscovery%252Band%252Boptimization%252Bof%252Bnaphthalene-linked%252BP2-P4%252BMacrocycles%252Bas%252Binhibitors%252Bof%252BHCV%252BNS3%252Bprotease%26aulast%3DBowsher%26aufirst%3DMichael%26date%3D2018%26volume%3D28%26issue%3D1%26spage%3D43%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Ammazzalorso</span>, <span class="hlFld-ContribAuthor ">Barbara  De Filippis</span>, <span class="hlFld-ContribAuthor ">Letizia  Giampietro</span>, <span class="hlFld-ContribAuthor ">Rosa  Amoroso</span>. </span><span class="cited-content_cbyCitation_article-title">N
              -acylsulfonamides: Synthetic routes and biological potential in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (6)
                                     , 1094-1105. <a href="https://doi.org/10.1111/cbdd.13043" title="DOI URL">https://doi.org/10.1111/cbdd.13043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13043%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DN%252B-acylsulfonamides%25253A%252BSynthetic%252Broutes%252Band%252Bbiological%252Bpotential%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DAmmazzalorso%26aufirst%3DAlessandra%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D6%26spage%3D1094%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen J.  Chawner</span>, <span class="hlFld-ContribAuthor ">Manuel J.  Cases-Thomas</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>2017 </em>
                                    (34)
                                     , 5015-5024. <a href="https://doi.org/10.1002/ejoc.201701030" title="DOI URL">https://doi.org/10.1002/ejoc.201701030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDivergent%252BSynthesis%252Bof%252BCyclopropane-Containing%252BLead-Like%252BCompounds%25252C%252BFragments%252Band%252BBuilding%252BBlocks%252Bthrough%252Ba%252BCobalt%252BCatalyzed%252BCyclopropanation%252Bof%252BPhenyl%252BVinyl%252BSulfide%26aulast%3DChawner%26aufirst%3DStephen%2BJ.%26date%3D2017%26date%3D2017%26volume%3D2017%26issue%3D34%26spage%3D5015%26epage%3D5024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangdi  Li</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Current therapy for chronic hepatitis C: The role of direct-acting antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2017,</strong> <em>142 </em>, 83-122. <a href="https://doi.org/10.1016/j.antiviral.2017.02.014" title="DOI URL">https://doi.org/10.1016/j.antiviral.2017.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2017.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DCurrent%252Btherapy%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BThe%252Brole%252Bof%252Bdirect-acting%252Bantivirals%26aulast%3DLi%26aufirst%3DGuangdi%26date%3D2017%26volume%3D142%26spage%3D83%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya  P Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">HCV NS3/4A Protease and its Emerging Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Analytical & Pharmaceutical Research</span><span> <strong>2017,</strong> <em>4 </em>
                                    (4)
                                     <a href="https://doi.org/10.15406/japlr.2017.04.00108" title="DOI URL">https://doi.org/10.15406/japlr.2017.04.00108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.15406/japlr.2017.04.00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.15406%2Fjaplr.2017.04.00108%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Analytical%2520%2526%2520Pharmaceutical%2520Research%26atitle%3DHCV%252BNS3%25252F4A%252BProtease%252Band%252Bits%252BEmerging%252BInhibitors%26aulast%3DP%2BGupta%26aufirst%3DSatya%26date%3D2017%26date%3D2017%26volume%3D4%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0001.jpeg" id="rightTab-GRAPHIC-d7e1157-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Model of <b>2</b> bound to the active site of HCV NS3 protease. (b–d) Models of the P1 element of analogues <b>6</b>, <b>7</b>, and <b>8</b> bound to the S1 subpocket of HCV NS3 protease.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Model of the (<i>S</i>)-configuration CF<sub>3</sub> group of <b>17</b> bound to the S4 groove. (b) Model of the (<i>R</i>)-configuration CF<sub>3</sub> group of <b>18</b> bound to the S4 groove.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of P1 Bi-cyclopropane-Based Dipeptide <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>2</sub>N<sub>2</sub>, Pd(OAc)<sub>2</sub>, ether, 0 °C to RT, 78%; (b) NaOH, MeOH, H<sub>2</sub>O, reflux, 98%; (c) CDI, cyclopropanesulfonamide, DBU, THF, reflux to RT, 88%; (d) 4 M HCl, dioxane, RT, quantitative yield; (e) HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 93%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. An Alternative Route for Synthesis of P1 Bi-cyclopropanedipeptide <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1<i>R</i>,2<i>S</i>)-ethyl 1-amino-2-vinylcyclopropanecarboxylate (HCl salt, <b>37</b>), HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 88%; (b) CH<sub>2</sub>N<sub>2</sub>, Pd(OAc)<sub>2</sub>, ether, 0 °C to RT, 88%; (c) NaOH, MeOH, H<sub>2</sub>O, reflux, quantitative yield; (d) CDI, cyclopropanesulfonamide, DBU, THF, reflux to RT, 94%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of P1 Bi-cyclopropane-Based Tripeptide <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4 M HCl, dioxane, RT, quantitative yield; (b) HATU, <i>i</i>-Pr<sub>2</sub>NEt, (<i>S</i>)-2-(<i>tert</i>-butoxycarbonylamino)-2-cyclohexylacetic acid, DCM, RT, 92%; (c) 4 M HCl, dioxane, RT, quantitative yield; (d) <b>44</b>, <i>i</i>-Pr<sub>2</sub>NEt, DCM, RT, 98%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/medium/jm-2016-00821x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single crystal X-ray structure of <b>29</b>. The molecular structure of <b>29</b> free acid determined by X-ray crystallography from a monohydrate crystal. Water molecules are excluded for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00821/20160901/images/large/jm-2016-00821x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00821&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kim, W. R.</span><span> </span><span class="NLM_article-title">Global epidemiology and burden of hepatitis C</span> <span class="citation_source-journal">Microbes Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span><span class="refDoi"> DOI: 10.1016/S1286-4579(02)01649-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2FS1286-4579%2802%2901649-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=12467763" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=1219-1225&author=W.+R.+Kim&title=Global+epidemiology+and+burden+of+hepatitis+C&doi=10.1016%2FS1286-4579%2802%2901649-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1286-4579%2802%2901649-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1286-4579%252802%252901649-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DW.%2BR.%26atitle%3DGlobal%2520epidemiology%2520and%2520burden%2520of%2520hepatitis%2520C%26jtitle%3DMicrobes%2520Infect.%26date%3D2002%26volume%3D4%26spage%3D1219%26epage%3D1225%26doi%3D10.1016%2FS1286-4579%2802%2901649-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">WHO</span><span> </span><span class="NLM_article-title">Hepatitis C global prevalence (update)</span> <span class="citation_source-journal">Weekly Epidemiol. Rec.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10645164" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1999&pages=425-427&author=WHO&title=Hepatitis+C+global+prevalence+%28update%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DHepatitis%2520C%2520global%2520prevalence%2520%2528update%2529%26jtitle%3DWeekly%2520Epidemiol.%2520Rec.%26date%3D1999%26volume%3D74%26spage%3D425%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hanafiah, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groeger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiersma, S. T.</span><span> </span><span class="NLM_article-title">Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span><span class="refDoi"> DOI: 10.1002/hep.26141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.26141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23172780" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1333-1342&author=K.+M.+Hanafiahauthor=J.+Groegerauthor=A.+D.+Flaxmanauthor=S.+T.+Wiersma&title=Global+epidemiology+of+hepatitis+C+virus+infection%3A+new+estimates+of+age-specific+antibody+to+HCV+seroprevalence&doi=10.1002%2Fhep.26141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhep.26141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26141%26sid%3Dliteratum%253Aachs%26aulast%3DHanafiah%26aufirst%3DK.%2BM.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520infection%253A%2520new%2520estimates%2520of%2520age-specific%2520antibody%2520to%2520HCV%2520seroprevalence%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D1333%26epage%3D1342%26doi%3D10.1002%2Fhep.26141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hajarazadeh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grebely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span> </span><span class="NLM_article-title">Epidemiology and natural history of HCV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnrgastro.2013.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23817321" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=553-562&author=B.+Hajarazadehauthor=J.+Grebelyauthor=G.+J.+Dore&title=Epidemiology+and+natural+history+of+HCV+infection&doi=10.1038%2Fnrgastro.2013.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.107%26sid%3Dliteratum%253Aachs%26aulast%3DHajarazadeh%26aufirst%3DB.%26aulast%3DGrebely%26aufirst%3DJ.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26atitle%3DEpidemiology%2520and%2520natural%2520history%2520of%2520HCV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D10%26spage%3D553%26epage%3D562%26doi%3D10.1038%2Fnrgastro.2013.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Gravitz, L.</span><span> </span><span class="NLM_article-title">Introduction: a smouldering public-health crisis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">474</span><span class="NLM_x">, </span> <span class="NLM_fpage">S2</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span><span class="refDoi"> DOI: 10.1038/474S2a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2F474S2a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=474&publication_year=2011&pages=S2-4&author=L.+Gravitz&title=Introduction%3A+a+smouldering+public-health+crisis&doi=10.1038%2F474S2a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F474S2a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F474S2a%26sid%3Dliteratum%253Aachs%26aulast%3DGravitz%26aufirst%3DL.%26atitle%3DIntroduction%253A%2520a%2520smouldering%2520public-health%2520crisis%26jtitle%3DNature%26date%3D2011%26volume%3D474%26spage%3DS2%26epage%3D4%26doi%3D10.1038%2F474S2a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Pathophysiology of hepatitis C virus infection and related liver disease</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.tim.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.tim.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=96-102&author=J.-M.+Pawlotsky&title=Pathophysiology+of+hepatitis+C+virus+infection+and+related+liver+disease&doi=10.1016%2Fj.tim.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DPathophysiology%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520related%2520liver%2520disease%26jtitle%3DTrends%2520Microbiol.%26date%3D2004%26volume%3D12%26spage%3D96%26epage%3D102%26doi%3D10.1016%2Fj.tim.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, T.</span><span> </span><span class="NLM_article-title">Pathogenesis of hepatitis C-associated hepatocellular carcinoma</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">S62</span><span class="NLM_x">–</span> <span class="NLM_lpage">S71</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1053%2Fj.gastro.2004.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=15508105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGmtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2004&pages=S62-S71&author=T.+J.+Liangauthor=T.+Heller&title=Pathogenesis+of+hepatitis+C-associated+hepatocellular+carcinoma&doi=10.1053%2Fj.gastro.2004.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of hepatitis C-associated hepatocellular carcinoma</span></div><div class="casAuthors">Liang, T. Jake; Heller, Theo</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5, Suppl. 1</span>),
    <span class="NLM_cas:pages">S62-S71</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Epidemiol., clin., and virol. data have shown a close assocn. between chronic infection with hepatitis C virus (HCV) and the development of hepatocellular carcinoma (HCC).  In many countries of the developed world, HCV infection accounts for more than half of the cases of HCC.  HCC usually arises after 2-4 decades of infection, typically in the context of an underlying cirrhosis.  Treatment of hepatitis C with interferon-alpha can lead to sustained clearance of HCV, and small prospective studies as well as larger retrospective analyses suggest that interferon therapy leads to a decrease in the incidence of HCC.  Without a reliable tissue culture system or a small animal model of HCV infection, anal. of the mechanisms by which HCV leads to cancer has been difficult.  Nevertheless, both in vitro expression systems and in vivo transgenic mice studies suggest that HCV has an inherent carcinogenic potential.  Understanding the pathogenesis of HCV-assocd. HCC is important in developing effective means of prevention and treatment of this highly malignant form of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3d-IaWg73rVg90H21EOLACvtfcHk0liMuZC8UyYoQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGmtb7F&md5=57f58df6ef197dcf191bfb8d5e53301f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DHeller%26aufirst%3DT.%26atitle%3DPathogenesis%2520of%2520hepatitis%2520C-associated%2520hepatocellular%2520carcinoma%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D127%26spage%3DS62%26epage%3DS71%26doi%3D10.1053%2Fj.gastro.2004.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Brown, R. S.</span><span> </span><span class="NLM_article-title">Hepatitis C and liver transplantation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature04083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnature04083" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=973-978&author=R.+S.+Brown&title=Hepatitis+C+and+liver+transplantation&doi=10.1038%2Fnature04083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature04083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04083%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DR.%2BS.%26atitle%3DHepatitis%2520C%2520and%2520liver%2520transplantation%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D973%26epage%3D978%26doi%3D10.1038%2Fnature04083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Rising mortality associated with hepatitis C virus in the United States, 2003–2013</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1093/cid/ciw111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1093%2Fcid%2Fciw111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=26936668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A280%3ADC%252BC28jms1GmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=1287-1288&author=K.+N.+Lyauthor=E.+M.+Hughesauthor=R.+B.+Jilesauthor=S.+D.+Holmberg&title=Rising+mortality+associated+with+hepatitis+C+virus+in+the+United+States%2C+2003%E2%80%932013&doi=10.1093%2Fcid%2Fciw111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013</span></div><div class="casAuthors">Ly Kathleen N; Hughes Elizabeth M; Jiles Ruth B; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1287-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the United States, hepatitis C virus (HCV)-associated mortality is increasing.  From 2003-2013, the number of deaths associated with HCV has now surpassed 60 other nationally notifiable infectious conditions combined.  The increasing HCV-associated mortality trend underscores the urgency in finding, evaluating, and treating HCV-infected persons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoe_9g9I16MQwxfk_AGB-EfW6udTcc2eYl_rpRf75k0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jms1GmsA%253D%253D&md5=46b872aaba7df1c731a1a068f2f5da54</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciw111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciw111%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DHughes%26aufirst%3DE.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DRising%2520mortality%2520associated%2520with%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%252C%25202003%25E2%2580%25932013%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D62%26spage%3D1287%26epage%3D1288%26doi%3D10.1093%2Fcid%2Fciw111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sr George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+Sr+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0ljvrXOcL2t3aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSr%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grand-Maître, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre-Paquette, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.-M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-activity+study+on+a+novel+series+of+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0li1Tq4_r8LkVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-activity%2520study%2520on%2520a%2520novel%2520series%2520of%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6466</span><span class="NLM_x">–</span> <span class="NLM_lpage">6476</span><span class="refDoi"> DOI: 10.1021/jm100690x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100690x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6466-6476&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=D.+N.+Goudreauauthor=P.+K.+Bhardwajauthor=J.+Bordeleauauthor=M.+B%C3%B6sauthor=Y.+Bousquetauthor=M.+G.+Cordingleyauthor=J.+Duanauthor=P.+Forgioneauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=S.+H.+Kawaiauthor=J.+Naudauthor=M.+A.+Poupartauthor=P.+W.+White&title=Discovery+of+a+potent+and+selective+noncovalent+linear+inhibitor+of+the+hepatitis+C+virus+NS3+protease+%28BI+201335%29&doi=10.1021%2Fjm100690x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Goudreau, Nathalie; Bhardwaj, Punit K.; Bordeleau, Josee; Bos, Michael; Bousquet, Yves; Cordingley, Michael G.; Duan, Jiamin; Forgione, Pat; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Goulet, Sylvie; Halmos, Ted; Kawai, Stephen H.; Naud, Julie; Poupart, Marc-Andre; White, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6466-6476</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Terminal carboxylic acid contg. inhibitors of the NS3 protease are reported.  A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described.  A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors.  The introduction of a C8 Me group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well.  Exploration of C8-substitutions led to the identification of the bromo deriv. as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors.  Structure-activity studies on the C8-bromo derivs. ultimately led to the discovery of clin. candidate 29 (BI 201335), a very potent and selective inhibitor of genotype1 NS3 protease with a promising PK profile in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxIrNdDYPMvbVg90H21EOLACvtfcHk0lhzEdVQhVKHNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLvI&md5=cec8d519d94e2946dd2700d4e0d4476e</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1021%2Fjm100690x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100690x%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DGoudreau%26aufirst%3DD.%2BN.%26aulast%3DBhardwaj%26aufirst%3DP.%2BK.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBousquet%26aufirst%3DY.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DForgione%26aufirst%3DP.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DNaud%26aufirst%3DJ.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520noncovalent%2520linear%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520%2528BI%2520201335%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6466%26epage%3D6476%26doi%3D10.1021%2Fjm100690x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.bmcl.2008.07.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=18678486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=%C3%85.+Rosenquistauthor=M.+Nilssonauthor=L.+Salvador-Odenauthor=T.+I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+Wahlingauthor=K.+Wickstromauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure-activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3%2F4A+protease+leading+to+the+discovery+of+TMC435350&doi=10.1016%2Fj.bmcl.2008.07.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350</span></div><div class="casAuthors">Raboisson, Pierre; de Kock, Herman; Rosenquist, Asa; Nilsson, Magnus; Salvador-Oden, Lourdes; Lin, Tse-I.; Roue, Natalie; Ivanov, Vladimir; Wahling, Horst; Wickstrom, Kristina; Hamelink, Elizabeth; Edlund, Michael; Vrang, Lotta; Vendeville, Sandrine; Van de Vreken, Wim; McGowan, David; Tahri, Abdellah; Hu, Lili; Boutton, Carlo; Lenz, Oliver; Delouvroy, Frederic; Pille, Geert; Surleraux, Dominique; Wigerinck, Piet; Samuelsson, Bertil; Simmen, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4853-4858</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">SAR anal. performed with a limited set of cyclopentane-contg. macrocycles led to the identification of TMC435350 (I) as a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).  TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies.  TMC435350 is currently being evaluated in the clinics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbRb8GhLBkJ7Vg90H21EOLACvtfcHk0lhzEdVQhVKHNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbvE&md5=001abd8307658a926479ff77496b6ff9</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.088%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DWahling%26aufirst%3DH.%26aulast%3DWickstrom%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure-activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858%26doi%3D10.1016%2Fj.bmcl.2008.07.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilja, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraznenok, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nystrom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span><span class="refDoi"> DOI: 10.1002/anie.200906696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fanie.200906696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVaktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1652-1655&author=M.+D.+Cummingsauthor=J.+Lindbergauthor=T.-I.+Linauthor=H.+de+Kockauthor=O.+Lenzauthor=E.+Liljaauthor=S.+Fellanderauthor=V.+Baraznenokauthor=S.+Nystromauthor=M.+Nilssonauthor=L.+Vrangauthor=M.+Edlundauthor=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.+Raboissonauthor=K.+Simmen&title=Induced-fit+binding+of+the+macrocyclic+noncovalent+inhibitor+TMC435+to+its+HCV+NS3%2FNS4A+protease+target&doi=10.1002%2Fanie.200906696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9eR"><div class="casContent"><span class="casTitleNuber">9e</span><div class="casTitle"><span class="NLM_cas:atitle">Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target</span></div><div class="casAuthors">Cummings, Maxwell D.; Lindberg, Jimmy; Lin, Tse-I.; de Kock, Herman; Lenz, Oliver; Lilja, Elisabet; Fellander, Sara; Baraznenok, Vera; Nystrom, Susanne; Nilsson, Magnus; Vrang, Lotta; Edlund, Michael; Rosenquist, Asa; Samuelsson, Bertil; Raboisson, Pierre; Simmen, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1652-1655, S1652/1-S1652/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We have detd. the crystal structure of the macrocyclic inhibitor TMC435 bound to its HCV NS3/4A protease target at a resoln. of 2.4 Å, providing at. detail of induced fit to an extended S2 subsite.  The complex structure helps to rationalize the impact of key modifications in the optimization path that led to 1, and is guiding our understanding of resistance patterns.  Future modeling and structure-based design efforts aimed at NS3/NS4A protease should benefit from the new structure, which represents the first example of a noncovalent NS3/NS4A protease-inhibitor complex deposited in the PDB and details the induced fit involved in accommodating a large P2 substituent.  Inhibitors with large P2 groups that occupy the extended S2 subsite probe the crystallog. obsd. helicase-protease interface, and it is hoped that future studies will clarify the relevance of interfacial contacts to protease activity and protease inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEYqCPA57hLVg90H21EOLACvtfcHk0ljk6gWcioxIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVaktbs%253D&md5=535b340784d1af62df32e8cf3bd3fe87</span></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1002%2Fanie.200906696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200906696%26sid%3Dliteratum%253Aachs%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DLilja%26aufirst%3DE.%26aulast%3DFellander%26aufirst%3DS.%26aulast%3DBaraznenok%26aufirst%3DV.%26aulast%3DNystrom%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DInduced-fit%2520binding%2520of%2520the%2520macrocyclic%2520noncovalent%2520inhibitor%2520TMC435%2520to%2520its%2520HCV%2520NS3%252FNS4A%2520protease%2520target%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D1652%26epage%3D1655%26doi%3D10.1002%2Fanie.200906696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BeumontMauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=%C3%85.+Rosenquistauthor=B.+Samuelssonauthor=P.+O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+BeumontMauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9fR"><div class="casContent"><span class="casTitleNuber">9f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0ljk6gWcioxIeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumontMauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1021/ja711120r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2-P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fja711120r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9gR"><div class="casContent"><span class="casTitleNuber">9g</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Based Approach to Potent P2-P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Liverton, Nigel J.; Holloway, M. Katharine; McCauley, John A.; Rudd, Michael T.; Butcher, John W.; Carroll, Steven S.; DiMuzio, Jillian; Fandozzi, Christine; Gilbert, Kevin F.; Mao, Shi-Shan; McIntyre, Charles J.; Nguyen, Kevin T.; Romano, Joseph J.; Stahlhut, Mark; Wan, Bang-Lin; Olsen, David B.; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4607-4609</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors.  Optimization of initial compds. provided 25a.  The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYenMBNqdeLVg90H21EOLACvtfcHk0ljVcXns9Uj2MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D&md5=5e7bb98bdb19c30bebb30f03a702838d</span></div><a href="/servlet/linkout?suffix=cit9g&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2-P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609%26doi%3D10.1021%2Fja711120r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.-L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.-S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9hR"><div class="casContent"><span class="casTitleNuber">9h</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0ljPQPfyO6ZoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit9h&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9iR"><div class="casContent"><span class="casTitleNuber">9i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0ljPQPfyO6ZoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit9i&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">P2-Quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-Quinazolinones+and+bis-macrocycles+as+new+templates+for+next-generation+hepatitis+C+virus+NS3%2F4a+protease+inhibitors%3A+discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9jR"><div class="casContent"><span class="casTitleNuber">9j</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lhVgmsWLAp4rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit9j&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-Quinazolinones%2520and%2520bis-macrocycles%2520as%2520new%2520templates%2520for%2520next-generation%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitors%253A%2520discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Neelamkavil, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockunier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chackalamannil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chelliah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clasby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colandrea, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eagen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcantonio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruck, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperbeck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velazquez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of MK-8831, A novel spiro-proline macrocycle as a pan-genotypic HCV- NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=111-116&author=S.+F.+Neelamkavilauthor=S.+Agrawalauthor=T.+Baraauthor=C.+Bennettauthor=S.+Bhatauthor=D.+Biswasauthor=L.+Brockunierauthor=N.+Buistauthor=D.+Burnetteauthor=M.+Cartwrightauthor=S.+Chackalamannilauthor=R.+Chaseauthor=M.+Chelliahauthor=A.+Chenauthor=M.+Clasbyauthor=V.+J.+Colandreaauthor=I.+W.+Daviesauthor=K.+Eagenauthor=Z.+Guoauthor=Y.+Hanauthor=J.+Howeauthor=C.+Jayneauthor=H.+Josienauthor=S.+Kargmanauthor=K.+Marcantonioauthor=S.+Miaoauthor=R.+Millerauthor=A.+Noltingauthor=P.+Pintoauthor=M.+Rajagopalanauthor=R.+T.+Ruckauthor=U.+Shahauthor=A.+Sorianoauthor=D.+Sperbeckauthor=F.+Velazquezauthor=J.+Wuauthor=Y.+Xiaauthor=S.+Venkatraman&title=Discovery+of+MK-8831%2C+A+novel+spiro-proline+macrocycle+as+a+pan-genotypic+HCV-+NS3%2F4a+protease+inhibitor&doi=10.1021%2Facsmedchemlett.5b00425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9k&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00425%26sid%3Dliteratum%253Aachs%26aulast%3DNeelamkavil%26aufirst%3DS.%2BF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DBara%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DC.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DBiswas%26aufirst%3DD.%26aulast%3DBrockunier%26aufirst%3DL.%26aulast%3DBuist%26aufirst%3DN.%26aulast%3DBurnette%26aufirst%3DD.%26aulast%3DCartwright%26aufirst%3DM.%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DChelliah%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DClasby%26aufirst%3DM.%26aulast%3DColandrea%26aufirst%3DV.%2BJ.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26aulast%3DEagen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJayne%26aufirst%3DC.%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DMarcantonio%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DNolting%26aufirst%3DA.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DRajagopalan%26aufirst%3DM.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DShah%26aufirst%3DU.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DSperbeck%26aufirst%3DD.%26aulast%3DVelazquez%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520MK-8831%252C%2520A%2520novel%2520spiro-proline%2520macrocycle%2520as%2520a%2520pan-genotypic%2520HCV-%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D111%26epage%3D116%26doi%3D10.1021%2Facsmedchemlett.5b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condroski, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serebryany, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenglowsky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madduru, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geck Do, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stengel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigelman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, S. D.</span><span> </span><span class="NLM_article-title">Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1021/jm400164c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400164c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1753-1769&author=Y.+Jiangauthor=S.+W.+Andrewsauthor=K.+R.+Condroskiauthor=B.+Buckmanauthor=V.+Serebryanyauthor=S.+Wenglowskyauthor=A.+L.+Kennedyauthor=M.+R.+Madduruauthor=B.+Wangauthor=M.+Lyonauthor=G.+A.+Dohertyauthor=B.+T.+Woodardauthor=C.+Lemieuxauthor=M.+Geck+Doauthor=H.+Zhangauthor=J.+Ballardauthor=G.+Vigersauthor=B.+J.+Brandhuberauthor=P.+Stengelauthor=J.+A.+Joseyauthor=L.+Beigelmanauthor=L.+Blattauthor=S.+D.+Seiwert&title=Discovery+of+danoprevir+%28ITMN-191%2FR7227%29%2C+a+highly+selective+and+potent+inhibitor+of+hepatitis+C+virus+%28HCV%29+NS3%2F4A+protease&doi=10.1021%2Fjm400164c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9lR"><div class="casContent"><span class="casTitleNuber">9l</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease</span></div><div class="casAuthors">Jiang, Yutong; Andrews, Steven W.; Condroski, Kevin R.; Buckman, Brad; Serebryany, Vlad; Wenglowsky, Steve; Kennedy, April L.; Madduru, Machender R.; Wang, Bin; Lyon, Michael; Doherty, George A.; Woodard, Benjamin T.; Lemieux, Christine; Do, Mary Geck; Zhang, Hailong; Ballard, Joshua; Vigers, Guy; Brandhuber, Barbra J.; Stengel, Peter; Josey, John A.; Beigelman, Leonid; Blatt, Lawrence; Seiwert, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1753-1769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system.  Through structure-based drug design and optimization, macrocyclic peptidomimetic mols. bearing both a lipophilic P2 isoindoline carbamate and a P1/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepd. that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7).  Danoprevir (compd. 49) was selected as the clin. development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species.  X-ray crystallog. studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to the iterative structure-based design strategy of the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplS3sgoIBu_7Vg90H21EOLACvtfcHk0lhlW38-EwUFPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D&md5=2a979cd1202b9360bcef316dddd8382f</span></div><a href="/servlet/linkout?suffix=cit9l&amp;dbid=16384&amp;doi=10.1021%2Fjm400164c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400164c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DCondroski%26aufirst%3DK.%2BR.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DA.%2BL.%26aulast%3DMadduru%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DWoodard%26aufirst%3DB.%2BT.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DGeck%2BDo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DStengel%26aufirst%3DP.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520danoprevir%2520%2528ITMN-191%252FR7227%2529%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1753%26epage%3D1769%26doi%3D10.1021%2Fjm400164c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Sheng, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, W. E.,  IV</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerffler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pakdaman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyun, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C. U.</span><span> </span><span class="NLM_article-title">Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1396</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.bmcl.2011.12.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1394-1396&author=X.+C.+Shengauthor=A.+Casarezauthor=R.+Caiauthor=M.+O.+Clarkeauthor=X.+Chenauthor=A.+Choauthor=W.+E.+Delaneyauthor=E.+Doerfflerauthor=M.+Jiauthor=M.+Mertzmanauthor=R.+Pakdamanauthor=H.-J.+Pyunauthor=T.+Roweauthor=Q.+Wuauthor=J.+Xuauthor=C.+U.+Kim&title=Discovery+of+GS-9256%3A+a+novel+phosphinic+acid+derived+inhibitor+of+the+hepatitis+C+virus+NS3%2F4A+protease+with+potent+clinical+activity&doi=10.1016%2Fj.bmcl.2011.12.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DX.%2BC.%26aulast%3DCasarez%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DR.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DPakdaman%26aufirst%3DR.%26aulast%3DPyun%26aufirst%3DH.-J.%26aulast%3DRowe%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DC.%2BU.%26atitle%3DDiscovery%2520of%2520GS-9256%253A%2520a%2520novel%2520phosphinic%2520acid%2520derived%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%2520with%2520potent%2520clinical%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1394%26epage%3D1396%26doi%3D10.1016%2Fj.bmcl.2011.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1755&author=P.+M.+Scolaauthor=A.+Wangauthor=A.+C.+Goodauthor=L.-Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.+Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.+H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1755%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Langendorff, O.</span><span> </span><span class="NLM_article-title">Untersuchungen am uberleberden saugerleizen</span> <span class="citation_source-journal">Pfluegers Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1895</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span><span class="refDoi"> DOI: 10.1007/BF01812150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2FBF01812150" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1895&pages=291-332&author=O.+Langendorff&title=Untersuchungen+am+uberleberden+saugerleizen&doi=10.1007%2FBF01812150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2FBF01812150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01812150%26sid%3Dliteratum%253Aachs%26aulast%3DLangendorff%26aufirst%3DO.%26atitle%3DUntersuchungen%2520am%2520uberleberden%2520saugerleizen%26jtitle%3DPfluegers%2520Arch.%26date%3D1895%26volume%3D61%26spage%3D291%26epage%3D332%26doi%3D10.1007%2FBF01812150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lhJgzgzHGBGAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span> </span><span class="NLM_article-title">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5387</span><span class="NLM_x">–</span> <span class="NLM_lpage">5396</span><span class="refDoi"> DOI: 10.1128/AAC.01186-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.01186-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=22869577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5387-5396&author=F.+McPheeauthor=A.+K.+Sheafferauthor=J.+Friborgauthor=D.+Hernandezauthor=P.+Falkauthor=G.+Zhaiauthor=S.+Levineauthor=S.+Chaniewskiauthor=F.+Yuauthor=D.+Barryauthor=C.+Chenauthor=M.+S.+Leeauthor=K.+Mosureauthor=L.-Q.+Sunauthor=M.+Sinzauthor=N.+A.+Meanwellauthor=R.+J.+Colonnoauthor=J.+Knipeauthor=P.+Scola&title=Preclinical+profile+and+characterization+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir+%28BMS-650032%29&doi=10.1128%2FAAC.01186-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span></div><div class="casAuthors">McPhee, Fiona; Sheaffer, Amy K.; Friborg, Jacques; Hernandez, Dennis; Falk, Paul; Zhai, Guangzhi; Levine, Steven; Chaniewski, Susan; Yu, Fei; Barry, Diana; Chen, Chaoqun; Lee, Min S.; Mosure, Kathy; Sun, Li-Qiang; Sinz, Michael; Meanwell, Nicholas A.; Colonno, Richard J.; Knipe, Jay; Scola, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5387-5396</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients chronically infected with HCV genotype 1 when combined with alfa interferon and/or the NS5A replication complex inhibitor daclatasvir.  ASV competitively binds to the NS3/4A protease complex, with Ki values of 0.4 and 0.24 nM against recombinant enzymes representing genotypes 1a (H77) and 1b (J4L6S), resp.  Selectivity was demonstrated by the absence of any significant activity against the closely related GB virus-B NS3 protease and a panel of human serine or cysteine proteases.  In cell culture, ASV inhibited replication of HCV replicons representing genotypes 1 and 4, with 50% effective concns. (EC50s) ranging from 1 to 4 nM, and had weaker activity against genotypes 2 and 3 (EC50, 67 to 1,162 nM).  Selectivity was again demonstrated by the absence of activity (EC50, >12 μM) against a panel of other RNA viruses.  ASV exhibited additive or synergistic activity in combination studies with alfa interferon, ribavirin, and/or inhibitors specifically targeting NS5A or NS5B.  Plasma and tissue exposures in vivo in several animal species indicated that ASV displayed a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥110-fold above the inhibitor EC50s obsd. with HCV genotype-1 replicons.  Based on these virol. and exposure properties, ASV holds promise for future utility in a combination with other anti-HCV agents in the treatment of HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvSH5FRWqFbVg90H21EOLACvtfcHk0lhJgzgzHGBGAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL&md5=9bbf4ea33b5c4ef48850ade4af9cfd1d</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1128%2FAAC.01186-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01186-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DScola%26aufirst%3DP.%26atitle%3DPreclinical%2520profile%2520and%2520characterization%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520%2528BMS-650032%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5387%26epage%3D5396%26doi%3D10.1128%2FAAC.01186-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/hep.24724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders&doi=10.1002%2Fhep.24724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fhep.24724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villegas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1128/AAC.05854-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.05854-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1838-1844&author=C.+Pasquinelliauthor=F.+McPheeauthor=T.+Eleyauthor=C.+Villegasauthor=K.+Sandyauthor=P.+Sheridanauthor=A.+Perssonauthor=S.-P.+Huangauthor=D.+Hernandezauthor=A.+K.+Sheafferauthor=P.+Scolaauthor=T.+Marburyauthor=E.+Lawitzauthor=R.+Goldwaterauthor=M.+Rodriguez-Torresauthor=M.+DeMiccoauthor=D.+Wrightauthor=M.+Charltonauthor=W.+K.+Kraftauthor=J.-C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Single-+and+multiple-ascending-dose+studies+of+the+NS3+protease+inhibitor+asunaprevir+in+subjects+with+or+without+chronic+hepatitis+C&doi=10.1128%2FAAC.05854-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1128%2FAAC.05854-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05854-11%26sid%3Dliteratum%253Aachs%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DVillegas%26aufirst%3DC.%26aulast%3DSandy%26aufirst%3DK.%26aulast%3DSheridan%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DDeMicco%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DD.%26aulast%3DCharlton%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DW.%2BK.%26aulast%3DLopez-Talavera%26aufirst%3DJ.-C.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DSingle-%2520and%2520multiple-ascending-dose%2520studies%2520of%2520the%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520in%2520subjects%2520with%2520or%2520without%2520chronic%2520hepatitis%2520C%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1838%26epage%3D1844%26doi%3D10.1128%2FAAC.05854-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options&doi=10.1016%2Fj.jhep.2012.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lhqrtOt0hxhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.jhep.2012.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+pegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders&doi=10.1016%2Fj.jhep.2013.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0lhqrtOt0hxhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520pegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499%26doi%3D10.1016%2Fj.jhep.2013.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2091</span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=2083-2091&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D2083%26epage%3D2091%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Poole, R.</span><span> </span><span class="NLM_article-title">Daclatasvir + asunaprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1007/s40265-014-0279-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2Fs40265-014-0279-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25117197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1559-1571&author=R.+Poole&title=Daclatasvir+%2B+asunaprevir%3A+first+global+approval&doi=10.1007%2Fs40265-014-0279-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir + Asunaprevir: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1559-1571</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.  Daclatasvir + asunaprevir has received its first global approval in this indication in Japan.  Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication.  This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF9-lXzdKBdbVg90H21EOLACvtfcHk0lgM3jwYAm609Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M&md5=efde97ee214598388e1db80bb303d1c6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0279-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0279-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%26atitle%3DDaclatasvir%2520%252B%2520asunaprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1559%26epage%3D1571%26doi%3D10.1007%2Fs40265-014-0279-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1053/j.gastro.2013.10.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-naive+patients+with+HCV+genotype+1+infection&doi=10.1053%2Fj.gastro.2013.10.057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-naive%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429%26doi%3D10.1053%2Fj.gastro.2013.10.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rege, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1204</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2Fj.jhep.2014.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=25559328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1204-1206&author=T.+Hassaneinauthor=K.+D.+Simsauthor=M.+Bennettauthor=N.+Gitlinauthor=R.+Lawitzauthor=T.+Nguyenauthor=L.+Websterauthor=Z.+Younossiauthor=H.+Schwartzauthor=P.+J.+Thuluvathauthor=H.+Zhouauthor=B.+Regeauthor=F.+McPheeauthor=N.+Zhouauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=A.+Griffiesauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=A+randomized+trial+of+daclatasvir+in+combination+with+asunaprevir+and+beclabuvir+in+patients+with+chronic+hepatitis+C+virus+genotype+4+infection&doi=10.1016%2Fj.jhep.2014.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection</span></div><div class="casAuthors">Hassanein, Tarek; Sims, Karen D.; Bennett, Michael; Gitlin, Norman; Lawitz, Eric; Nguyen, Tuan; Webster, Lynn; Younossi, Zobair; Schwartz, Howard; Thuluvath, Paul J.; Zhou, Helen; Rege, Bhaskar; McPhee, Fiona; Zhou, Nannan; Wind-Rotolo, Megan; Chung, Ellen; Griffies, Amber; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1204-1206</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This article study on randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.  This exploratory evaluation, 12 wk of treatment with the IFN- and ribavirin-free combination of daclatasvir, asunaprevir and beclabuvir was well tolerated and resulted in a high rate of SVR in previously untreated patients with chronic HCV genotype 4 infection, consistent with previous results in genotype 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcm7Cxr3vteLVg90H21EOLACvtfcHk0lgsxkgridz2fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWksrs%253D&md5=32599c24e540bf543d1e471ab5e12b0f</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DLawitz%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DRege%26aufirst%3DB.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DA%2520randomized%2520trial%2520of%2520daclatasvir%2520in%2520combination%2520with%2520asunaprevir%2520and%2520beclabuvir%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25204%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D1204%26epage%3D1206%26doi%3D10.1016%2Fj.jhep.2014.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Toyota, J; Karino, Y.; Suzuki, F.; Ikeda, F.; Ido, A.; Tanaka, K.; Takaguchi, K.; Naganuma, A.; Tomita, E.; Chayama, K.; Fujiyama, S.; Inada, Y.; Yoshiji, H.; Watanabe, H.; Ishikawa, H.; Hu, W.; McPhee, F.; Linaberry, M.; Yin, P. D.; Swenson, E. S.; Kumada, H.</span><span> </span><span class="NLM_article-title">Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection</span>.  <span class="citation_source-journal">J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span>ASAP, DOI <span class="refDoi"> DOI: 10.1007/s00535-016-1245-6</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1007%2Fs00535-016-1245-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=26456168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J+Toyota&author=Y.+Karino&author=F.+Suzuki&author=F.+Ikeda&author=A.+Ido&author=K.+Tanaka&author=K.+Takaguchi&author=A.+Naganuma&author=E.+Tomita&author=K.+Chayama&author=S.+Fujiyama&author=Y.+Inada&author=H.+Yoshiji&author=H.+Watanabe&author=H.+Ishikawa&author=W.+Hu&author=F.+McPhee&author=M.+Linaberry&author=P.+D.+Yin&author=E.+S.+Swenson&author=H.+Kumada&title=Daclatasvir%2Fasunaprevir%2Fbeclabuvir+fixed-dose+combination+in+Japanese+patients+with+HCV+genotype+1+infection&doi=10.1007%2Fs00535-016-1245-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1007%2Fs00535-016-1245-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00535-016-1245-6%26sid%3Dliteratum%253Aachs%26aulast%3DToyota%26aufirst%3DJ%26atitle%3DDaclatasvir%252Fasunaprevir%252Fbeclabuvir%2520fixed-dose%2520combination%2520in%2520Japanese%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Gastroenterol.%26date%3D2015%26doi%3D10.1007%2Fs00535-016-1245-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wang, X. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A.</span><span> </span><span class="NLM_article-title">Hepatitis C virus inhibitors</span>. U.S. Patent 6,995,174,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=X.+A.+Wang&author=L.-Q.+Sun&author=S.-Y.+Sit&author=N.+Sin&author=P.+M.+Scola&author=P.+Hewawasam&author=A.+C.+Good&author=Y.+Chen&author=J.+A.+Campbell&title=Hepatitis+C+virus+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26atitle%3DHepatitis%2520C%2520virus%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system and its application to molecular studies</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=657-664&author=T.+Pietschmannauthor=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system+and+its+application+to+molecular+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%2520and%2520its%2520application%2520to%2520molecular%2520studies%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2001%26volume%3D4%26spage%3D657%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span><span class="refDoi"> DOI: 10.3851/IMP1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.3851%2FIMP1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=21817192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ejtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=705-718&author=A.+K.+Sheafferauthor=M.+S.+Leeauthor=D.+Hernandezauthor=S.+Chaniewskiauthor=F.+Yuauthor=P.+Falkauthor=J.+Friborgauthor=G.+Zhaiauthor=F.+McPhee&title=Development+of+a+chimeric+replicon+system+for+phenotypic+analysis+of+NS3+protease+sequences+from+HCV+clinical+isolates&doi=10.3851%2FIMP1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates</span></div><div class="casAuthors">Sheaffer, Amy K.; Lee, Min S.; Hernandez, Dennis; Chaniewski, Susan; Yu, Fei; Falk, Paul; Friborg, Jacques; Zhai, Guangzhi; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">705-718</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Background: To support clin. development of HCV non-structural protein (NS) 3 protease inhibitors (PIs), phenotypic monitoring of patient isolates is a prerequisite for understanding the emergence of resistance.  HCV isolates typically fail to replicate in cell culture, necessitating the use of alternative phenotyping methods.  Methods: An NS3 protease chimeric replicon system was developed to monitor the phenotype of clin. isolates.  The transfer of NS3 protease domain sequences from HCV-infected patients to the background of genotype (Gt) 1a-H77c, 1b-Con1 and 2a-JFH-1 lab strain replicons adapted to high-level cell culture replication was investigated.  Results: NS3 protease sequences derived from HCVGt 1a or Gt 1b infected patients were transferred into Gt 1a and 1b replicons, resp.  Replication was detected for 20% of Gt 1a and 75% of Gt 1b sequences.  Incorporation of known cell culture adaptive change NS3-E17GG improved replication of Gt 1b but not of Gt 1a sequences.  Transfer of Gt 1a clin. sequences into the Gt 1b background enhanced replication and allowed phenotypic anal. of all sequences.  A correlation was obsd. between clin. isolate sequence polymorphisms and reduced susceptibility to NS3 PI.  In mixed populations contg. known NS3 PI resistance changes NS3-R155K or D168E/V, sensitivity of resistance detection was ≥10%.  Conclusions: An HCV replicon capable of supporting phenotypic characterization of patient-derived HCV NS3 protease sequences was developed.  Pre-existence of amino acid changes assocd. with NS3 PI resistance highlights the need for combination therapies in the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJOI_kZXu-LVg90H21EOLACvtfcHk0lizIhFrzPkSBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ejtb%252FN&md5=bfc492cd71ce4dbbbc9ce17e2b8f83c5</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.3851%2FIMP1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP1825%26sid%3Dliteratum%253Aachs%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520replicon%2520system%2520for%2520phenotypic%2520analysis%2520of%2520NS3%2520protease%2520sequences%2520from%2520HCV%2520clinical%2520isolates%26jtitle%3DAntiviral%2520Ther.%26date%3D2011%26volume%3D16%26spage%3D705%26epage%3D718%26doi%3D10.3851%2FIMP1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1002/jps.24356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1002%2Fjps.24356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=2813-2823&author=K.+W.+Mosureauthor=J.+O.+Knipeauthor=M.+Browningauthor=V.+Aroraauthor=Y.+Z.+Shuauthor=T.+Phillipauthor=F.+Mcpheeauthor=P.+Scolaauthor=A.+Balakrishnanauthor=M.+G.+Soarsauthor=K.+Santoneauthor=M.+Sinz&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+asunaprevir+%28BMS-650032%29%2C+a+potent+hepatitis+C+virus+NS3+protease+inhibitor&doi=10.1002%2Fjps.24356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fjps.24356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24356%26sid%3Dliteratum%253Aachs%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBrowning%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DPhillip%26aufirst%3DT.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DSantone%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D2813%26epage%3D2823%26doi%3D10.1002%2Fjps.24356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gillis, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Applications of fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8315</span><span class="NLM_x">–</span> <span class="NLM_lpage">8359</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+fluorine+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lizIhFrzPkSBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Diana, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevear, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldous, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldous, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutko, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gendron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oglesby, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkots, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reurnan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerniak, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppermand, J.</span><span> </span><span class="NLM_article-title">Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1021/jm00008a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADyaK2MXkvVWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1355-1371&author=G.+D.+Dianaauthor=P.+Rudewiczauthor=D.+C.+Pevearauthor=T.+J.+Nitzauthor=S.+C.+Aldousauthor=D.+J.+Aldousauthor=D.+T.+Robinsonauthor=T.+Draperauthor=F.+J.+Dutkoauthor=C.+Aldiauthor=G.+Gendronauthor=R.+C.+Oglesbyauthor=D.+L.+Volkotsauthor=M.+Reurnanauthor=T.+R.+Baileyauthor=R.+Czerniakauthor=T.+Blockauthor=R.+Rolandauthor=J.+Oppermand&title=Picornavirus+inhibitors%3A+trifluoromethyl+substitution+provides+a+global+protective+effect+against+hepatic+metabolism&doi=10.1021%2Fjm00008a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism</span></div><div class="casAuthors">Diana, Guy D.; Rudewicz, Patrick; Pevear, Daniel C.; Nitz, Theodore J.; Aldous, Suzanne C.; Aldous, David J.; Robinson, David T.; Draper, Tandy; Dutko, Frank J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several modifications of the oxazoline ring of WIN 54954, a broad spectrum antipicornavirus compd., have been prepd. to address the acid lability and metabolic instability of this compd.  The authors have previously shown that the oxadiazole analog (I) displayed comparable activity against a variety of rhinoviruses and appeared to be stable to acid.  A monkey liver microsomal assay was developed to examine the metabolic stability in vitro of both compds., and it was detd. that WIN 54954 displayed 18 metabolic products while I was converted to 8 products.  Two major products of I were detd. by LC-MS/MS to be monohydroxylated at each of the terminal Me groups.  Replacement of the Me on the isoxazole ring with a trifluoromethyl group, while preventing hydroxylation at this position, did not reduce the sensitivity of the mol. to microsomal metab. at other sites.  However, the (trifluoromethyl)oxadiazole not only prevented hydroxylation at this position but also provided protection at the isoxazole end of the mol., resulting in only two minor products to the extent of 4%.  The major product was identified as the monohydroxylated compd.  The global metabolic protective effect of trifluoromethyl group on the oxadiazole ring was further demonstrated by examg. a variety of analogous including heterocyclic replacements of the isoxazole ring.  In each case, the trifluoromethyl analog displayed a protective effect when compared to the corresponding Me analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnMwEotZAx-bVg90H21EOLACvtfcHk0liQZo9X7ANt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvVWqtLs%253D&md5=36a8ac2604f10f57d2aad9b131d84734</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a014%26sid%3Dliteratum%253Aachs%26aulast%3DDiana%26aufirst%3DG.%2BD.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DPevear%26aufirst%3DD.%2BC.%26aulast%3DNitz%26aufirst%3DT.%2BJ.%26aulast%3DAldous%26aufirst%3DS.%2BC.%26aulast%3DAldous%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DD.%2BT.%26aulast%3DDraper%26aufirst%3DT.%26aulast%3DDutko%26aufirst%3DF.%2BJ.%26aulast%3DAldi%26aufirst%3DC.%26aulast%3DGendron%26aufirst%3DG.%26aulast%3DOglesby%26aufirst%3DR.%2BC.%26aulast%3DVolkots%26aufirst%3DD.%2BL.%26aulast%3DReurnan%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DT.%2BR.%26aulast%3DCzerniak%26aufirst%3DR.%26aulast%3DBlock%26aufirst%3DT.%26aulast%3DRoland%26aufirst%3DR.%26aulast%3DOppermand%26aufirst%3DJ.%26atitle%3DPicornavirus%2520inhibitors%253A%2520trifluoromethyl%2520substitution%2520provides%2520a%2520global%2520protective%2520effect%2520against%2520hepatic%2520metabolism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1355%26epage%3D1371%26doi%3D10.1021%2Fjm00008a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalchick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">(2<i>R</i>)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-<i>a</i>]pyrazin-7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5D-triazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+a+potent%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255D-triazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520a%2520potent%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Barnes-Seeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatsis, P.</span><span> </span><span class="NLM_article-title">Metabolically stable tertbutyl replacement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/ml400045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=514-516&author=D.+Barnes-Seemanauthor=M.+Jainauthor=L.+Bellauthor=S.+Ferreiraauthor=S.+Cohenauthor=X.+H.+Chenauthor=J.+Aminauthor=B.+Snodgrassauthor=P.+Hatsis&title=Metabolically+stable+tertbutyl+replacement&doi=10.1021%2Fml400045j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1021%2Fml400045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400045j%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DAmin%26aufirst%3DJ.%26aulast%3DSnodgrass%26aufirst%3DB.%26aulast%3DHatsis%26aufirst%3DP.%26atitle%3DMetabolically%2520stable%2520tertbutyl%2520replacement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D514%26epage%3D516%26doi%3D10.1021%2Fml400045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Huchet, Q. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratochwil, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span> </span><span class="NLM_article-title">Fluorination patterning: a study of structural motifs that impact physicochemical properties of relevance to drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9041</span><span class="NLM_x">–</span> <span class="NLM_lpage">9060</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9041-9060&author=Q.+A.+Huchetauthor=B.+Kuhnauthor=B.+Wagnerauthor=N.+A.+Kratochwilauthor=H.+Fischerauthor=M.+Kansyauthor=D.+Zimmerliauthor=E.+M.+Carreiraauthor=K.+Muller&title=Fluorination+patterning%3A+a+study+of+structural+motifs+that+impact+physicochemical+properties+of+relevance+to+drug+discovery&doi=10.1021%2Facs.jmedchem.5b01455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19eR"><div class="casContent"><span class="casTitleNuber">19e</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorination Patterning: A Study of Structural Motifs That Impact Physicochemical Properties of Relevance to Drug Discovery</span></div><div class="casAuthors">Huchet, Quentin A.; Kuhn, Bernd; Wagner, Bjorn; Kratochwil, Nicole A.; Fischer, Holger; Kansy, Manfred; Zimmerli, Daniel; Carreira, Erick M.; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9041-9060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a collection of 3-substituted indole derivs. incorporating partially fluorinated Pr and Bu groups is described along with an in-depth study of the effects of various fluorination patterns on their properties, such as lipophilicity, aq. soly., and metabolic stability.  The exptl. observations confirm predictions of a marked lipophilicity decrease imparted by a vic-difluoro unit when compared to the gem-difluoro counterparts.  The data involving the comparison of the two substitution patterns is expected to benefit mol. design in medicinal chem. and, more broadly, in life as well as materials sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp49KCeC1WDm7Vg90H21EOLACvtfcHk0lgRm6MthYIWlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsrzM&md5=20d7a36b75501c02570744857c82f325</span></div><a href="/servlet/linkout?suffix=cit19e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01455%26sid%3Dliteratum%253Aachs%26aulast%3DHuchet%26aufirst%3DQ.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKratochwil%26aufirst%3DN.%2BA.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DFluorination%2520patterning%253A%2520a%2520study%2520of%2520structural%2520motifs%2520that%2520impact%2520physicochemical%2520properties%2520of%2520relevance%2520to%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9041%26epage%3D9060%26doi%3D10.1021%2Facs.jmedchem.5b01455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3670</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1128/AAC.00308-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1128%2FAAC.00308-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=22508297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2is7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3670-3681&author=F.+McPheeauthor=J.+Friborgauthor=S.+Levineauthor=C.+Chenauthor=P.+Falkauthor=F.+Yuauthor=D.+Hernandezauthor=M.+S.+Leeauthor=S.+Chaniewskiauthor=A.+K.+Sheafferauthor=C.+Pasquinelli&title=Resistance+analysis+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir&doi=10.1128%2FAAC.00308-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir</span></div><div class="casAuthors">McPhee, Fiona; Friborg, Jacques; Levine, Steven; Chen, Chaoqun; Falk, Paul; Yu, Fei; Hernandez, Dennis; Lee, Min S.; Chaniewski, Susan; Sheaffer, Amy K.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3670-3681</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor demonstrating efficacy in alfa interferon-sparing, direct-acting antiviral dual-combination regimens (together with the NS5A replication complex inhibitor daclatasvir) in patients chronically infected with HCV genotype 1b.  Here, we describe a comprehensive in vitro genotypic and phenotypic anal. of asunaprevir-assocd. resistance against genotypes 1a and 1b using HCV replicons and patient samples obtained from clin. studies of short-term asunaprevir monotherapy.  During genotype 1a resistance selection using HCV replicons, the primary NS3 protease substitutions identified were R155K, D168G, and I170T, which conferred low- to moderate-level asunaprevir resistance (5- to 21-fold) in transient-transfection susceptibility assays.  For genotype 1b, a higher level of asunaprevir-assocd. resistance was obsd. at the same selection pressures, ranging from 170- to 400-fold relative to the wild-type control.  The primary NS3 protease substitutions identified occurred predominantly at amino acid residue D168 (D168A/G/H/V/Y) and were assocd. with high-level asunaprevir resistance (16- to 280-fold) and impaired replication capacity.  In asunaprevir single-ascending-dose and 3-day multiple-ascending-dose studies in HCV genotype 1a- or 1b-infected patients, the predominant pre-existing NS3 baseline polymorphism was NS3-Q80K.  This substitution impacted initial virol. response rates in a single-ascending-dose study, but its effects after multiple doses were more ambiguous.  Interestingly, for patient NS3 protease sequences contg. Q80 and those contg. K80, susceptibilities to asunaprevir were comparable when tested in an enzyme assay.  No resistance-assocd. variants emerged in these clin. studies that significantly impacted susceptibility to asunaprevir.  Importantly, asunaprevir-resistant replicons remained susceptible to an NS5A replication complex inhibitor, consistent with a role for asunaprevir in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNf2shzFcn47Vg90H21EOLACvtfcHk0lhMUsj5L1ogTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2is7s%253D&md5=713c87d4123a5769f47eb51d52ebd044</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.00308-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00308-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DResistance%2520analysis%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D3670%26epage%3D3681%26doi%3D10.1128%2FAAC.00308-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Scola, P. M.; Sun, L.-Q.; Gillis, E. P.; Bowsher, M. S.; Chen, J.; Wang, X. A.; Sit, S.-Y.; Chen, Y.; Zheng, Z.; D’Andrea, S.; Sin, N.; Venables, B.; Mull, E.; Chen, Q.; Kandhasamy, S.; Pulicharla, N.; Vishwakrishnan, S.; Reddy, S.; Trivedi, R.; Sinha, S.; Sivaprasad, S.; Rao, A.; Desai, S.; Ghosh, K.; Rajamani, R.; Friborg, J.; Levine, S.; Chen, C.; Falk, P.; Jenkins, S.; Kramer, M.; Haskel, R.; Johnson, K.; Loy, J.; Levesque, P.; Zhu, J.; Cockett, M.; Meanwell, N. A.; McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery of a second generation, pan genotype NS3/4A protease inhibitor (BMS-986144) for the treatment of hepatitis C</span>. 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16–20,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-309.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+M.+Scola&author=L.-Q.+Sun&author=E.+P.+Gillis&author=M.+S.+Bowsher&author=J.+Chen&author=X.+A.+Wang&author=S.-Y.+Sit&author=Y.+Chen&author=Z.+Zheng&author=S.+D%E2%80%99Andrea&author=N.+Sin&author=B.+Venables&author=E.+Mull&author=Q.+Chen&author=S.+Kandhasamy&author=N.+Pulicharla&author=S.+Vishwakrishnan&author=S.+Reddy&author=R.+Trivedi&author=S.+Sinha&author=S.+Sivaprasad&author=A.+Rao&author=S.+Desai&author=K.+Ghosh&author=R.+Rajamani&author=J.+Friborg&author=S.+Levine&author=C.+Chen&author=P.+Falk&author=S.+Jenkins&author=M.+Kramer&author=R.+Haskel&author=K.+Johnson&author=J.+Loy&author=P.+Levesque&author=J.+Zhu&author=M.+Cockett&author=N.+A.+Meanwell&author=F.+McPhee&title=Discovery+of+a+second+generation%2C+pan+genotype+NS3%2F4A+protease+inhibitor+%28BMS-986144%29+for+the+treatment+of+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520second%2520generation%252C%2520pan%2520genotype%2520NS3%252F4A%2520protease%2520inhibitor%2520%2528BMS-986144%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">The human <i>V</i>ss and clearance values for compound <b>29</b> were determined via allometric scaling using species-invariant modeling of preclinical species. Absorption kinetics in humans were assumed to be the average determined from rat, dog and monkey following solution dosing. The efficacious dose was projected by translating the in vitro replicon potency to clinical viral load decline as stated in ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">18</a>, and this resulted in a once daily dose projection of 6 mg for <b>29</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Paulissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubert, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teyssie, Ph.</span><span> </span><span class="NLM_article-title">Transition metal catalysed cyclopropanation of olefin</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1466</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)84656-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1016%2FS0040-4039%2801%2984656-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1972&pages=1465-1466&author=R.+Paulissenauthor=R.+J.+Hubertauthor=Ph.+Teyssie&title=Transition+metal+catalysed+cyclopropanation+of+olefin&doi=10.1016%2FS0040-4039%2801%2984656-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2984656-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252984656-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaulissen%26aufirst%3DR.%26aulast%3DHubert%26aufirst%3DR.%2BJ.%26aulast%3DTeyssie%26aufirst%3DPh.%26atitle%3DTransition%2520metal%2520catalysed%2520cyclopropanation%2520of%2520olefin%26jtitle%3DTetrahedron%2520Lett.%26date%3D1972%26volume%3D13%26spage%3D1465%26epage%3D1466%26doi%3D10.1016%2FS0040-4039%2801%2984656-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P. M.</span><span> </span><span class="NLM_article-title">A facile synthesis of 1-substituted cyclopropylsulfonamides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span><span class="refDoi"> DOI: 10.1055/s-2006-933130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;key=10.1055%2Fs-2006-933130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=725-728&author=J.+Liauthor=D.+Smithauthor=H.+S.+Wongauthor=J.+A.+Campbellauthor=N.+A.+Meanwellauthor=P.+M.+Scola&title=A+facile+synthesis+of+1-substituted+cyclopropylsulfonamides&doi=10.1055%2Fs-2006-933130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933130%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DA%2520facile%2520synthesis%2520of%25201-substituted%2520cyclopropylsulfonamides%26jtitle%3DSynlett%26date%3D2006%26spage%3D725%26epage%3D728%26doi%3D10.1055%2Fs-2006-933130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hiebert, S.; Rajamani, R.; Sun, L.-Q.; Mull, Eric; Gillis, E. P.; Bowsher, M. S.; Zhao, Q.; Meanwell, N. A.; Renduchintala, K. V.; Sarkunam, K.; Nagalakshmi, P.; Babu, P. V. K. S.; Scola, P. M.</span><span> </span><span class="NLM_article-title">Preparation of macrocyclic peptides, especially proline-containing peptides, as inhibitors of hepatitis C virus replication</span>. World Patent Application, WO 2012151195.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hiebert%2C+S.%3B+Rajamani%2C+R.%3B+Sun%2C+L.-Q.%3B+Mull%2C+Eric%3B+Gillis%2C+E.+P.%3B+Bowsher%2C+M.+S.%3B+Zhao%2C+Q.%3B+Meanwell%2C+N.+A.%3B+Renduchintala%2C+K.+V.%3B+Sarkunam%2C+K.%3B+Nagalakshmi%2C+P.%3B+Babu%2C+P.+V.+K.+S.%3B+Scola%2C+P.+M.+Preparation+of+macrocyclic+peptides%2C+especially+proline-containing+peptides%2C+as+inhibitors+of+hepatitis+C+virus+replication.+World+Patent+Application%2C+WO+2012151195."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHiebert%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520macrocyclic%2520peptides%252C%2520especially%2520proline-containing%2520peptides%252C%2520as%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>Full X-ray crystallographic data have been deposited with the Cambridge Crystallographic Data Center (CCDC reference number 1491198). Copies of the data can be obtained free of charge via the internet at <a href="http://www.ccdc.cam.ac.uk" class="extLink">http://www.ccdc.cam.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Full+X-ray+crystallographic+data+have+been+deposited+with+the+Cambridge+Crystallographic+Data+Center+%28CCDC+reference+number+1491198%29.+Copies+of+the+data+can+be+obtained+free+of+charge+via+the+internet+at+http%3A%2F%2Fwww.ccdc.cam.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d7e6693-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i61"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00821">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48002"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00821">10.1021/acs.jmedchem.6b00821</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES codes and GT-1a/1b inhibitory activity for compounds <b>6</b>–<b>29</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00821/suppl_file/jm6b00821_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00821/suppl_file/jm6b00821_si_001.csv">jm6b00821_si_001.csv (3.59 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00821&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00821%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00821" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a87526fa924cb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
